[go: up one dir, main page]

CA2385589A1 - Inhibitors of factor xa - Google Patents

Inhibitors of factor xa Download PDF

Info

Publication number
CA2385589A1
CA2385589A1 CA002385589A CA2385589A CA2385589A1 CA 2385589 A1 CA2385589 A1 CA 2385589A1 CA 002385589 A CA002385589 A CA 002385589A CA 2385589 A CA2385589 A CA 2385589A CA 2385589 A1 CA2385589 A1 CA 2385589A1
Authority
CA
Canada
Prior art keywords
group
4alkyl
substituted
compound
conh2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002385589A
Other languages
French (fr)
Inventor
Bing-Yan Zhu
Zhaozhong Jon Jia
Robert M. Scarborough
James Kanter
Yonghong Song
Wenrong Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2385589A1 publication Critical patent/CA2385589A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Controls And Circuits For Display Device (AREA)
  • Dot-Matrix Printers And Others (AREA)
  • Facsimile Image Signal Circuits (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compounds of formula A Q D E G J X in which D is a direct link, a substitute d or unsubsituted phenyl or naphtyl gourp or a heterocyclic ring system; G is substituted or unsubstituted phenyl or a heterocyclic ring system; X is a substituted or unsubstituted phenyl or naphtyl group or a heterocyclic ring system; and the other variables are as defined in the claims, their salts an d compositions related thereto having activity against mammalian factor Xa are disclosed, The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

Description

INHIBITORS OF FACTOR Xa Cross Reference to Related Applications This application claims benefit of priority under 35 U.S.C. ~ 119(e) to U.S.
Provisional Application No. 60/154,332 filed on September 17, 1999, which is herein incorporated in its entirety by reference.
Field of the Invention This invention relates to novel compounds which are potent and highly selective inhibitors of isolated factor Xa or when assembled in the prothrombinase complex. These compounds show selectivity for factor Xa versus other proteases of the coagulation (e.g.
thrombin, fVIIa, flXa) or the fibrinolytic cascades (e.g. plasminogen activators, plasmin).
In another aspect, the present invention relates to novel non-amidino-containing compounds, their pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof which are useful as potent and.specific inhibitors of blood coagulation in mammals. In yet another aspect, the invention relates to methods for using these inhibitors as therapeutic agents for disease states in mammals characterized by coagulation disorders.
Background of the Invention Hemostasis, the control of bleeding, occurs by surgical means, or by the physiological properties of vasoconstriction and coagulation. This invention is particularly concerned with blood coagulation and ways in which it assists in maintaining the integrity of mammalian circulation after injury, inflammation, disease, congenital defect, dysfunction or other disruption. Although platelets and blood coagulation are both involved in thrombus formation, certain components of the coagulation cascade are primarily responsible for the amplification or acceleration of the processes involved in platelet aggregation and fibrin deposition.
Thrombin is a key enzyme in the coagulation cascade as well as in hemostasis.
Thrombin plays a central role in thrombosis through its ability to catalyze the conversion of fibrinogen into fibrin and through its potent platelet activation activity.
Direct or indirect inhibition of thrombin activity has been the focus of a variety of recent anticoagulant strategies as reviewed by Claeson, G., "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System", Blood Coag. Fibrinol. ~, 411-436 (1994). Several classes of anticoagulants currently used in the clinic directly or indirectly affect thrombin (i.e.
heparins, low-molecular weight heparins, heparin-like compounds and coumarins).
A prothrombinase complex, including Factor Xa (a serine protease, the activated form of its Factor X precursor and a member of the calcium ion binding, gamma carboxyglutamyl (Gla)-containing, vitamin K dependent, blood coagulation glycoprotein family), converts the zymogen prothrombin into the active procoagulant thrombin.
Unlike thrombin, which acts on a variety of protein substrates as well as at a specific receptor, factor Xa appears to have a single physiologic substrate, namely prothrombin.
Since one molecule of factor Xa may be able to generate up to 138 molecules of thrombin (Elodi et al., Thromb. Res. 15, 617-619 (1979)), direct inhibition of factor Xa as a way of indirectly inhibiting the formation of thrombin may be an efficient anticoagulant strategy.
Therefore, it has been suggested that compounds which selectively inhibit factor Xa may be useful as in vitro diagnostic agents, or for therapeutic administration in certain thrombotic disorders, see e.g., WO 94/13693. .
Polypeptides derived from hematophagous organisms have been reported which are highly potent and specific inhibitors of factor Xa. United States Patent 4,588,587 describes anticoagulant activity in the saliva of the Mexican leech, Haementeria officinalis. A principal component of this saliva was shown to be the polypeptide factor Xa inhibitor, antistasin (ATS), by Nutt, E. et al., "The Amino Acid Sequence of Antistasin, a Potent Inhibitor of Factor Xa Reveals a Repeated Internal Structure", J. Biol.
Chem., 263, 10162-10167 (1988). Another potent and highly specific inhibitor of Factor Xa, called tick anticoagulant peptide (TAP), has been isolated from the whole body extract of the soft tick Ornithidoros moubata, as reported by Waxman, L., et al., "Tick Anticoagulant Peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa"
Science, 2~4 , 593-596 (1990).
Factor Xa inhibitory compounds which are not large polypeptide-type inhibitors have also been reported including: Tidwell, R.R. et al., "Strategies for Anticoagulation With Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors", Thromb.
Res., 1~, 339-349 (1980); Turner, A.D. et al., "p-Amidino Esters as Irreversible Inhibitors of Factor IXa and Xa and Thrombin", Biochemistry,~~, 4929-4935 (1986); Hitomi, Y. et al., "Inhibitory Effect of New Synthetic Protease Inhibitor (FUT-175) on the Coagulation System", Haemostasis, 15, 164-168 (1985); Sturzebecher, J. et al., "Synthetic Inhibitors of Bovine Factor Xa and Thrombin. Comparison of Their Anticoagulant Efficiency", Thromb. Res., 5~, 245-252 (1989); Kam; C.M. et al., "Mechanism Based Isocoumarin Inhibitors for Trypsin and Blood Coagulation Serine Proteases: New Anticoagulants", Biochemistry, ~, 2547-2557 (1988); Hauptmann, J. et al., "Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors", Thromb. Haemost., ~, 220-223 ( 1990); and the like.
Others have reported Factor Xa inhibitors which are small molecule organic compounds, such as nitrogen containing heterocyclic compounds which have amidino substituent groups, wherein two functional groups of the compounds can bind to Factor Xa at two of its active sites. For example, WO 98/28269 describes pyrazole compounds having a terminal C(=NH)-NHZ group; WO 97/21437 describes benzimidazole compounds substituted by a basic radical which are connected to a naphthyl group via a straight or branched chain alkylene,-C(=O) or -S(=O)2 bridging group; WO

describes compounds having a 4-phenyl-N-alkylamidino-piperidine and 4-phenoxy-N-alkylamidino-piperidine group connected to a 3-amidinophenyl group via a carboxamidealkyleneamino bridge; and EP 798295 describes compounds having a 4-phenoxy-N-alkylamidino-piperidine group connected to an amidinonaphthyl group via a substituted or unsubstituted sulfonamide or carboxamide bridging group.
There exists a need for effective therapeutic agents for the regulation of hemostasis, and for the prevention and treatment of thrombus formation and other pathological processes in the vasculature induced by thrombin such as restenosis and inflammation. In particular, there continues to be a need for compounds which selectively inhibit factor Xa or its precursors. Compounds are needed which selectively or preferentially bind to Factor Xa. Compounds with, a higher affinity for binding to Factor Xa than to thrombin are desired, especially those compounds having good bioavailability or other pharmacologically desirable properties.

Summary of the Invention The present invention relates to novel compounds which inhibit factor Xa, their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, and pharmaceutically acceptable compositions thereof which have particular biological properties and are useful as potent and specific inhibitors of blood coagulation in mammals. In another aspect, the invention relates to methods of using these inhibitors as diagnostic reagents or as therapeutic agents for disease states in mammals characterized by undesired thrombosis which have coagulation disorders, such as in the treatment or prevention of any thrombotically mediated acute coronary or cerebrovascular syndrome, any thrombotic syndrome occurnng in the venous system, any coagulopathy, and any thrombotic complications associated with extracorporeal circulation or instrumentation, and for the inhibition of coagulation in biological samples.
In certain embodiments, this invention relates to novel compounds which are potent and highly selective inhibitors of isolated factor Xa when assembled in the prothrombinase complex. These compounds show selectivity for factor Xa versus other proteases of the coagulation cascade (e.g. thrombin, etc.) or the fibrinolytic cascade, and are useful as diagnostic reagents as well as antithrombotic agents.
In one embodiment, the present invention provides compounds comprising a five-membered heterocyclic ring structure having from 1-4 hetero atoms selected from the group consisting of N, O and S or a bicyclic ring system comprising the 5-membered heterocyclic ring structure wherein the bicyclic ring structure may have 1-5 hetero atoms selected from the group consisting of N, O and S, and wherein the overall compound has an essentially neutral pH. Preferably, a pH of about pH 5-8, more preferably, about pH
6-7.5 and most preferably, about pH 7Ø The compounds according to the invention are potent and selective inhibitors of factor Xa versus other proteases of the coagulation cascade (e.g. thrombin, etc.) or the fibrinolytic cascade, and are useful as diagnostic reagents as well as antithrombotic agents. Particular embodiments of the compounds of the present invention are set forth below as preferred embodiments and include all pharmaceutically acceptable isomers, salts, hydrates,~solvates and prodrug derivatives thereof.

In certain aspects of this invention, compounds are provided which are useful as diagnostic reagents. In another aspect, the present invention includes pharmaceutical compositions comprising a pharmaceutically effective amount of the compounds of this invention and a pharmaceutically acceptable carrier. In yet another aspect, the present invention includes methods comprising using the above compounds and pharmaceutical compositions for preventing or treating disease states characterized by undesired thrombosis or disorders of the blood coagulation process in mammals, or for preventing coagulation in stored blood products and samples. Optionally, the methods of this invention comprise administering the pharmaceutical composition in combination with an to additional therapeutic agent such as an antithrombotic and/or a thrombolytic agent and/or an anticoagulant.
The preferred compounds also include their pharmaceutically acceptable isomers, hydrates, solvates, salts and prodrug derivatives.
Detailed Description of the Invention Definitions In accordance with the present invention and as used herein, the following terms are defined with the following meanings, unless explicitly stated otherwise.
The term "alkenyl" refers to a trivalent straight chain or branched chain unsaturated aliphatic radical. The term "alkinyl" (or "alkynyl") refers to a straight or branched chain aliphatic radical that includes at least two carbons joined by a triple bond.
If no number of carbons is specified alkenyl and alkinyl each refer to radicals having from 2-12 carbon atoms.
The term "alkyl" refers to saturated aliphatic groups including straight-chain, branched-chain and cyclic groups having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms.' The term "cycloalkyl" as used herein refers to a mono-, bi-, or tricyclic aliphatic ring having 3 to 14 carbon atoms and preferably 3 to 7 carbon atoms.

As used herein, the terms "carbocyclic ring structure " and " C3_~6 carbocyclic mono, bicyclic or tricyclic ring structure" or the like are each intended to mean stable ring structures having only carbon atoms as ring atoms wherein the ring structure is a substituted or unsubstituted member selected from the group consisting of a stable monocyclic ring which is an aromatic ring ("aryl") having six ring atoms; a stable monocyclic non-aromatic ring having from 3 to 7 ring atoms in the ring; a stable bicyclic ring structure having a total of from 7 to 12 ring atoms in the two rings wherein the bicyclic ring structure is selected from the group consisting of ring structures in which both of the rings are aromatic, ring structures in which one of the rings is aromatic and ring structures in which both of the rings are non-aromatic; and a stable tricyclic ring structure having a total of from 10 to 16 atoms in the three rings wherein the tricyclic ring structure is selected from the group consisting of ring, structures in which three of the rings are aromatic, ring structures in which two_of the rings are aromatic and ring structures in which three of the rings are non-aromatic. In each case, the non-aromatic rings when present in the monocyclic, bicyclic or tricyclic ring structure may independently be saturated, partially saturated or fully saturated. Examples of such carbocyclic ring structures include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).
Moreover, the ring structures described herein may be attached to one_ or more indicated pendant groups via any carbon atom which results in a stable structure. The term "substituted" as used in conjunction with carbocyclic ring structures means that hydrogen atoms attached to the ring carbon atoms of ring structures described herein.may be substituted by one or more of the substituents indicated for that structure if such substitutions) would result in a stable compound.
The term "aryl" which is included with the term "caibocyclic ring structure"
refers to an unsubstituted or substituted aromatic ring, substituted with one, two or three substituents selected from loweralkoxy, loweralkyl, loweralkylamino, hydroxy, aminoloweralkyl, hydroxyloweralkyl, halogen, cyano, hydroxyl, mercapto, nitro, thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy and carboxamide, including but not limited to carbocyclic aryl, heterocyclic aryl, and biaryl groups and the like, all of which may be optionally substituted. Preferred aryl groups include phenyl, halophenyl, loweralkylphenyl, napthyl, biphenyl, phenanthrenyl and naphthacenyl.
'The term "arylalkyl" which is included with the term "carbocyclic aryl"
refers to one, two, or three aryl groups having the number of carbon atoms designated, appended to an alkyl group having the number of carbon atoms designated. Suitable arylalkyl groups include, but are not limited to, benzyl, picolyl, naphthylmethyl, phenethyl, benzyhydryl, trityl, and the like, all of which may be optionally substituted.
As used herein, the term "heterocyclic ring" or "heterocyclic ring system" is intended to mean a substituted or unsubstituted member selected from the group consisting of stable monocyclic ring having from 5-7 members in the ring itself and having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S; a stable bicyclic ring structure having a total of from 7 to 12 atoms in the two rings wherein at least one of the two rings has from 1 to 4 hetero atoms selected from N, O
and S, including bicyclic ring structures wherein any of the described stable monocyclic heterocyclic rings is fused to a hexane or benzene ring; and a stable tricyclic heterocyclic ring structure having a total of from 10 to 16 atoms. in the three rings wherein at least one of the three rings has from 1 to 4 hetero atoms selected from the group consisting of N, O
and S. Any nitrogen and sulfur atoms present in a heterocyclic ring of such a heterocyclic ring structure may be oxidized. Unless indicated otherwise the terms "heterocyclic ring"
or "heterocyclic ring system" include aromatic rings, as well as non-aromatic rings which can be saturated, partially saturated or fully saturated non-aromatic rings.
Also, unless indicated otherwise the term "heterocyclic ring system" includes ring structures wherein all of the rings contain at least one hetero atom as well as structures having less than all of the rings in the ring structure containing at least one hetero atom, for example bicyclic ring structures wherein one ring is a benzene ring and one of the rings has one or more hetero atoms are included within the term "heterocyclic ring systems" as well as bicyclic ring structures wherein each of the two rings has at least one hetero atom.
Moreover, the ring structures described herein may be attached to one or more indicated pendant groups via any hetero atom or carbon atom which results in a stable structure.
Further, the term "substituted" means that one or more of the hydrogen atoms on the ring carbon atoms) or nitrogen atoms) of the each of the rings in the ring structures described herein may be replaced by one or more of the indicated substituents if such replacements) would result in a stable compound. Nitrogen atoms in a ring structure may be quaternized, but such compounds are specifically indicated or are included within the term "a pharmaceutically acceptable salt" for a particular compound. When the total 'number of O and S
atoms in a single heterocyclic ring is greater than 1, it is preferred that such atoms not be adjacent to one another. Preferably, there are no more that 1 O or S ring atoms in the same ring of a given heterocyclic ring structure.
Examples of monocylic and bicyclic heterocylic ring systems, in alphabetical order, are acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pryidooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl; pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H=quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl. Preferred heterocyclic ring structures include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, imidazolyl, indolyl, benzimidazolyl, 1H-indazolyl, oxazolinyl, or isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocylic ring structures.

As used herein the term "aromatic heterocyclic ring system" has essentially the same definition as for the monocyclic and bicyclic ring systems except that at least one ring of the ring system is an aromatic heterocyclic.ring or the bicyclic ring has an aromatic or non-aromatic heterocyclic ring fused to an aromatic carbocyclic ring structure.
The terms "halo" or "halogen" as used herein refer to Cl, Br, F or I
substituents.
The term "haloalkyl", and the like, refer to an aliphatic carbon radicals having at least one hydrogen atom replaced by a Cl, Br, F or I atom, including mixtures of different halo atoms. Trihaloalkyl includes trifluoromethyl and the like as preferred radicals, for example.
The term "methylene" refers to -CH2-.
The term "pharmaceutically acceptable salts" includes salts of compounds derived from the combination of a compound and an organic or inorganic acid. These compounds are useful in both free base and salt form. In practice, the use of the salt form amounts to use of the base form; both acid and base addition salts are within the scope of the present invention.
"Pharmaceutically acceptable acid addition salt" refers to salts retaining the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malefic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicyclic acid and the like.
"Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine,.2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline, and caffeine.
"Biological property" for the purposes herein means an in vivo effector or 10 antigenic function or activity that is directly or indirectly performed by a compound of this invention that are often shown by in vitro assays. Effector functions include receptor or ligand binding, any enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to an extracellular matrix or cell surface molecules, or any structural role.
Antigenic functions include possession of an epitope or antigenic site that is capable of reacting with antibodies raised against it.
In the compounds of this invention, carbon atoms bonded to four non-identical substituents are asymmetric. Accordingly, the compounds may exist as diastereoisomers, enantiomers or mixtures thereof. The syntheses described herein may employ racemates, enantiomers or diastereomers as starting materials or intermediates.
Diastereomeric products resulting from such syntheses may be separated by chromatographic or crystallization methods, or by other methods known in the art. Likewise, enantiomeric product mixtures may be separated using the same techniques or by other methods known in the art. Each of the asymmetric carbon atoms, when present in the compounds of this invention, may be in one of two configurations (R or S) and both are within the scope of the present invention.
Preferred Embodiments The invention provides a compound of the formula (I):

A-Q-D-E-G-J-X
wherein:
A is selected from:
(a) C,-C6-alkyl;
(b) C3-C8-cycloalkyl;
(c) -N(Rz,R3), -C(=NRZ)-R3, -C(=NRZ)N(RZ,R3), -N(R3)-C(=NRZ)N(R2, R3)-, and N(RZ)C(=NR3)-Rz (d) phenyl, which is independently substituted with 0-2 R' substituents;
(e) naphthyl, which is independently substituted with 0-2 R' substituents; and (f) a monocyclic or fused bicyclic heterocyclic ring system having from S to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R' substituents;
R' is selected from:
Halo, -CN, -C(=O)-N(R2, R3), -NO2, -SOZN(R2, R3), -SOZRZ, -(CH2)mNR2R3, -(CHZ),n-C(=NR3)-R2, -(CHZ)"; C( NRZ)-N(RZ,R3), -(CHZ)m-N(R2)-C(=NR2)-N(RZ,R3), -(CHZ)mNR2-C3_bheterocyclics, C,~alkyl, CZ_balkenyl, C2_balkynyl, C3_ 8cycloalkyl, Co~alkylC3_gcycloalkyl, -CF3, -OR2, and a 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C,.~alkyl-CN, C,~alkyl, Cz_balkenyl, CZ_balkynyl, C3_8cycloalkyl, Co~alkylC3_$cycloalkyl and -NO2;
Rz and R3 are independently selected from the group consisting of:

-H, -ORa, -N(-Ra, -Rb), -C,~alkyl, -Cz_6alkenyl, -CZ_balkynyl, -C3_8cycloalkyl, -Co~alkylC3_$cycloalkyl, -Co~alkylphenyl and -Co~alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C,.~alkyl-CN, -C,~alkyl, -Cz_balkenyl, -CZ_6alkynyl, -C3_8cycloalkyl, -Co~alkylC3_ 8cycloalkyl, -CN, and -NOz;
or RZ and R3 taken together can form a 3-8 membered cycloalkyl or a heterocyclic ring system, wherein the heterocyclic ring system may have from 3 to 10 ring atoms, with 1 to 2 rings being in the ring system and contain from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic ring system may be independently replaced with a member selected from the group consisting of halo, C»alkyl-CN, -C~_4alkyl, -CZ_6alkenyl, -C2_balkynyl, -C3_ 8cycloalkyl, -Co~alkylC3_gcycloalkyl and -N02;
Ra and Rb are independently selected from the group consisting of -C,~alkyl, -CZ_6alkenyl, -CZ~alkynyl, -C3_8cycloalkyl, -Co~alkylC3_gcycloalkyl, or Ra and Rb can be taken together with a nitrogen atom to which they are attached to form a 3-8 heterocyclic ring sytem containing 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic ring system may be independently replaced with a member selected from the group consisting of halo, -CN, -C»alkyl, -CZ~alkenyl, -CZ_balkynyl, -C3_8cycloalkyl, -Co~alkylC3_8cycloalkyl and -NO2;
m is an integer of 0-2; ,.
Q is selected from the group consisting of a direct link, divalent -C~-4alkyl, divalent -CZ-4alkenyl, divalent -C2~alkynyl, -C(=O)-, -C(=NH)-, -C(=NMe)-, -N(-R4)-, -N(-R4)-CHz-, -C(=O)-N(-R4)-, -N(-R4)-C(=O)-, -S(=O)2-, -O-, -S(=O)2-N(-R4)- and N(-R4)-S(=O)2-, wherein one or more hydrogens on each of the divalent C1-4alkyl, divalent CZ-4alkenyl and divalent CZ~alkynyl moieties can be replaced with a -R4 group;
R4 is selected from the group consisting of:

-H, -CF3, -C»alkyl, -CZ.~alkenyl, -CZ_6alkynyl, -C3_gcycloalkyl, -Co~alkylC3_ gcycloalkyl, -Co~alkylphenyl and -Co~alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, -C~.~alkyl, -CZ_6alkenyl, -CZ_balkynyl, -C3_gcycloalkyl, -Co~alkylC3_$cycloalkyl, -CN, -CF3, and -N02;
D is selected from the group consisting of (a) a direct link;
(b) phenyl, which is independently substituted with 0-2 Rla substituents;
(c) naphthyl, which is independently substituted with 0-2 Rya substituents;
and (d) monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be subsituted from 0-2 Rla substituents;
Rla is selected from the group consisting of halo, C,~alkyl, CZ_balkenyl, CZ_6alkynyl, C3_gcycloalkyl, Co~alkylC3_$cycloalkyl, -CN, -NO2, (CHZ)"NRzaR3a~ 502~2aR3a~ SOZR2a~ CF3, ORza, and a 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from N, O
and S, wherein from 1-4 hydrogen atoms on the aromatic heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C~.~alkyl, CZ.~alkenyl, CZ_balkynyl, C3_gcycloalkyl, Co~alkylC3_ 8cycloalkyl, -CN and -NO2;
RZa and R3a are independently selected from the group consisting of -H, Cl~alkyl, C2_balkenyl, CZ_balkynyl, C3_8cycloalkyl, Co~alkylC3_8cycloalkyl, Co~alkylphenyl and Co~alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C»alkyl, Cz_6alkenyl, Cz_6alkynyl, C3_8cycloalkyl, Co~alkylC3_$cycloalkyl, -CN and -NOz;
n is an integer of 0-2;
E is selected from the group consisting of a direct link, -(CHz)q-C(=O)-, -(CHz)q N(-RS)-C(=O)-(CHz)x , -(CHz)q C(=O)-N(-RS)-(CHz)x-~ -(CH2)9 N(-RS)-(CHz)X > > -(CHz)q N(RS)CO-NR6(CHz)X and -SOz-;
q and x are independently an integer of 0-2;
RS and R6 are independently selected from the group, consisting of H, -C,~alkyl, -C1_balkyloxy, -Cz_balkenyl, -Cz_balkynyl, -C3_$cycloalkyl, -Co_6alkylC3_$cycloalkyl, -C,~alkyl-C(=O)-OH, -Co_6alkyl-(carbocyclic aryl), -Co~alkyl-(monocyclic heteroaryl) and -C~.~alkyl-C(=O)-O-Cl~alkyl, wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety and the monocyclic heteroaryl moieties may be independently replaced with a member selected from the group consisting of halo, -C,~alkyl, -Cz_6alkenyl, -Cz_balkynyl, -C3_8cycloalkyl, -Co~alkylC3_8cycloalkyl, -S(=O)z-OH, -CN, -CF3 and -NOz;
G is selected from the group consisting of phenyl, which is substituted with 0-2 Rib groups; and a 5-6 membered aromatic and non-aromatic heterocyclic ring containing 1-4 hetero atoms selected from N, O and S wherein the heterocyclic ring is substituted with 0-2 Rlb groups; , R~b is independently selected from the group consisting of:
halo, -C~_6alkyl, -Cz_6alkenyl, -Cz_6alkynyl, -C3_8cycloalkyl, -Co_6alky1C3_gcycloalkyl, -C,.~alkyl-C(=O)-OH, -CN, -COORzb, -CONRzbR3b~ -NOz, -S(=O)z-OH, -N(-Rzb, -R3b)~ -C(-O)-N(-Rzb~ -R3b)~ -S(=O)z-N(-Rzb~ -R3b)~ -S(-O)z-Rzb~ -CF3, -O-Rzb, -O-CHz-CHz-O-Rzb~ -O-CHz-C(=O)-O-Rzb -N(-Rzb)-CHz-CHz-O-R2b~ -N(-CHz-CHz-O-Rzb)z~ -N(_Rzb)-C(=O)-R36 -N(-Rzb)-S(=O)z-R3b, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S substituted with 0-4 R'b~ groups;
alternatively, when two R'b may be present on adjacent ring atoms of G and 5 combine to form a benzene ring substituted with 0-4 R'b~ groups or a 5-6 membered aromatic or non-aromatic heterocyclic ring having 1-3 heteroatoms selected from N, O and S substituted with 0-4 R'b~ groups;
in a second alternative, one of the R'b groups of G can cylize with the -N-RS
group of E to form a 5-7 membered heterocyclic ring containing 1-4 heteroatoms 10 selected from N, O and S, which is subtituted with 0-4 R'b~ groups, wherein two of the R'b~ groups attached to the same ring carbon may form a (=O) group;
Rzb and R3b are independently selected from the group consisting of -H, -C,_balkyl, -C»alkyloxy, -Cz_balkenyl, -Cz_6alkynyl, -C3_gcycloalkyl, -Co_6alkylC3_gcycloalkyl and -Co_6alkyl-(carbocyclic aryl), wherein from 0-4 15 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, -C,~alkyl, -Cz_6alkenyl, -Cz_6alkynyl, -C3_8cycloalkyl, -Co~alkylC3_gcycloalkyl, -S(=O)z-OH, -CN, -CF3 and -NOz;
R'b~ is independently selected from the group consisting of:
halo, -C1_6alkyl, -CZ_balkenyl, -Cz_balkynyl, -C3_gcycloalkyl, -Co_6a1ky1C3_gcycloalkyl, -C,~alkyl-C(=O)-OH, -CN, -NOz, -S(=O)z-OH, -N(-Rzb~, -R3b~)~ -C(=O)-N(-Rzby -R36~)~ -S(-O)z-N(-R2b~~ _R36~)~ -S(-O)z-Rzb~~ -CF3, -O-Rzb -O-CHz-CHz-O-Rzb~~ -O_CHz-C(=O)-O-Rzb~~ -N(-Rzb~)-CHz-CHz-O-Rzb -N(-CHz-CHz-O-Rzb')z~ -N(-Rzb~)-C(=O)-R3b~ and -N(-Rzb')-S(=O)z-R3b'i Rzb~ and R3b~ are independently selected from the group consisting of -H, -C~_balkyl, -C,_6alkoxy, -Cz_6alkenyl, -Cz_6alkynyl, -C3_$cycloalkyl, -Co_6a1ky1C3_8cycloalkyl and -Co_balkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, -C»alkyl, -Cz_balkenyl, -Cz_6alkynyl, -C3_$cycloakyl, -Co.aalkylC3_8cycloalkyl, -S(=O)z-OH, -CN, -CF3 and -NOz;
J is selected from the group consisting of a direct link, -S(=O)z-, -C(=O)-, -N(-R')-S(=O)z-, -C(=O)-N(-R')-S(=O)z-, -C(=O)-N(-R')-(CHz)r-~ -S(=O)z-N(-R') -(CHz)y-, and -N(-R')-C(=O)-(CHz)Y
y is an integer of 0-2;
R' is selected from the group consisting of -H, -Cz~alkyl, -Cz~alkenyl, -Cz_6alkynyl, -C3_gcycloalkyl, -Co_6alky1C3_gcycloalkyl, -C ~ _balkyl-C(=O)-OH, -C ~ _6alkyl-OH, -C, _6alkyl-O-C ~ alkyl, -Co_ 4alkyl-(carbocyclic aryl), -Co~alkyl-(monocyclic or bicyclic heterocyclic ring system having from 0-4 heteroatoms selected from the group consisting of N, O
and S), -CHz-C(=O)-O-C,~alkyl and -CHz-C(=O)-O-C,~alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety or the heterocyclic ring system may be independently replaced with a member selected from the group consisting of halo, -C,~alkyl, -Cz_6alkenyl, -Cz_ 6alkynyl, -C3_gcycloalkyl, -Co~alkylC3_8cycloalkyl, -S(=O)z-OH, -CN, -CF3 and -NOz X is selected from the group consisting of phenyl, which is substituted with 0-3 R'° groups;
naphthyl, which is substituted with 0-3 Rl~ groups;
a 6-membered heteroaromatic ring containing from 1-2 nitrogen atoms, wherein the ring is substituted with 0-3 Rl° groups; and a fused heterobicyclic ring system, wheiein the ring system contains 1-3 heteroatoms selected from N, O and S and is substituted with 0-3 R'°
groups;
R'° is independently selected from the group consisting of halo, -CF3, -C,_balkyl, -Cz_balkenyl, -Cz_balkynyl, -C3_8cycloalkyl, -Co_6a1ky1C3_8cycloalkyl, -C,.~alkyl-C(=O)-OH, -CF3, -CN, -NOz, -(CHz)Z N(-Rz~, -Rs~)~ -C(=O)-N(-Rz~~ -R3~)~ -C(-NH)-N~-R2~~ -R3~)~ _C~ NMe)-N(-RZ°, _R3~)~
-S(=O)z-N(-Rz~~ -R3~)~ -S(=O)z-Rz°~ -S(=O)z-O H, -CF3, -O-Rz°, -O(-CHz)Z O-Rz~, -O(-CHz)Z C(=O)-O-Rz'~ -N(-Rzc)~ -O(-CHz)Z O-Rz'~ -NL(-CHz)Z O-Rz°~2~
-(CHz)~ N(-Rz~)-C(=O)-R3~, -(CHz)Z N(-Rz~)-S(=O)z-R3~, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;
z is an integer of 0-4;
Rz~ and R3~ are independently selected from the group consisting of l0 -H, -C,_balkyl, -C,_balkyloxy, -Cz_balkenyl, -Cz_balkynyl, -C3_8cycloalkyl, -Co_6alky1C3_$cycloalkyl and -Co_balkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, -C»alkyl, -Cz~alkenyl, -Cz_balkynyl, -C3_$cycloalkyl, -Co~alkylC3_8cycloalkyl, -15 S(=O)z-OH, -CN, -CF3 and -NOz;
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The invention also provides a compound of the formula (I):
A-Q-D-E-G-J-X
20 wherein:
A is selected from the group consisting o~
-Cl.~alkyl and -C3_8cycloalkyl;
phenyl, which is substituted with 0-2 R' groups;
naphthyl, which is substituted with 0-2 R' groups; and a 5-10 membered aromatic or non-aromatic heterocyclic ring system which may be a monocyclic ring system or a fused bicyclic ring system, wherein the heterocyclic ring system contains 1-4 heteroatoms selected from N, O and S and is substituted with 0-2 R' groups;
R' is independently selected from the group consisting of halo, -C,.~alkyl, -CN, -NOz, -(CHz)m-N(-Rz,-R3), -C(=O)-N(-Rz,-R3), -S(=O)z-N(-R2~-R3)~ -S(°O)z-R2~ -(CHz)m-C( NR3)-R2~ -(CH2)m C(°NR2)-N(R2~R3)~ -(CH2)m N(Rz)-C(=NRz)-N(Rz,R3), -CF3, -(CHz)m-O-Rz and a 5-6 membered aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;
R2 and R3 are independently selected from the group consisting of -H, -C, alkyl, or Rz and R3 taken together can form a 3-8 membered cycloalkyl or a heterocyclic ring system, wherein the heterocyclic ring system may have from 3 to 10 ring atoms, with 1 to 2 rings being in the ring system and contain from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic ring system may be independently replaced with a member selected from the group consisting of halo, C,-C4-alkyl-CN, -C»alkyl, -Cz_6alkenyl, -Cz_6alkynyl, -C3_gcycloalkyl, -Co~alkylC3_8cycloalkyl and -NOz;
m is an integer of 0-2;
Q is selected from the group consisting of:
a direct link, -CI-4alkyl, -Cz-4alkenyl, -Cz~alkynyl, -C(=O)-, -C(=NH)-, -C(=NMe)-, -N(-R4)-, -N(-R4)-CH2-, -C(=O)-N(-R4)-, -N(-R4)-C(=O)-, -S(=O)2-, -O-~ -S(-O)z-N(-R4)- and N(-R4)-S(=O)z-;
R4 is selected from the group consisting of -H, -CF3, -C,~alkyl, D is selected from the group consisting of a direct link;
phenyl, which is substituted with 0-2 Rya groups; and a S-10 membered aromatic or non-aromatic heterocyclic ring system which may be a monocyclic ring system or a fused bicyclic ring system, wherein the heterocyclic ring system contains 1-4 heteroatoms selected from N, O and S and the ring system is substituted with 0-2 Rya groups;
R'a is independently selected from the group consisting of halo, -C,~+alkyl, -CN, -NO2, -(CHZ)"N(-RZa, _R3a), -S(=O)Z-N(-RZa, _R3a)~
-S(=O)2-RZa, -CF3, -(CHZ)"ORZa, -C(=O)-O-R2a, -C(_O)-N(-R2a, -R3a) and a 5-6 membered aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;
n is an integer of 0-2;
RZa and R3a are independently selected from the group consisting of -H, -CF3 and -C ~ alkyl, E is selected from the group consisting of a direct link, -(CHZ)q C(=O)-, -(CHZ)q-N(-RS)-C(=O)-(CHZ)X-, -(CHZ)q C(=O)-N(-RS)-(CHz)X-, -(CHZ)a'N(-RS)-(CHz)X-, -(CHZ)q N(RS)CO-NR6(CHZ)X- and -SOZ-;
RS and R6 are each H, -C~.~alkyl, -CZ_6alkenyl, -CZ_6alkynyl, -C3_gcycloalkyl, or -Co~alkylC3_$cycloalkyl;
q and x are independently an integer of 0-2;
G is selected from the group consisting o~
phenyl, which is substituted with 0-2 Rib groups; and a 5-6 membered aromatic and non-aromatic heterocyclic ring containing 1-4 hetero atoms selected from O, S and N, wherein the heterocyclic ring is substituted with 0-2 Rib groups;
Rib is independently selected from the group consisting of:
5 halo, -C,-aalkyl, -CN, -NOz, -N(-Rzb, -R3b)~ -C(-O)-N(-Rzb, -R36)~ -S(_O)z_N(-Rzb, -R3b)~ -S(-O)2'RZb~ -CF3~ -O-Rzb> -O-CHz-CHz-O-R2b~ -O-CHz-C(-O)-O-Rzb -N(-Rzb)-CHz-CHz-O-R2b~ _N(-CHz-CHz-O-Rzb)z~ _N(_Rzb)-C(-O)-R3b -N(-Rzb)-S(=O)z-R3b and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;
10 alternatively, when two Rib may be present on adjacent ring atoms of G and combine to form a benzene ring substituted with 0-4 R~b~ groups or a 5-6 membered aromatic or non-aromatic heterocyclic ring having 1-3 heteroatoms selected from N, O and S substituted with 0-4 Rib' groups;
in a second alternative, one of the Rlb groups of G can cylize with the -N-RS
15 group of E to form a 5-7 membered saturated, unsaturated or partially unsaturated heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, which is substituted with 0-4 Rlb~ groups, wherein two of the R~b~ groups attached to the same ring carbon may form a (=O) group;
Rzb and R3b are independently selected from the group consisting of 20 -H, -CF3, -C»alkyl and -Cl~alkyl-(carbocyclic aryl);
R'b' is independently selected from the group consisting of halo, -C1-aalkYl, -CN, -NOz, -N(-Rzn~~ _R36~)~ -COO)-N(-Rzb~~ -R3b~)~ -S(-O)z-N(_ Rzb~~ -R3b~)~ -S(-O)z-Rzb~~ -CF3, -O-Rzb', -O-CHz-CHz-O-Rzby -O-CHz-C(=O)-O-Rzb~~ -N(-Rzb~)-CHz-CHz-O-Rzb~~ -N(-CHz-CHz-O-Rzb~)z -N(_R2b')-C(-O)-R3b'' -N(-R2b')-s(=O)2-R3bl~
Rzb' and R3b' are independently selected from the group consisting of -H, -C»alkyl and ~l~alkyl-(carbocyclic aryl);
J is selected from the group consisting of a direct link, -S(=O)2-, -C(=O)-, -N(-R')-S(=O)z-, -C(=O)-N(-R')-S(=O)Z-, -C(=O)-N(-R')-(CHZ)y , -S(=O)2-N(-R')-, -(CHZ)y and -N(-R')-C(=O)-(CHZ)y ;
y is an integer of 0-2;
R' is selected from the group consisting of -H, -CL~alkyl, -CZ_balkenyl, -CZ_balkynyl, -Co_4alkyl-(carbocyclic aryl), -Co~alkyl-(heterocyclic ring system), -CHZ-C(=O)-O-C~_4alkyl and -CHZ-C(=O)-O-Cl~alkyl-(carbocyclic aryl);
X is selected from the group consisting of:
phenyl, which is substituted with 0-3 R~~ groups;
naphthyl, which is substituted with 0-3 R'° groups;
a 6-membered heteroaromatic ring containing from 1-2 nitrogen atoms, wherein the ring is substituted with 0-3 Rl' groups; and a fused heterobicyclic ring system, wherein the ring system contains 1-3 heteroatoms selected from N, O and S and is substituted with 0-3 R'' groups;
Rl° is independently selected from the group consisting of halo, -C1-aalkyl, -CN, -NO2, -(CHZ)Z N(-RZ', _R3'), _C(=O)-N(-RZ°, _R3°), -C~ NH)-N(-R2~~ -Rs~)~ _C~ NMe)-N(-RZ', _R3~)~ -S(=O)rN(-Rz'~ -R3~)~ -S(=O)2-RZ°, -S(=O)2-O -, -CF3, -O-RZ°, -O-CH2-CHz-O-Rz~, -O-CHZ-C(=O)-O-Rz~, -N(-R2~)-CHZ-CHz-O-RZ', -N(_CHZ-CHZ-O-R2~)2, -(CHZ)Z N(-R2~)-C(=O)-R3°, -(CH2)Z N(-RZ')-S(=O)2-R3°, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;
z is an integer of 0-2;

RZ~ and R3° are independently selected from the group consisting of:
-H, -C»alkyl and -Cl~alkyl-(carbocyclic aryl);
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
The present invention also provides compounds of the formula (I):
A-Q-D-E-G-J-X
wherein:
A is selected from the group consisting of:
N~ NY Me SOyNHZ SOpNHMe SOzMe CNZNHz N .
\ / \ ~ \ ~ \ ~ \ ~ \ ~ \ Me CONHz CN SOZNHz SOyNHZ SOZNHZ SOzMe SOzMe SOZMe N\
\ ~ \ ~ \ ~ \ ~ \
F CI Br F CI Br F
/ /
N\ N NC HzNOC HpNHzC NC HyNOC
\ I \ ~ \ ~ \ N/ \ N/ \ N/ \
CI Br HzNHpC MezNH2C MezN HZN NHz CHZNHZ CN NMez N/ \ N/ \ N/ \ / \ N/ ~ N/ \ N/ \ N/ \
CHZNMez SOZNHZ SOZMe CONHZ HzN N HZNHZ ~N N-N/ \ N/ \ N/ \ N/ \ NON N\ I N\ ~ N\
HzN NHZ CHyNHz NHz CHZNHz CN
N=N ~-N / \ / \ N/ N / \ / \ N~\
N N
N\ I ~N ~=N Et ~ ~N ~N N
SOpMe NHZ HpN MezN HpNHpC HZNOC NC
N/ \ N/ \ N/ \ N/ \ N/ \ N/ \ N/ \ ~N
\=N \=N ~=N ~N ~N ~N ~N N=~

~N- ~N~ HzN~N~ M N N HN~N_ O~N- S N OzS~N_ H
NHz CN- Me-N ~N- Me-N~ HN ~N- HN~ ~N- ~N- ~N-Me, Et, Et, Me, Oz ~N- CN- N- N- N- CN- N- M N- N- N- N-Me Me Et~ H
Me Me H
E .N- H,N- N N N ~N ~ O~ ~ S~ ~ N~ 'N
Me M rNe N N// ~ ~ ~ N ~ p ~ N~ ~ N~ ~ N
H Me Et NH- M ~ NH- HzN
N O~ g N N HzN HzN
H Me Et Me, Me Me Me H Me Me N Me N H2N-CHz- N-CHz- N-CHz- Me N-CHz- Me~--N- Me~-O-2 2 H Me Me Me Me Q is selected from the group consisting of:
a direct link, -C(--NH), -C(=NMe)-, -C(=O)-, -CHZ-, -NH-, -N(-CH3)-, -O-, -NH-CHz-, -CHz-NH-, -N(-CH3)-CHZ-, and -CHZ-N(-CH3)-;
D is selected from the group consisting of F CI Br CN
/ \ /_N --CN / \ / \ / \ / \
CH2NH2 Me F F F CI Br / \ / \ / \ / \ / \ / \ / \
F F
N~ ~N_ - ~ _ ~ S I p y M~ Me HN ~ ~ NH N ~ ~ N -C
HN NH MAN N a ~N~ ~N~ ~N~ ~N~
E is selected from the group consisting of a direct link, -NH-C(=O)-, -N(-CH3)-C(=O)-, -N(-CHZCOZH)-C(=O)-, -C(=O)-NH-, -C(=O)-N(-CH3)-, -NH-CHZ- and -CHZ-NH-;
G is selected from the group consisting of 1b 1b RlbRlb R1b 1b 1b 1b R R
R ~/- -1( R R ~' Ri / ~N Rib /NON Rib / \ / \ Rib ~N ~N N Rib N N
I I I
R1b Rib R1b R1b R1b R1b R1b N- N N
/ N ~ N O ~ N ~N N N
I I ~ I
Rib R1b R1b R1b 1b R1b R1b ~~Rib .-.C Rib S N S R / N 02S N S02 I
Rib Rib R1b R1b R1b R1b R1b $02 N O \ S \
/,N // Rib // Rib // Rib ~ Rib ~ Rib 1b 1b 1b 1b 1b 1b 1b 1b R ~ R R R R R R R Rib Rib Rib 1b 1b Rib w O w S w N.Rib ~ ~ Rib \ / R
Rib Rib Rib R1b R1b 1b R1b Rib ~1b R1b N- 1b - 1b ~ ~ Rib N ,N Rib R ~ R ~ -~~ NI
\ R1b ~ R1b \ Rib ~ N Rib ~ N
Rib N~Rib / \ / \ / \
/ \ ~ ~N / ~N
N N
Rlb is independently selected from the group. consisting of -H, -Me, -CF3, -F, -Cl, -Br, -SOZMe, -CN, -CONHZ, -CONMe2, -NHZ, -NO2, -NHCOMe, -NHSOZMe, -CHZNHZ and -COZH;
5 J is selected from the group consisting of a direct link, -NH-, -O-, -S(=O)2-, -S(=O)z-NH, -NH-S(=O)2-, -C(=O)-, -NH-C(=O)- and -C(=O)-NH-;

X is selected from the group consisting of I ~ ~ I
I ~ ~ Me02S ~ ~ H2N02S ~ ~ 02N i i H NH C I i i I i i HO I i i H2N I i i H2N I ~ ~ H I ~ ~ Me0 I ~ ~ H2N
O O O
w w w w w w w w N I i i I ~ i CI I ~ i Br I i i F
I , , F I i i CI I i i Br I i i w w CI ~ ~ Br ~ ~ F w w CI
I ~ ~ I ~ ~ I ~ ~ F I ~ ~ c1 I ~ ~ Br I ~ ~ F I ~ ~ F I ~ ~ CI
Br , , CI , , Br , , F

Br I ~ ~ F I ~ ~ F I ~ ~ CI F I ~ ~ gr I ~ ~ I ~ ~ I ~ ~ ~ , I F
OH ~ ~ OMe ~ ~ NHZ O
CI / \ I Br ~ \ I F ~ \ I CI
O S
Br / , F / , CI / , Br ~ I ~ I S ~ I
~2 ~2 ~2 F N \ I CI N \ I Br H H H F

I CI / ~ I Br S ~ I F S ~ I CI S ~ I Br S ~ I F

S ~ I CI S ~ I Br N ~ I F N ~ I CI N ~ I Br~S ~ I F

N ~ N F N CI N Br I CI ~/ ~ I gr ~ ~ I ~S ~ I
H
H2N02 Me02 02N F
N w ~ N w ~ N ~ I / \ / \ / \ / \
H H H N

/ \ / \ N \ /
\ F /
\ CI
/ \ Br / \ OMe / \ N \ F N \ CI N \ Br N \ OMe ~~ ~N~\ --F
OH

N N N H2N02 Me02 02N
~N~CI -(N~Br ~N~-OMe / \ F / \ F / \
-F

/ \ H2N02 F / Me02S
\ F 02N
/ \ F
/ \ .
F / \
CI /
\ CI
/ \ CI

F H2N0 N H2NH2 H2N02 Me02 02N
/ \ CI / \ CI / \ CI / \ ~CI / \ Br / \ Br / \
-~-Br F H2NOC H2NH2C H2N02 Me02S 02N
/ \ Br / \ Br / \ Br / ~ OMe / \ OMe / \ OMe / \ OMe / \ OMe / \ / ~ \ / \ / \ / \
F CI Br OMe F
Me02 02N F H2N0 N H2NH2 / \ / \ / \ / \ / \ / \
F F F F F F

H2N02 Me02 02N F H2N0 N H2NH2C
/ \ / \ / \ / \ / \ / \ / \
CI CI CI CI CI CI CI
H2N02 Me02 02N F H2N0 N H2NH2 / \ / \ / \ / \ / \ / \ / \
Br Br Br Br Br Br Br / \ F / \ F / \ F / \ CI / \ CI / \ CI / \ Br F CI Br F CI Br F

/ \ Br / \ Br / \ OMe / \ OMe / \ OMe / \
CI Br F CI Br Me02 02N F H2N0 N H2NH2C
/ \ / \ / \ / \ / \ / \ N \

N \ \ N \ N \ N \ i \ r \
F \ CI \ Br \ V \ V \
F CI Br / \ / \ / \ / \ O / ..\ S / \ NH / \ NMe Me02 , H2N02 H2N0 \ / \ / \ N / \ NH \ / \ \ / \ \ / \
-N -N -N -N

H2NH2C N F 02N Me02 NC
\ / \ \ / \ \ / \ \ / \ / \ \ / \ /
NH -NH

\ / \ / \ / \ ./ ' \ / / \
-NH -NH -NH -NH -NH O

Me02S H2N02 H2N0 H2NH2C NC F
\ / \ / \ / \ / \ / \ /
O -O -O -O -O -O

\ / -O \ N -CN \ ~N \ N Me \ N OMe CI \ N Br \ ~ \ ~N \ ~N \ ~N \ ~N
CI Br NH O

F
Me02S I ~ ~ F Me02S I ~ ~ CI Me02 I ~ ~ Br Me02S I
~ CI ~ ~ Br Me02S I ~ ~ MeOzS I ~ ~ HzN02S I ~ ~ F H2N02S I ~ ~ CI
F ~ ~ CI ~ ~ Br H2N02 I ~ ~ Br H2N02S ~ ~ ~ H2N02 ~ ~ ~ H2N02S
w w w w w w w w F
02N ~ ~ ~ F 02 I ~ ~ CI 02N I ~ ~ Br 02N I
~ CI ~ ~ Br 02N ~ i i 02N ~ i i N ~ i i F N ~ i ~ CI
~ F ~ ~ CI ~ ~ Br N ~ i ~ gr N ~ i i N ~ ~ i N ~ i i F
H2NOC I ~ ~ F H2NOC I ~ ~ CI H2NOC I ~ ~ Br H2N0 I
w w CI ~ ~ Br w w w w H2N0 I ~ ~ H2N0 I ~ ~ H2NH2 I ~ ~ F H2NH2 I ~ ~ CI
~ F . ~ ~ CI ~ ~ Br H2NH2 I ~ ~ Br H2NH2 I ~ ~ H NH I ~ ~ H NH I

I ~ ~ F
HO ~ ~ F HO ~ ~ CI HO ~ ~ Br HO

~ CI ~ ~ Br H I ~ ~ H I ~ ~ Me0 I ~ ~ F Me0 I ~ ~
CI

~ F I ~ ~ CI I ~ ~ Br Me0 ~ ~ Br Me0 ~ ~ Me0 ~ ~ Me0 I ~ ~ F
H2N ~ ~ F H2N ~ ~ CI H2N ~ ~ Br H2N

I w w CI I w w Br I w w F I ~ ~ CI
H2 ~ ~ H2N ~ ~ Me02S ~ ~ F Me02 ~ ~ F
~ Br ~ ~ .F ~ ~ CI ~ ~ Br Me0 I ~ ~ F Me0 S I ~ ~ CI Me02S I ~ ~ CI Me02S I ~ ~ CI

w w F w w CI w w Br w w F
MeOzS I ~ ~ Br Me02 I ~ ~ Br Me02 I ~ ~ Br H2N02 I ~ ~ F
~ CI I w w Br , I w w F I ~ ~ CI
H2N02S ~ ~ F H2N02S ~ ~ F H2N02S ~ ~ CI H2NO2 i ~ CI
~ Br ~ ~ F ~ ~ CI ~ ~ Br H2N02 I ~ H2N02S I ~ ~ Br H2N02S I ~ HZN02S I ~ ~
~ CI ~ Br Br ~ F ~ ~ CI . I ~ ~ Br I ~ ~ F
02N I i i 02N I i i F 02N ~ ~ F 02N ~ ~ CI
F

I w w CI I w w Br I w w F I ~ ~ CI
02N ~ ~ CI 02N ~ ~ CI 02N ~ ~ Br 02N ~ ~ Br ~ F ~ ~ CI ~ ~ Br I
2N I ~ ~ Br N I , , F N , , F N ~ ~ F

I ~ ~ F I ~ ~ CI I ~ ~ Br I ~ ~ F
N ~ ~ CI N ~ ~ CI N ~ ~ CI N ~ ~ Br I ~ ~ CI I ~ ~ Br I ~ ~ F I ~ ~ CI
N ~ ~ Br N ~ ~ Br HZNO ~ ~ F H2N0 ~ ~ F
Br ~ ~ F ~ ~ CI ~ ~ Br H2NOC I ~ ~ F H2N0 I ~ ~ CI H2N0 I ~ ~ CI H2N0 I ~ ~ CI
F ~ ~ CI ~ ~ Br I ~ ~ F
H NOC I ~ ~ Br H NO I ~ ~ Br HzNO I ~ ~ Br HzNHz ~ ~ F
z z w w CI w w Br w w F w w CI
H2NHz I ~ ~ F H2NH2C I ~ ~ F H2NHz I ~ ~ CI H2NHz I ~ ~ CI
w w Br w w F w w CI w w Br H2NHz I ~ ~ CI H2NHz I ~ ~ Br H2NHz I ~ ~ Br HzNHz I ~ ~ Br w w F w w CI ~ ~ Br w w F
H2N I ~ ~ F HzN I ~ ~ F HzN I ~ ~ F H2N I i ~ CI
H H 'H 'H
~ CI ~ ~ Br ~ ~ F ~ ~ CI
H2N I ~ i CI H2N I ~ ~ CI H2N I i i Br H2N I ~ ~ gr H H H H
w w Br NHz NHz NHz I
H2N i i Br I i ~ I i i I i i ~ H F CI Br NHz NHz NHz NHz I I I I
F ~ ~ F ~ ~ F F ~ ~ CI F ~ ~ Br NH2 NHz NHz NHz .N ~ .N ~ .N ~ .N
I ~ ~ I ~ ~ I
F N v v H2N02S Me02S
NHz NHz NHz NHz ~ .N I ~ .N I ~ ..N I ~ .N
H NO I i i H2NHz i i HOz i i OzN i i z r \ N \ N \ N \ N \
~F \ CI \ Br \ F \ CI
'--(F F F CI CI
N \ N \ N \ - N \~
\ Br \ F \ CI '_ ( rBr CI Br Br '--(Br and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
The compounds listed in the following 53 tables are an embodiment of the present invention:

Table 1 wherein:
Rlb is selected from the group consisting of-H, -CH3 and -CF3.
Table 2 wherein:
Real and R~~ are independently selected from the group consisting of -H, -F, -Cl and -Br;

R~b is selected from the group consisting of-H, -CH3 and CF3; and R'°2 is selected from the group consisting of -H, -F, -Cl, -Br, -OH, -OCH3 and NH2.
Table 3 wherein:
Rlb is selected from the group consisting of-H, -CH3 and ~F3; and Rl°2 is selected from the group consisting of -H, -F, -Cl, -Br, -OH, -OCH3 and NH2.

Table 4 wherein:
Real and R~a2 are independently selected from the group consisting of -H, -F, -Cl and -Br;
Rlb is selected from the group consisting of -H, -CH3 and -CF3; and 5 R'°' is selected from the group consisting of -F, -Cl, -Br, -CN, -CHZNHZ, -CHzOH, -CONH2, -C(=NH)NH2, -C02H, -COZMe, -SOZMe, -SOZNHZ, -OH, -NH2, and -NO2.

Table 5 wherein:
Rla~ and R~~ are independently selected from the group consisting of -H, -F, -Cl and -Br;
Rlb is selected from the group consisting of-H, -CH3 and-CF3; and R1~3 is selected from the group consisting of -H, -F, -Cl, -Br, -OH, -OCH3 and NH2.

Table 6 wherein:
Rla~ and R~~ are independently selected from the group consisting of -H, -F, -Cl and -Br;
Rib is selected from the group consisting of -H, -CH3, -CF3, -CHZCH3, -CF2CF3, -CH2NH2, -CONH2, -S02CH3, -SOZNH2, NHZCOCH3 and NHZCOCF3;
R''1 is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, CONH2, -C(=NH)NH2, -COzH, -COZMe, -SOZMe,.-SOzNHz, -OH, -NHZ, and -NO2;
R~~z is selected from the group consisting of -H, -F, -Cl, -Br, -OH, -OCH3, and NH2;
and R'°3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2.

Table 7 wherein:
R' is selected from the group consisting of -H, NH2, -SOZNH2, -SOZCH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CHZNHZ, -CHZNH(CH3), -CH2N(CH3)z;
R'' is selected from the group consisting of -H, -NH2, -SOZNH2, -SOZCH3, -CN, -CONHZ, -CONH(CH3), -CON(CH3)2, -CHZNHz, -CHZNH(CH3), -CHZN(CH3)z;
Real and Ria2 are independently selected from the group consisting of -H, -F, -Cl and -Br;
Rlb is selected from the group consisting of -H, -CH3, -CF3, -CHZCH3, -CFZCF3, -CH2NH2, -CONH2, -SOzCH3, -SOZNH2, NHZCOCH3 and NH2COCF3;
R~'~ is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONHZ, -C(=NH)NH2, -COzH, -COZMe, -SOZMe, -SOzNH2, -OH, -NH2, and -NOZ;
R~~z is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2; and R'°3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NHZ.

Table 8 R'°, wherein:
R' is selected from the group consisting of -SOZNH2, -SOZCH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CHzNH2, -CHzNH(CH3), -CHZN(CH3)2;
Rib is selected from the group consisting of -H, -CH3 and -CF3;
R'°1 is selected from the group consisting of -H, -F, -CI, -Br, -CN, -CHZNH2, -CHZOH, -CONH2, -C( NH)NH2, -COZH, -COZMe, -SOzMe, -SOZNH2, -OH, -NHZ, and -NO2;
R~'Z is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2; and Rl°3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NHZ.

Table 9 R", wherein:
A is selected from the group consisting of:
R~' M Et M E E M a ,J- ~N- \N- ~ N- N- CN- ~N- CN- C .N-H H H M ~ Me Et ~/~
a a Me~N- CN- N- CN- CN- N- M~t'~' M N- N- N- D~N- H~N- Me-~N-N ~ H M

Rla~ and R~az are independently selected from the group consisting of -H, -F, -C1 and -Br;
Rlb is selected from the group consisting of -H, -CH3, -CF3, -CHZCH3, -CFZCF3, -CHZNH2, -CONH2, -SOZCH3, -SOZNH2, NHzCOCH3 and NHZCOCF3;
Rl~~ is selected from the group consisting of-H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONHZ, -C(=NH)NH2, -COzH, -COZMe, -SOZMe, -SOZNH2, -OH, -NHZ, and -NOz;
R''2 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NHz; and R'°3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2.
Table 10 wherein:
A-Q is selected from the group consisting of:

C~ C~- C~- C~- C~- C~ C'~-- C~- C~-N ; NH N N
Me Et Me Et Me Me Me Me a C~-- C~- C'~--N- C'~-~- C~-~. C~-~ C~
H N
Me Me Me Me Me Me Hz Me ~~N- ~ ~ N- N- N- ~~--N-C- ~~N-C2 NH ~ O S H \
Me Me H H HZ I~ Hz ~~N~ C? C'~~CZ ~-N CZ ~~~CZ ~'~~C- ~-N-C-O S NH
Me N\\ z /~1 ~~N-C? H~N- Me-~N- M ~N- Hfy fJ- Me-~ -Me HOC- HzC C O _ HZN MezN Me3N Men ~ M83~ N \N N
Me M
OZNHz O2NHz OzMe OZMe ONHz ONHz CHZNHz HZNHz i i i i i i i i N- NN- N- N - NN- NN- NN- NN-M M Me M
N~N- NYN- NYN ,- .
~IM(e CONHz CHZNHz R~a~ and R~az are independently selected from the group consisting of -H, -F, -Cl and -Br;
Rlb is selected from the group consisting of -H, ~H3, -CF3, -CHZCH3, -CFZCF3, -CH2NH2, -CONHz, -SOZCH3, -SOZNH2, NHZCOCH3 and NHZCOCF3;
Rl°1 is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONH2, -C(=NH)NHz, -COZH, -COZMe, -SOZMe, -SOZNHz, -OH, -NH2, and -N02;
Rnz is selected from the group consisting of-H, -F; -Cl, -Br, -OH, -OCH3, and NH2; and Rl°3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NHZ.

Table 11 R,°, wherein:
R' is selected from the group consisting of -SOZNH2, -SOzCH3, ~N, -CONHZ, -CONH(CH3), -CON(CH3)2, -CHZNH2, -CHZNH(CH3), -CHZN(CH3)z;
R'b is selected from the group consisting of-H, -CH3 and ~F3;
R'a' and R'a2 are independently selected from the group consisting of -H, -F, -Cl and -Br;
R''' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONHZ, -C(=NH)NH2, -COZH, -COZMe, -S02Me, -SOZNHZ, -OH, -NH2, and -NOZ;
R'°2 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2;
to R'°3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NHz; and G is selected from the group consisting of R,b, Rlb2 R,D3 I
wherein:
R'b' is selected from the group consisting of-H, -CH3 and-CF3;
R'bz is selected from the group consisting of-H, -CH3 and-CF3; and Table 12 ,a, ,cH ,e, H ~ ~ N G A ~ ~ ~ H G
R~~ / R,c, R,a2 / R'°' R,cs ~ / R,ca ~ /
R,cz Rxz R"
R~' Rtb3 is selected from the group consisting of-Cl, -NHz, -CH3 and-CF3.
wherein:
A is selected from the group consisting of Me M
I-l M~ EL\ M~ Et Et~
N- N- N- N- \N- N- C N- ~ N- Ct~1-- N-H H H Me Me Et Me Me M N- N- N- N- N- ~~ Me~f~h-M N- N-- ~ O~N= H~N- Me-~t~
_ _ O _ H N MAN' R'b is selected from the group consisting of-H, -CH3 and -CF3;
R'a' and R'~ are independently selected from the group consisting of-H, -F, -Cl and-Br;
R''' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHzNH2, -CHZOH, -CONH2, -C(=NH)NH2, -COZH, -COZMe, -SOZMe, -SOZNH2, -OH, -NH2, and -NO2;
5 R'°Z is selected from the group consisting of-H, -F, -CI, -Br, -OH, -OCH3, and NH2;
R'°3 is selected from the group consisting of-H, -F, -CI, -Br, -OH, -OCH3, and NHZ; and G is selected from the group consisting of:
R~ei Rmz Rtb3 ~N ~ N \N
wherein:
R'b' is selected from the group consisting of=H, -CH3 and-CF3;
10 Riba is selected from the group consisting of-H, -CH3 and -CF3; and R'b3 is selected from the group consisting of-Cl, -NHZ, -CH3 and -CF3.
Table 13 wherein:
A-Q is selected from the group consisting of C~-- C~ C~ C'~ C~ .C~- C~-- C~-- C
Me Et Me Et ~~Na O S H ~ S
Me Me N Me Me Me a Me N Me N- N-C ~~N-Cz NH ~ O S H rN
Me Me Me Me H HZ ~ ~
~~N-CZ H~N- Me-~N- ~N- H~ Me-fy N-S' M ~/ ~/e Me M8 H H~C H~C HiC N- ~O- N- N- N-HZN MezN Me3N Me3 Me3C ~N ~N
Me M
OZNHp OpNH2 OpMe OZMe ONHy NHZ CHzNHZ HZNH2 i i i i i i i i N- N- N-N N N N~ ~~ N ~ N-M M M M
NY N- N,\ 'N- NY N- N~
IY
Me CONHz CHZNHZ
Rib is selected from the group consisting of-H, -CH3 and -CF3;
Rla~ and R~a2 are independently selected from the group consisting of -H, -F, -Cl and -Br;
R~~~ is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONHZ, -C(=NH)NH2, -COZH, -COZMe, -SOzMe, -S02NH2, -OH, -NH2, and -NOZ;
R~~z is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2;
R'°3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2; and G is selected from the group consisting of R7Dt Rlb2 R7b3 ~N ~ N \N
wherein:
R'b' is selected from the group consisting of-H, -CH3 and ~F3;
R'b2 is selected from the group consisting of-H, -CH3 and-CF3; and R'b3 is selected from the group consisting of -Cl, -NHZ, -CH3 and -CF3.
Table 14 R~'~
R~'~ R"~
wherein:

R' is selected from the group consisting of -SOzNH2, -SOzCH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CHzNH2, -CHZNH(CH3), -CHZN(CH3)2;
Rib is selected from the group consisting of -H, -CH3, -CF3;
Rl°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONH2, -C(=NH)NH2, -COZH, -COZMe, -SOzMe, -SOZNH2, -OH, -NH2, and -NO2;
R~~Z is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2; and R'°3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2.

Table 15 R,~, R,c.
Roc.
wherein:

SO
A is selected from the group consisting of:
Me I-' Me Et\ M E' Et\
N- \N- N- ~ /N- N- CN- ~N- CN- N-H H ~ M~ M6 Et~
Me Me M N- N- N- N- N- ~~ Me-( ,N-M N- Q ,N- ~(.~ Oz~N- H~N- Me-N~N-N- - - OZ N- Hn 'N- M~ ~N-Rib is selected from the group consisting of-H, -CH3 and -CF3;
R~~l is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONH2, -C(=NH)NHz, -COZH, -COZMe, -SOZMe, -SOZNHz, -OH, -NH2, and -NO2;
R''2 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2; and R~~3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2.

Table 16 R" R~' wherein:
A-Q is selected from the group consisting of C'~- C~-- C~-- C~- C~- C~- C~- C~.- C~-N N O NH N N
H
Me Et Me Et Me ~y Me Me Me Me N- N- N-O S
Me Me N 8 Me Me a M8 H Me C~--~ C ~~r C~-~ C~-~ ~r NH ~ O S
Me Me CN Me Hz ~~~e Hz ~ H ~ H Me Hz ~ \ M8 Hz ~ ~~~ Cz .~N-C- ~N-C- N-C- ~--N-C- ~--~C-O
Me Me Hz /~/
~~N-C? H~N- Me-K N- M ~N- HIy ,N- Me-~ -a Hz HzC- HzC- HzC- O- i i i N- , , , ~ N- NN- N-HpN /MezN Me3N Me3C Me M M
OZNHz OZNHz OzMe OZMe ONHz CONHz HzNHz CHzNHz i i\ i i\ i i\ i i\
N N- ~N- ~N- N N- N N- /N- /N- N N-M N N M M N N M
NYN- NYN- N'\ N
Me CONHz ~ZNHz Rlb is selected from the group consisting of -H, -CH3 and -CF3;
R''' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHzOH, -CONH2, -C(=NH)NH2, -COzH, -COZMe, -SOZMe, -SOZNHZ, -OH, -NH2, and -NOZ;
R~~2 is selected from the group consisting of-H, -F,'=CI, -Br, -OH, -OCH3, and NH2; and R''3 is selected from the group consisting of-H, -F, -CI, -Br, -OH, -OCH3, and NHZ.

Table 17 t fat Rte Rf fat Rtb Rt R1b \N I ~ ~ / I \N I ~ ~ ~ ' \N
N ~ N N
Rf~ O / Rlcf O / Rmf O / Rlc1 \ ~ \ ~ \
Rtes ~ / Rtc3 ~ / Rtc3 ~ /
Rlcz Rtcz Rlc2 O O
1 Rla1 1b f tat tb f 1b R R R
I ~ \ I I \N I ~ \ / I \N I ~ ~ ~ I \N
N N \~ N N
Rte Rlct Rlc1 Rlct O \ ~ O \ . ~ O
Rica ~ / Rlc9 / _ Rlc3 ~ /
Rx2 Rtc2 Rlc2 t Rta1 1b 1 1a1 1b f tb R R R
I ~ \ I I \N I ~ \ ~ I \N I ~ ~ ~ I \N
f~ N N~ N ~f~
Rfaz O / Rtc1 O / Rict O / Rlcf \ ~ \ ~ \
Rlc3 ~ / Rtc7 ~ / Rtn9 ~ /
Rtc2 Rtn2 Rlcz Rt Rlaf 1b t 1a1 1b f 1b / R / R / R
I ~ I \ I ~ I \ I
I ~N \ N rj N ~ N t~N
Rf~ O / Rtct O / Rtct O / Rtnt \ \ ~ \
Rlcs / Rtca ~ / Rlns ~ /
Rlc2 Rlc2 Rlcz 1 Rla1 1b , 1 1a1 1b f t6 R / R
I ~ \ I ~ I \N I ~' \ ~' ~ I \N I \ ~ ~~ ~ \N
N ~ N
Rf~ O / Rtci O / Rtnt O / Rtct \ \ ~ \
Rtc9 / Rtc~ ~ / Rlc9 ~ /
Rtc2 Rtc2 Rto2 Table 17 (continued) R"' R"' wherein:
Rl is selected from the group consisting of -SOZNH2, -SOZCH3, ~N, -CONH2, -CONH(CH3), -CON(CH3)z, -CHZNH2, -CHZNH(CH3), -CHzN(CH3)2;
R~a~ and Rl~ are independently selected from the group consisting of-H, -F, -Cl and Br;
Rlb is selected from the group consisting of-H, -CH3 and -CF3;
Rm is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONHz, -C(=NH)NHZ, -COZH, -COZMe, -SOzMe, -SOZNHz, -OH, -NHz, and -N02;
Rl°2 is selected from the group consisting of-H, -F, -CI, -Br, -OH, -OCH3, and NHz; and l0 R'°3 is selected from the group consisting of-H, -F, -CI, -Br, -OH, -OCH3, and NH2.

Table 18 NH tat Rtn N CH Rtat Rtt Rtt A ~ I I iN A I ~ I I ~N A~~ I iN
N N \~ N \N
Rte O / Rtct O / Rin O / Rmt Rt'7 / Rtns ~ / Rtca ~ /
Rtc2 Rt'2 Rtcz Rtat Rte /CH3 tet tb Rte NH _ N _ A ~ I I iN A I ~ I I iN A ~ I iN
~N N ,N N ,N
Rte O / Rtct O / Rtct O / Rtct Rtc3 ~ / Rtcs ~ / Rtc7 /
Rtc2 Rtc2 Rtn2 Rt.t tn /CH3 tat Rtn Rtn H _ H~ _ A ~ I I N N A ~ N I NON . A~~ I t~N
Rte O / Rtnt O / Rtct O / Rtct Rtc9 ~ / Rtc7 ~ / Rt'3 ~ /
Rtnz Rtc2 Rt'2 Rtet Rtn CH tat Rtn Rtn H / i a / O /
A ~ I I ~N A ~ l I ~N A~~ I ~N
\I~ N \~j N \N' Rte O / Rtct O / Rtct O / Rtct Rtc~ ~ / RtcJ ~ / Rtn3 ( /
Rtcz Rtc2 Rtc2 Rtat Rtc CH3 tot Rtb Rtc NH _ A ~ I I .iN A ~ I. I ~N . , A~~ I ~N
\N N \~ N \~
Rt'z O / Rtct O / Rtat O / Rtct Rtc3 ~ / Rtc3 ~ / Rtc3 ~ /
Rtc2 Rt'2 Ri'2 Table 18 (continued) wherein:
A is selected from the group consisting of:
Me I-l Mg E' Me E' Et~ M
N- \N- N- /\N- /N- J.f- CN- ~N- CN- N-H H H M6 MA Et Me ' Me M N- N- N- N- N- ~~ M~N-M N- ~N- ~N- O~N- H~N- Me-I ~N-N- N- N- H ~N- Me~ ~N-R'a' and R'~ are independently selected from the group consisting of-H, -F, -Cl and Br;
R'b is selected from the group consisting of-H, -CH3 and -CF3;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNHz, -CHZOH, -CONH2, -C( NH)NH2, -COZH, -COZMe, -SOZMe, -SOZNHZ, -OH, -NH2, and -NO2;
R'~2 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2; and R'~3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NHZ.

Table 19 tat Rte Rtat Rto Rte A ~ / I /N A Q ~ ~ I ~N A Q I /N
N N ~~ N ~N
Rte O / Rut O / Rut ~ / Rut Rus ~ / Rica ~ / Ru3 ~ /
Ru2 Ruz Rtcz Rtat Rtb tat tb Rtt A_Q ~ ~ I NiN A_ ~ N I NiN A-~~ I I~N
Rte O / Rut ~ / Rut ~ / Rut Ru7 / Ru3 ~ / Ru7 ~ /
Rtc2 Rtc2 Rtc2 Riai Ric tat Rtn Rte A_Q - I ~N A-Q - I ~N A_Q~~ I ~N
N
Rta2 O / Rut p / Rut O / Rut Ric9 ~ / Ru9 ~ / Rtc9 ~ /
Rtc2 , Ricz Ru2 Rtat / Rtc tat / tb / Rtn A-Q ~ ~ I ~N A-Q ~ l I ~N A-Q~~ I ~N
~~j N ~I~ N ~t~
Rte O / Rut O / Rtct O / Rut Ru3 ~ / Ru3 / Rica ~ /
Rice Ruz Ru2 Rtat / Rtt tat Rie Rin A a ~ / ~ I ~N A \ / ~ I ~N A ~ ~ I ~N
N N t~ N W f~
Rte O / Rut O / Rui O / Rut Rtc3 ~ / Ru3 ~ / Ru3 ~ /
Ru2 Ru2 Ru2 Table 19 (continued) wherein:
A-Q is selected from the group consisting of C'~ C~- C~-- C~ C~ C~- C~-- C~-- C
N N NH N N
H \
Me Et Me Et C:~ C~ ~ C~~ C~-~ C~~ C
H \
Me Me Me Me Me Me Me H N Me - N- N- N- ~ ~~N-C? ~~N-Cz NH t'l S H rN
Me Mg Me H Me H Me H Me H Me Hz ~~ Hz C~N-CZ C~-N-Cz ~N-C2 ~~-- N-CZ ~~N-C- ~ ~ N-C-Me z //~~
~~NB C? H~N- Me-~N- M ~- HIy tJ- Me-~ -Me Mg H2~ ~ HiC- HiC- HiC- C N- ~- N- N- i N-HZN MezN Me3N Me3 Me3 ~N ~N ~N
Me M
O2NHz pzNHz OZMe OZMe ONHz ONHz CHZNHz HZNHz i i i i i i i i N- ANN- ~ N- NN- N- ANN- C~N- NN-M M M M
NY N- N'' ,N- NY N- N
Me CONHz CHZNHz Rla~ and R~az are independently selected from the group consisting of-H, -F, -Cl and Br;
Rib is selected from the group consisting of -H, -CH3 and -CF3;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNHz, -CHZOH, -CONHz, -C(--NH)NHz, -COZH, -COZMe, -SOZMe, -SOzNHz, -OH, -NHz, and -NOz;
Rl~z is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NHz; and Rl'3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NHz.

Table 20 wherein:
R' is selected from the group consisting of -SOZNHz, -SOZCH3, ~N, -CONHz, -CONH(CH3), -CON(CH3)z, -CHzNHz, -CHzNH(CH3), -CHzN(CH3)z;
5 Real and R~~ are independently selected from the group consisting of -H, -F, -Cl and -Br;
R''1 is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHzNHz, -CHZOH, -CONHz, -C(=NH)NHz, -COZH, -COZMe, -SOZMe, -SOzNHz, -OH, -NHz, and -NOz;
RI°z is selected from the group consisting of -H, -F, -Cl, -Br, and -OCH3;
Ru3 is selected from the group consisting of -H,~ -F, -Cl, -Br, -OH, -OCH3, NHz, 10 CONHz, -CHZNHz, -CHZNHCH3, -CHZN(CH3)z, -C(=NH)NHz; and G is selected from the group consisting of Ribt Rtb2 Rib3 ~N ~ \N NN .
wherein:
R~b~ is selected from the group consisting of-H, -CH3 and-CF3;
R~bz is selected from the group consisting ofj H, -CH3 and -CF3;
15 R~b3 is selected from the group consisting of-Cl, =NHz, -CH3 and-CF3.

Table 21 wherein:
Rl is selected from the group consisting of -SOZNHz, -SOZCH3, -CN, -CONHz, -CONH(CH3), -CON(CH3)z, -CHzNHz, -CHzNH(CH3), -CHzN(CH3)z;
R'a' and R'~ are independently selected from the group consisting of -H, -F, -Cl and -Br;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHzNHz, -CHZOH, -CONHz, -C(=NH)NHz, -COZH, -COZMe, -SOZMe, -SOZNHz, -OH, -NHz, and -NOz;
R'~z is selected from the group consisting of -CHz-, -O-, -NH-, -N(CH3)-, -CHzCHz-, -O-CHz-, -NH-CHz-, and -N(CH3)-CHz-;
R'~3 is selected from the group consisting of-CHz-, -O-, -NH-, -N(CH3)-, and -CH(NHz)-and G is selected from the group consisting of Rlb1 Rtb1 Rlb2 R1D3 ~N N \N ~~N ~N NN ~ ~ ~ ~ \N
wherein:
R'b' is selected from the group consisting of-H, -CH3 and-CF3;
R'bz is selected from the group consisting of-H, -CH3 and-CF3; and R~b3 is selected from the group consisting of-Cl, -NHz, -CH3 and -CF3.
Table 22 wherein:
R' is selected from the group consisting of -SOZNHz, -SOzCH3, -CN, -CONHz, -CONH(CH3), -CON(CH3)z, -CHzNHz, -CHzNH(CH3), -CHZN(CH3)z;
Real and Rl~z are independently selected from the group consisting of -H, -F, -Cl and -Br;
R~~~ is selected from the group consisting of-H, -F, -Cl, -Br, -CN, -CHZNHz, -CH20H, -CONHz, -C(=NH)NHz, -COZH, -COZMe, -SOZMe, -SOZNHz, -OH, -NHz, and -NOz;
Rl'z is selected from the group consisting of -H, -F, -Cl, -Br, and -OCH3;
Rl°3 is selected from the group consisting of -H, -F, -Cl, -Br, -OH, -OCH3, NHz, -CONHz, -CHZNHz, -CHzNHCH3, -CHZN(CH3)z, -C(=NH)NHz; and G is selected from the group consisting of R~e~ Rie~ Rit\z Rica NiN ' \N N ' \N N ~ ~ ~N
wherein:

R~b~ is selected from the group consisting of-H, -CH3 and ~F3;
R~bz is selected from the group consisting of-H, -CH3 and ~F3; and R~b3 is selected from the group consisting of ~1, -NH2, -CH3 and ~F3.
Table 23 wherein:
R'°' R' is selected from the group consisting of -SOZNH2, -SOZCH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CHZNH2, -CHZNH(CH3), -CH2N(CH3)2;
R~a~ and R~~ are independently selected from the group consisting of -H, -F, -Cl and -Br;

R'°I is selected from the group consisting of -H, -F, -C1, -Br, -CN, -CHZNH2, -CHZOH, -CONHz, -C(=NH)NHz, -COZH, -COZMe, -SOZMe, -SOZNH2, -OH, -NH2, and -NO2;
R'~2 and R'°3 are independently selected from the group consisting of-H, -F, -Cl, -Br, and -OCH3; and G is selected from the group consisting of Rlb1 Rlb1 Rlb2 Rlb3 N ~N N ~N ~~N ~N N ~ ~ N
wherein:
Ribs is selected from the group consisting of -H, -CH3 and -CF3;
R~b2 is selected from the group consisting of-H, -CH3 and -CF3; and R~b3 is selected from the group consisting of-Cl, -NHZ, -CH3 and-CF3.
Table 24 R~'~
R"' wherein:

R' is selected from the group consisting of -SOZNH2, -SOZCH3, -CN, -CONHz, -CONH(CH3), -CON(CH3)2, -CHZNH2, -CH2NH(CH3), -CHZN(CH3)2;
Real and R~~ are independently selected from the group consisting of -H, -F, -Cl and -Br;
R''1 is selected from the group consisting of-H, -F, -Cl, -Br, -CN, -CHZNH2, -CH20H, -5 CONHZ, -C(=NH)NH2, -COZH, -COZMe, -SOZMe, -SOZNH2, -OH, -NH2, and -NOZ;
Rl'2 is selected from the group consisting of-CH-, and N-;
R''3 is selected from the group consisting of NH-, and -0-; and G is selected from the group consisting of R~e~ Riei R~e2 Rlb3 N \N ~ ~~N ~N N ~ ~ ,N
N
wherein:
10 R~b~ is selected from the group consisting of-H, -CH3 and-CF3;
Rib2 is selected from the group consisting of -H, -CH3 and -CF3; and R~b3 is selected from the group consisting of -Cl, -NHz, -CH3 and -CF3.

Table 25 Rm wherein:
R' is selected from the group consisting of -SOZNH2, -S02CH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CHZNH2, -CH2NH(CH3), -CHZN(CH3)z;
R'a' and R'~ are independently selected from the group consisting of -H, -F, -Cl and -Br;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNHz, -CHZOH, -CONH2, -C(=NH)NH2, -COZH, -COZMe, -SOZMe, -SOZNH2, -OH, -NHz, and -NOZ;
R'°2 is selected from the group consisting of-CHZ-, -O- and NH-;
R'°3 is selected from the group consisting of-CH-, -C(NHZ)- and N-; and G is selected from the group consisting of R~ei Riot Rie2 R~ea N
wherein:

R'b' is selected from the group consisting of-H, -CH3 and-CF3;
R'b2 is selected from the group consisting of -H, -CH3 and -CF3; and R'b3 is selected from the group consisting of ~1, -NH2, -CH3 and -CF3.
Table 26 Rtc7 plat ~ ~R'ct ola2 ~ ~R'ct R"
NH O O O
A~~H G 4~~H G
R1C / Rtct Rlc9 \ ~ Ric9 Rxz R'c2 wherein:
A is selected from the group consisting of Me M
M E M E E
N- ~N- ~N- N- ~N- ~N- CN- ~N- CN- N-H H H Me Me Et a M N- N- N- N- N- Me~N-M N- N- ~N- OZ~N- H~N- Me-~N-O - ~N- OTi \N- H N- M N-Real and R~~ are independently selected from the group consisting of -H, -F, -C1 and -Br;
Rl°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONH2, -C(=NH)NHZ, -COZH, -COZMe, -SOZMe, -SOZNH2, -OH, -NH2, and -NO2;
R'°2 is selected from the group consisting of -H, -F, -Cl, -Br, and -OCH3;
Rl°3 is selected from the group consisting of -H, -F, -Cl, -Br, -OH, -OCH3, NH2, -CONH2, -CHZNH2, -CHZNHCH3, -CHZN(CH3)2, -C( NH)NH2; and G is selected from the group consisting of Rlb1 R,b, Rlb2 R,b3 N \N ~ ~~N ~N N ~ ~ \N
N
wherein:
Ribs is selected from the group consisting of -H, -CH3 and -CF3;
Rlb2 is selected from the group consisting of-H, -CH3 and-CF3; and R'b3 is selected from the group consisting of -Cl, -NH2, -CH3 and -CF3.
Table 27 R,e, ,., q- ~ ~ N G q- ~ N N G q-~~H O G
R,az R,c, Rm' R,c, R,c3 ~ R,c3 ~ R,c3 Rmz R,cz R,c2 wherein:
A-Q is selected from the group consisting of:

C~ C~ C~ Co~- C~ C~ C~- C~-- C~-H
Me Et MB Et C~ C~ ~ C~NB C~~ C~~N~ C~~N
H \
Me Me N 8 Me ~ a a H Me CAN- C,~-r C~~- C '~~- ~r NH ~ S
Me H ~e H Me H Me Hz M8 Hz ~ Hz C~N-Cz C~~N-Cz CJ N_Cz ~~N-C- ~~N-C- , N-C-O
Me z ~~---N8 C? H~N- Me-~N- M~~N- H~ Me-Me Me Hz ~ - HOC- HOC- HiC- HN- O- ~ N / N- N-HZN MezN Me3N Me3C Me3 Me M
OzNHz SOZNHz OzMe OZMB ONHz NHz CHzNHz HzNHz i i i i i i i i N- ' N- N- N- N- N- N- N-N ~ ~ ~N ~N ~ ~N ~N
M M M M
NYN- NYN- NYN-Me CONHz CH2NHz R'a' and R~a2 are independently selected from the group consisting of -H, -F, -C1 and -Br;
Rt~l is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONH2, -C( NH)NH2, -COZH, -COzMe, -SOZMe, -SOZNH2, -OH, -NH2, and -NO2;
Rt~2 is selected from the group consisting of-H, -F, -Cl, -Br, and -OCH3;
Rl°3 is selected from the group consisting of -H, -F, ~-Cl, -Br, -OH, -OCH3, NH2, -CONH2, -CHZNH2, -CHZNHCH3, -CHZN(CH3)2, -C(=NH)NH2; and G is selected from the group consisting of Rlb1 Rtb7 Rtb2 Rlb7 I
N N N \N ~~N ~~tJ ~ ~ \N
wherein:
R~b~ is selected from the group consisting of -H, -CH3 and -CF3;
R~b2 is selected from the group consisting of-H, -CH3 and-CF3; and R~b3 is selected from the group consisting of-Cl, -NH2, -CH3 and-CF3.
Table 28 R1c Riai FH Rin Riai A NH I ~ N O G A ~ I ~ N O G A O I ~ N O G
N H N H N H
Rx1 / Rmt / Rtc1 Rlu7 ~ Rtc9 \ Rlc9 R~rz Rm Rtc2 wherein:

A is selected from the group consisting of Me M
M~ Et\ Me E< Et~ /~
N- N- N- /\N- N- /N- C N- ~ N- CN- C N-H ~ ~ M6 M~ E ~/t Me M N- N- N- N- ( ,N-- Me--( .N-M N- N- ~N- O~ H~N- Me-t ~N-N- N- N- O N- H N- Me~ -Rlai and R~~z are independently selected from the group consisting of -H, -F, -Cl and -Br;
R~~~ is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNHz, -CH20H, -CONHz, -C(=NH)NHz, -COzH, -COZMe, -SOZMe, -SOZNHz, -OH, -NHz, and -NOz;
Rl'z is selected from the group consisting of-H, -F, -Cl, -Br, and -OCH3;
Rl'3 is selected from the group consisting of -H, -F, -Cl, -Br, -OH, -OCH3, NHz, -CONHz, -CHzNHz, -CHZNHCH3, -CHzN(CH3)z, -C(-NH)NHz;
G is selected from the group consisting of Rm Rie~ R~bz Rata ~N ~ ~~N ~N N
i ~ ' \ i \ ~N
wherein:
Rlb1 is selected from the group consisting of-H, -CH3 and-CF3;
Rtbz is selected from the group consisting of-H, -CH3 and -CF3; and Rtb3 is selected from the group consisting of-Cl, -NHz, -CH3 and-CF3.

Table 29 ,., ,a, o ~H G
G A-~ I ~ N G
-N N
R,a2 R,c, Rx, Rm, R,c3~~ R,c~~ R,c7 R,c2 R,c2 R,c2 wherein:
A-Q is selected from the group consisting of:

C~ C~- C'~-- C~ C~- C~- C '~- C'~- C'~--N N O NH N N
H
Me Et Me Et Me Me Me Me C;~ C;~- ~- C~--t~ C'~-t~- C~t~ C~~- CSC
Me Me N a Me Me Me Me H Me N- ~ ~~~ ~ N-- ~~N- ~N- C~-N-C2 CN~---N-C2 NH ~ O S H t Me Me C~~~2 C~-N8 ~Z C'~ ~2 C~~Na ~2 C' Me N'\ Me Hz /~1 ~~N-C? H~N- Me-~N- ~ Hty ,N- Me-~ -S/ ~ M ~/e Me M8 Hz n HzC- HzC- HpC- HN-HZN MezN Me3N Me3C Me3 ~ _N ~ ~N ~ ~N ~
Me M
ozNHz S02NHz OZMe 02Me CONHz ONHz HZNHz CHZNHz i i i i i i i i N- ' N- _ N- N- N- N- N- N-N N N ~N ~N ~N ~N ~N
M M M M
NY N- NYN- NYN-Me CONHz CHzNHz R'a' and Rl~ are independently selected from the group consisting of -H, -F, -Cl and -Br;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONH2, -C(=NH)NHz, -COZH, -COZMe, -SOZMe, -SOzNHz, -OH, -NH2, and -NO2;
R'°z is selected from the group consisting of -CHZ-, -O-, -NH-, -N(CH3)-, -CHZCHZ-, -O-CHZ-, -NH-CH2-, and -N(CH3)-CHZ-;
R'°3 is selected from the group consisting of -CHZ-, -O-, -NH-, -N(CH3)-, and -CH(NHZ)-and G is selected from the group consisting of Rie~ R~ci R~e2 Rtb3 I ~N ~ ~~N ~~N I ~ I \N
N
wherein:
R'b' is selected from the group consisting of-H, -CH3 and-CF3;
R'b2 is selected from the group consisting of -H, -CH3 and -CF3; and R'b3 is selected from the group consisting of-Cl, -NHz, -CH3 and -CF3.

Table 30 A N~~H G A~~H O G
N/ Rtc Rtct N/ Rtct Rms \ ~ Rtc3 \
Rtcz Rtcz A N~~H G A~~H O G
Rtnt Rtnt Rtc~ \ \~ Rtc9 \ ' Rtcz Rtcz wherein:

A is selected from the group consisting of:
Me It M~ Et M~ Ef\ Et\ M
N- f~ \N- /N- N- N- CN- ~N- CN- N-H ~ H M8 M~ Et~
Me Me M N- N- N- N- N- ' ,N"- M~N-M N- N- ~tf- Oz~N- H~N- Me-N~N-N- N- O N- H'j N- MAN. \N
Rla' and R~a2 are independently selected from the group consisting of -H, -F, -Cl and -Br;
Rl°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNHZ, -CH20H, -CONH2, -C(=NH)NH2, -C02H, -COzMe, -SOZMe, -SOZNHz, -OH, -NH2, and -NOz;
R~~Z is selected from the group consisting of -H, -F, -Cl, -Br, and -OCH3;
R~~3 is selected from the group consisting of -H, -F, -Cl, -Br, -OH, -OCH3, NHz, -CONH2, -CHzNH2, -CHZNHCH3, -CHZN(CH3)2, -C(=NH)NH2, -C(=NH)NH(CH3), -C(=NH)NH(CH3)z; and G is selected from the group consisting of R~ei Rm Ricz Rtb3 i i \ ~N
I tJ N ~ ~~N ~N N I I
wherein:
R~bl is selected from the group consisting of -H, -CH3 and -CF3;
R~b2 is selected from the group consisting of -H, -CH3 and -CF3; and R~63 is selected from the group consisting of ~l, -NHZ, -CH3 and -CF3.
Table 31 4-~~H G
N
Rtct N~
Rica \
R~cz n- / H o G
N
Rice Rtc3 \
Rlc2 wherein:
A-Q is selected from the group consisting of C~ C~- C~- C~-- C~ C~- C~- C~ C
O NH N N
Me Et Me Et MN- N- MN- N-H \
Me Me MQ Me Me Me Me Me ~ \~N- ~~N- ~~N- ~N- CH~N-Cz CH~N-Cz /~.N
Me Me ~~Me Hz ~~~e Hz ~ Hz ,-NH Me Hz ~ Me Hz ~ \~~ Hz C- ~ ~N C- ~ N-C- ~~N-C- ~N-C- N-C-O
Me Me Hz ~
~~N-CZ H~N- Me-~N- ~~N- Hty N- Me S M / ~/ ~/e Me Hz~ _ HiC- H~IC- HiC- H/N- O- ~ N / N- ~ -N-HZN MezN Me3N Me3C Me3C ~N ~N
Me M
OZNHz S02NHz OZMe OZMe ONHz CONHz CHzNHz CHzNHz i i i i i i i i N- N- NN- N- NN- NN- NN- N-M M M M
NYN- NYN- NYN-Me CONHz CHzNHz R~a~ and RIa2 are independently selected from the group consisting of-H, -F, -Cl and -Br;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNHZ, -CH20H, -CONH2, -C(=NH)NHZ, -COzH, -COZMe, -SOZMe, -SOZNHZ, -OH, -NHZ, and -NO2;
R'°Z is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NH2;
R~~3 is selected from the group consisting of-H, -F, -Cl, -Br, -OH, -OCH3, and NHZ; and G is selected from the group consisting of R'e' R'n' R'tz R'es N \N ~ ~~N ~~N ~ ~ \N
wherein:
R'b' is selected from the group consisting of-H, -CH3 and -CF3;
R'bz is selected from the group consisting of-H, -CH3 and -CF3; and R'b3 is selected from the group consisting of-Cl, -NHZ, -CH3 and-CF3.
wherein:
Table 32 R'°' R'°' A is selected from the group consisting of M a M9 Et\ M E Et N- \N- /N- ~ ~N- \N- CN- ~N- N- N-H H H M ~ Me Et a Me M N- N- N- N- ' .N- M~N-M N- Q N- ~N- ~N- H~N- Me-~N-N ~ M N
R~a~ and Rl~ are independently selected from the group consisting of -H, -F, -Cl and -Br;
S R'°' is selected from the group consisting of-H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONH2, -C(=NH)NHz, -COZH, -COZMe, -SOZMe, -SOZNH2, -OH, -NHZ, and -NOz;
R~~z is selected from the group consisting of -H, -F, -Cl, -Br, and -OCH3; and G is selected from the group consisting of:
Rice R~t~ R~ez R7b3 N \N ~ ~~N ~N N ~ ~ \N
wherein:
10 Ribs is selected from the group consisting of-H, -CH3 and -CF3;
R~b2 is selected from the group consisting of-H, -CH3 and -CF3; and R~b3 is selected from the group consisting of-Cl, -NH2, -CH3 and -CF3.

wherein:
Table 33 R,°, R,c, Rx, A is selected from the group consisting of Me M
H Met Et\ M \ Et\ Et\ ~
N- N- N- - /N- - N- N- CN- ' 'N-/ / //
H H H Me Me Et /Me ~Me Me~N- CN- I .N- CN- CN- ~N- Me N-M JCN- O~N- ~N- Oz~N- HN~- Me-N~N-e~ ~~//M
N ~ _ ' \N- 0 ' \N HN' \N- Me~N~N

R'a' and R'~ are independently selected from the group consisting of -H, -F, -C1 and -Br;
R'~' is selected from the group consisting of-H, -F, -Cl, -Br, -CN, -CHzNH2, -CHZOH, -CONH2, -C(=NH)NHz, -COZH, -COZMe, -SOZMe, -SOZNH2, -OH, -NHZ, and -NO2;
R''2 is selected from the group consisting of-H, -F, -Cl, -Br, and -OCH3; and G is selected from the group consisting of Rlb1 Rlb1 Rtb2 Rlb3 NiN ~t~N ~fJiN ~ ~ \N
wherein:
R'b' is selected from the group consisting of-H, -CH3 and-CF3;
Ribz is selected from the group consisting of-H, -CH3 and-CF3; and Ribs is selected from the group consisting of-Cl, -NH2, -CH3 and-CF3.

Table 34 wherein:
R'°' A-Q is selected from the group consisting of C~ Ct~ C~-- C~-- C~- C~ C~-- C~- C '~
N N O NH N N
H
Me Et Me Et the i1e Me Me tyie C~ C~ ~ C , N- CAN- CAN- C~~ ~ ~N-H \
Me C~~ C ~~re C~Ne C;~~ ~-re C'~~~z C~--.~~z NH ~ S H N
Me Me Cu Me Hz ~ Me Hz ~~ Hz ~NH Me Hz ~ Me Hz ~ \~~ Hz ,, N-C- N-C- ~ N-C- ~N-C- ~N-C- N-C-N O
\Me 2 ~
~~Ne C? H~N- Me-~N- ~- HIy tJ- Me-Me Hz ~ ~ ~ _ H;C- H;C- H;C- ~N- '~O- 'N N- 'N N- yN-Me HzN MezN Me3N Me3C M8 tJM
OzNHz OzNHz OzMe OZMe ONHz CONHz CHzNHz CHZNHz i i i i i i i i N- N- N- N- N- N- N- N-N ~ ~ N N ~ N
M M M M
NY N- NY N- ~ N- N
Me CONHz ~zNHz R'a' and R'~ are independently selected from the group consisting of -H, -F, -Cl and -Br;
R''' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONH2, -C(=NH)NH2, -COZH, -COZMe, -SOZMe, -SOZNHz, -OH, -NH2, and -NOz;
R''2 is selected from the group consisting of -H, -F, -Cl, -Br, and -OCH3; and G is selected from the group consisting of R,c, R,e, R,cz R,e3 ~N ~ N
INN N~N I~N IN\\N ~N \~N I~N
wherein:
Ribs is selected from the group consisting of -H, -CH3 and -CF3;
R~b2 is selected from the group consisting of -H, -CH3 and -CF3; and Rlb3 is selected from the group consisting of-Cl, -NHz, -CH3 and-CF3.
Table 35 wherein:
R,°, A-Q is selected from the group consisting of C~ C~ C~- C~- C~-- C~- C~-- C~ C~--Me \ \ \
Et Me Et IN- CN MN- C~MN- C~MN- ~N
H \ S
Me Me 8 /~N\\ Me ty Me ~ a ~ Me N ~ ~~N- ~ - \- / N- ~N- C / C C / N-Cz NH ~ S H \
Me Me Me Me Me ~e ~ H
N-CZ N-Cs ~N-C? ~~N-Cz ~~N-Cz ~ ~ N-Cz O
\Me Me H Hz ~
~~N-C? H~N- Me-~N- ~N- HIy tJ- Me S' ~/ M ~/e Me MB
H2~~ - HxC- HzC- HzC- HN- /O- i N- i N- i N-HZN MezN Me3N Me3C Me3C
Me MQ
OZNHz SOZNHz OZMe OZMe ONHz CONHz CHZNHz CHZNHz ~N- ~N- N ~ N N- N N- N N-M tJ fJ M M M
~--~ ~~----~~ /CH3 O
NY N- N/\ 'N- ~~ N/ \ A N
N
Me CONHz CHZNHz wherein:
A is selected from the group consisting of Me M
I-t Me Et\ M~ E' Et\ /~
N- \N- N- N- N- N- CN- ~N- CN- C .N-H H H M~ Me Et/ ~/
Me Me M N- N- N- N- N- ' ,N- Me~N-M N- (z .N- ~~- O~N- H ~N- Me-N~N-N- N Oz N- Fi~ Me~ ~N-Real and R~az are independently selected from the group consisting of -H, -F, -CI and -Br;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHzNHz, -CHZOH, -CONHz, -C(=NH)NHz, -COZH, -COZMe, -SOZMe, -SOZNHz, -OH, -NHz, and -NOz;
R'~z and R~°3 are independently selected from the group consisting of-H, -F, -Cl, -Br, and -OCH3; and G is selected from the group consisting of Rtbt Rlbt Rtb2 R7D3 ~~N ~NiN
wherein:
R~b~ is selected from the group consisting of -H, -CH3 and -CF3;
Ribz is selected from the group consisting of-H, -CH3 and-CF3; and Ribs is selected from the group consisting of-Cl, -NHz, -CH3 and-CF3.

Table 36 ,., _ H o G _ H G _ H G
A ~ / A O \ / A Q
tee Rt't ,., Rt°t Rtct R / I R / I /
Rtc3\\ \ R,na \ Rtc3\\ \
~Rmz ~Rmz ~Rmz tet _ O _ ~
N G O ~ ~ N G A Q~~ H G
~N
tae Rtct tat Rtct Rtct R \ I R \ I \ I
Rtc\N-Yz R,c \~~z Rtn \N-Yz wherein:

A-Q is selected from the group consisting of:
C~ C~-- C~ C~- C~ C~ CN>-- C~-- C
Me Et Me Et Me Me Me Me Me ~ CAN- CAN- CAN- C~
H \
Me Me ~~--ff~y Me N Me N Me \ Me z Me Hz ~N~N- ~~N- N- N- N-C- C~N-C-Me d/~ M/a Me H ~Me Hz II a H N Me Hz IAe Hz C ~ N_C- C ~ N-c- ~N_c- ~N~tr-c- ~~--N_c-~/
Me ~~NB CZ H~N- Me-~N- H ~~N- HN~ - Me-''M
Me M8 v z z z H,N O- _ HzN N~~ Hz ~C Me NBC Me NBC Me3C Me3 M M
SOZNHz SOZNHz OzMe SOZMe CONHz CONHz CHZNHz CHZNHz N~ NN- NN- w ~ w N- NN- w N- NN-M M N ~ M ~ M
N~N- N- ~~~ ~ ~ NI'H N~~ CH3 O~~
'[(~~ A~ A-L- A
Me CONHz GHZNHz wherein:

A is selected from the group consisting of:
Me M
I-' M~ E~ MH Et Et~ /~
N- N- N- \N- \N- /N- CN- ~N- CN- < N-H H H M6 M~ E ~/t Me M N- N- N- N- N- ~t'~' M~N-M N- Q ,N- ~N- O~N- H ~N- Me-t ~N-N- Oz N- H ~N- Me~ ~N-RIa~ and R~~ are independently selected from the group consisting of -H, -F, -Cl and -Br;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CH2NH2, -CHZOH, -CONHz, -C(=NH)NH2, -COZH, -COZMe, -SOZMe, -SOzNH2, -OH, -NH2, and -NOZ;
RI~z is selected from the group consisting of-CHZ-, -O- and NH-;
Rl'3 is selected from the group consisting of-CH-, -C(NHZ)- and N-; and G is selected from the group consisting of:
Rmt Ribs R~ez Rtb3 N \N ~ ~~N ~~N ~ / \N
wherein:
10 R~b~ is selected from the group consisting of -H, -CH3 and -CF3;
R~bz is selected from the group consisting of =H, -CH3 and -CF3; and R~b3 is selected from the group consisting of -Cl, -NH2, -CH3 and -CF3.

wherein:
R' is selected from the group consisting of -SOZNH2, -SOZCH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CHzNHz, -CHzNH(CH3), -CHZN(CH3)2;
Rla is selected from the group consisting of -H, -F, -Cl and -Br;
Rlb~ is selected from the group consisting of -H, -CH3 and -CF3;
R~bz is selected from the group consisting of -Cl, -NH2, -CH3 and -CF3;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHzNHz, -CHZOH, -CONH2, -C(=NH)NH2, -COZH, -COZMe, -SOzMe, -SOZNHZ, -OH, -NHZ, and -NO2;
R'°2 is selected from the group consisting of-H, -F, -Cl and -Br;
and Table 37 R'°3 is selected from the group consisting of -H, -F, -C1 and -Br.
wherein:
Rtct R' is selected from the group consisting of -SOZNH2, -SOzCH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CHZNH2, -CHZNH(CH3), -CHZN(CH3)2;
R'a is selected from the group consisting of -H, -F, -Cl and -Br;
R'b' is selected from the group consisting of -H, -CH3 and -CF3;
R'b2 is selected from the group consisting of -Cl, -NH2, -CH3 and -CF3;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONHZ, -C(=NH)NHZ, -C02H, -COZMe, -SOZMe, -SOZNH2, -OH, -NH2, and -N02;
R'~z is selected from the group consisting of-H, -F, -Cl and -Br; and Table 3 8 R'~3 is selected from the group consisting of-H and -NH2.
R'°' wherein:
A-Q is selected from the group consisting of Table 39 C~-- C~- C~- C~-- C~-- C~- C
H , O NH N N
Me Et Me Et Me Me Me Me Me C~ ~- C
H
Me N- ~~~NB ~ MN- INe N C~N-CZ C~N-CZ
NH N H
Me Me ~~t~l-Cz ~~N-Cx ~N Cx ~ ~~--N-C: ~~N-C? ~~N O
CCSS~ ~~''J- IVs NH dN
Me Me H HZ
~~N-CZ H ~N- Me-~N- ~~N- HN~ - Me-~! lM
Me Me HpN ~ HzC- HzC- HzC- H/N- p- ~ ~ ~ ~ ~ N-~N~~ HZN MezN Me3N Me3C Me3L< ~N
Me M
SOZNHz SOZNHZ S02Me SOzMe CONHz CONHZ CHZNHZ CHzNHz N ~ ~N- ~N- N ~ N N- ' /N- N ~ N N-N~J- N~N- N~F- ~ ~ N'IH NII CH3 O~~
YJ,,, A~ A~ p-' i CONH2 ~ZNHZ
wherein:
A is selected from the group consisting of Me I-l Mg E' M Et\ Et~ /~
HN- HN- N- ~ N- ~- CN- ~N- CN- < =N-M~ M~ E ~/t Me Me M N- N- N- N- N- ~N- M~N-M N- N- ~N- O~N- H ~N- Me- ~N-~N- ~ O ~N- H ~~ Mew ~N-Rya is selected from the group consisting of -H, -F, -C1 and -Br;
Ribs is selected from the group consisting of-H, -CH3 and -CF3;
R~bz is selected from the group consisting of-Cl, -NH2, -CH3 and -CF3;
Rl°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHzOH, -CONHz, -C(--NH)NHZ, -C02H, -COZMe, -SOZMe, -SOZNH2, -OH, -NHz, and -NO2;
R'°2 is selected from the group consisting of-H, -F, -Cl and -Br;
and R~'3 is selected from the group consisting of -H, -F, -Cl and -Br.
10 wherein:
Table 40 A-Q is selected from the group consisting of C~- C~- C~-- C~ C~- C~ C'~- C~- C'~--H \ N O NH N N
Me Et Me Et Me Me Me Me C;~ C;~ ~ C~.?~ C~-N- C~t~ C
H \
Me ~~Ne ~~Ne ~~H- ~MN- C~"Ne Cz C~-f~Cz NH ~ O S H
Me Me H
C~Me Hz ~ \ Me Hz Me Hz ~ \ Me Hz ~ \ M8 Hz ~ ~ z N-C- ~~C- N-C- N~N-C- N-C- N-C
O ~ O
Me Me Hz ~~N-C? H~N- Me-~N- M~~N- Hty N- Me-Me Me Hz~ ~ H;C- H;C- HiC- N- O- ~ N- ~ N- ~ N-HZN MezN Me3N Me3~ Me3C ~N ~N
Me Me OZNHz OZNHz O2Me OZMe ONHz CONHz CHzNHz CHZNHz i i i i i i i i ANN- wNN- yN- wNN- wNN- yN- wNN- wNN-M IJ M M M
N'\ tJ- NY N- NY N- ~ ~ ~hi i CH3 O'I
A~ A~ A
CONHz CHZNHz wherein:
A is selected from the group consisting o~

Me M
M Et M E E /~
N- ~N- \N- ~N- /N- /N- CN- ~N- CN- ' 'N-H H H Me Me E vt Me Me M N- N- N- N- N- ~N- M~N-M
M N- Q N- ~N- OZ$ N- H~N- Me-N~N-O N H ~~ Me~ ~N-Rla is selected from the group consisting of -H, -F, -Cl and -Br;
Ribl is selected from the group consisting of -H, -CH3 and -CF3;
Rib2 is selected from the group consisting of -Cl, -NHZ, -CH3 and -CF3;
R~~~ is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNHZ, -CHZOH, -CONHz, -C(=NH)NH2, -COZH, -COZMe, -SOZMe, -SOZNHZ, -OH, -NH2, and -NO2;
R1~2 is selected from the group consisting of-H, -F, -Cl and -Br; and R1~3 is selected from the group consisting of-H and NH2.

Table 41 wherein:
Rl is selected from the group consisting of -SOZNHz, -SOZCH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CHZNHZ, -CHZNH(CH3), -CHZN(CH3)z;
Rya is selected from the group consisting of -H, -F, -Cl and -Br;
R~bl is selected from the group consisting of-H, -CH3 and -CF3;
R~b2 is selected from the group consisting of -Cl, -NH2, -CH3 and -CF3;
R''' is selected from the group consisting of-H, -F, -CN, -CHZNHZ, -CONH2, -SOZMe, -SOZNHZ and -NO2;
Rl°2 is selected from the group consisting of-H, -F, -Cl, -Br and-0CH3; and Rl°3 is selected from the group consisting of -H, -F, -Cl, Br, -OCH3, -CHZNH2, -CONHZ
and -C(N=H)NH2.

wherein:
RI is selected from the group consisting of -SOZNHZ, -SOzCH3, -CN, -CONHz, -CONH(CH3), -CON(CH3)2, -CHZNHZ, -CHZNH(CH3), -CHZN(CH3)2;
R'a is selected from the group consisting of -H, -F, -Cl and -Br;
Table 42 R~b~ is selected from the group consisting of-H, -CH3 and-CF3;
R~bz is selected from the group consisting of -CI, -NH2, -CH3 and -CF3;
R'°' is selected from the group consisting of -H, -F, -CN, -CHZNH2, -CONH2, -SOZMe, -SOZNHZ and -NOz;
R1~2 is selected from the group consisting of -H, -R, -CI, -Br and -0CH3; and R''3 is selected from the group consisting of -H, -F, -Cl, Br, -OCH3, -CHZNHZ, -CONHz and -C(N=H)NH2.
Table 43 wherein:
A-Q is selected from the group consisting of C~-- C~- C~- C~- C~-- C~ C~-- C~ C~-H \ N \ \
Me Et Me Et Me Me Me Me Me C~ C~. ~- C~-~- CAN- C~.N_ C
H \
Me Me Me N Me N Me N Me ~N- ~~N-C ~~t~.F--Cz NH ~ O S N
H
Me Me C- N-C- \ N-C- N-C- N-C- N-C-~~IB Hz ~ H ~ Hz ~NH Me Hz ~ Me Hz ~~MB Hz O
Me Me Hz ~
~~N-CZ H~N- Me-~N- M ~- Hty ,N- Me a Me Hz HOC- HOC- HzC- HN- ~O-Me HzN MezN Me3N Me3C Me3C
OZNHz 02NHz OZMe OZMe ONHz ONHz HZNHz CHZNHz i ~ ~ i ~ ~ ~ i N N- N- ~N- N N- N N- /N- N N- N
M N M M N Me ,CH3 NY N- NY N- NYN-N- A A I A
Me CONHz CHZNHz wherein:
A is selected from the group consisting of:

Me M
I-l Mg EZ\ M~ E' Et~
N- \N- N- N- /N- /N- C N- N- N- N
H H H M~ M8 Et Me Me Me~N- CN- I .N- CN- CN- ~~ M~N-M N- N- ~t~ pz~N- HN ~N- Me- ~N-N- N- pZ N- H ~N- Mew ~N-Rya is selected from the group consisting of -H, -F, -Cl and -Br;
R~b~ is selected from the group consisting of-H, -CH3 and-CF3;
Ribz is selected from the group consisting of -Cl, -NHZ, -CH3 and -CF3;
R'°1 is selected from the group consisting of -H, -F, -CN, -CHZNH2, -CONH2, -SOZMe, -SOZNHZ and -NO2;
Rl'2 is selected from the group consisting of -H, -F, -Cl, -Br and -0CH3; and Rl'3 is selected from the group consisting of -H, -F, -Cl, Br, -OCH3, -CHZNH2, -CONHZ
and -C(N=H)NH2.

Table 44 R,°, wherein:

A-Q is selected from the group consisting of C~- C~- C~- C~- C~- C~- C~- C~ C~-H N
Me Et . Me Et Me Me Me Me Me C~ C~-- ~- C~~- C~~- C~-N- C
O S
Me Me M Me \ Me Z Me Hs ~~N- ~~~e ~~ ~N- C~N-C- C~~C-NH ~ O S H t Me Me H ttyy H ~ HZ ~NH M8 HZ I HZ ~ \~Me \ ~C? ~~C- \ N-C- N-C- N-C- N-C-55/ ~ O
Me ~ Me H HZ~y ~~N-Cz H~N- Me-~N- ~~N- H~ - Me-S~ M / ~/ ~/e Me Me Hz HzC- HzC- Ii~C- HN- /p- ~ N_ HzN Me2N Me3N Me3C MeaC ~N ~N ~N
Me M
SOzNHz OzNHZ OZMe OZMe ONHZ ONHz HzNHz HZNHZ
i i i i i i i i \N N-- yN- yN- ' ~ ' ~ \ /N- ' ~ ' N-M M ~N N M N M 'N
NY N- NY N- NY N- ~ ~ ~H N CH3 O~~
N- AJ'- A~ AJ'--Me CONHZ CHZNHZ
wherein:
A is selected from the group consisting of Me M
H Mg E' M~ E' Et~
H\N- \~ N- N- N- /N- CN- ~N- CN- ~N-H H MA M~ Et Me Me Me-C .N- CN- ~N- CN- CN- ~~ Me-( .N-M N- N- ~N- OZ~N- H ~ - Me- ~N-~N- ~N- 02 ~~ H,,r \ - Me~ ~N-R'a is selected from the group consisting of -H, -F, -Cl and -Br;
Rlbt is selected from the group consisting of -H, -CH3 and --CF3;
Rtbz is selected from the group consisting of -Cl, -NH2, -CH3 and -CF3;
R''1 is selected from the group consisting of-H, -F, -CN, -CHZNH2, -CONHz, -SOZMe, -SOZNH2 and -NOz;
R~~z is selected from the group consisting of -H, -F, -Cl, -Br and -0CH3; and R~~3 is selected from the group consisting of -H, -F, -Cl, Br, -OCH3, -CHZNH2, -CONHZ
and -C(N=H)NH2.

Table 45 wherein:
Rl is selected from the group consisting of -SOzNHz, -SOZCH3, ~N, -CONHz, -CONH(CH3), -CON(CH3)z, -CHzNHz, -CHzNH(CH3), -CHZN(CH3)z;
R~a~ and Rhz are independently selected from the group consisting of -H, -F, -Cl and -Br;
R'°z and Rl'3 are independently selected from the group consisting of-H, -F, -Cl, -Br, and -OCH3; and G is selected from the group consisting of Rtb1 Rtbt Rtb2 Rlb3 \N
wherein:
R~b~ is selected from the group consisting of -H, -CH3 and -CF3;
R~bz is selected from the group consisting of -H, -CH3 and -CF3; and R~b3 is selected from the group consisting of -Cl, -NH2, -CH3 and -CF3.

Table 46 Rtc9 wherein:
R' is selected from the group consisting of -SOZNH2, -SOZCH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)Z, -CHZNH2, -CHZNH(CH3), -CHZN(CH3)2;
R~a~ and Ria2 are independently selected from the group consisting of -H, -F, -Cl and -Br;
R~~2 and R'°3 are independently selected from the group consisting of-H, -F, -Cl, -Br, and -OCH3; and G is selected from the group consisting of RIDt Ribt Rlb2 Rtb3 N ~N N ~N ~~N ~N ~ ~ ~N
I
I I I I
wherein:
R~bl is selected from the group consisting of-H, -CH3 and-CF3;
R~bz is selected from the group consisting of -H, -CH3 and -CF3; and Rib3 is selected from the group consisting of -Cl, -NH2, -CH3 and -CF3.
Table 47 wherein:
A-Q is selected from the group consisting of C~ C~-- C~- C~- C~ C- C~-- C~- C~--Me Et Me Et ~e S Me ie C \ N ~N- C~N- C~N- N-H
Me C;~~,~ C
NH t'~ O S N N
H
Me Me ~( ~ Hz C- ~N-C- \ N-C- ~N-C- ~N-C- N-C-C~Me Hz C Me Hz ~~ Hz ~NH M8 Hz ~ ' a Hz O
\Me ~~~8 CZ H~N- Me-~N- ~- H~ - Me-~ -S' M ~/e a Me Hz n HiC- HiC- HyC- HN- O- i i i ~N HzN MezN Me3N Me3C Mg3~ ~N N ~N N- N-Me Me OZNHz OZNHz OZMe OZMe ONHz ONHz CHZNHz HZNHz i i i i i i i i N ~ ~~ ~~ N N- N N- /N- N N- N N-M M M N M
~--t ~--~ /CH3 NYN- NY N- NY N- ~~ ~ fJ~
A A I A
Me CONHz CHZNHz wherein:
A is selected from the group consisting of:
Me M
I-l M~ E' Me E< Et~
N- N- N- \N- /N- N- N- ~N- CN- N-H H H Me M8 Et~
Me Me M N- N- N- N- N- ~~ M~N-M N- Q .N- ~N- O~N- HN~N- Me--NN~N-N- ~N- ~N- Oz N- H ~N- Mew CN-R~a~ and Rla2 are independently selected from the group consisting of -H, -F, -C1 and -Br;
Rl°z and R~~3 are independently selected from the group consisting of -H, -F, -Cl, -Br, and -OCH3; and G is selected from the group consisting of:
Riei Rm~ R~ez Rma NiN ~t~N ~N N ~ ~ \N
N
wherein:
R~bl is selected from the group consisting of-H, -CH3 and -CF3;
Rib2 is selected from the group consisting of-H, -CH3 and -CF3; and R~b3 is selected from the group consisting of -Cl, -NH2, -CH3 and -CF3.

Table 48 wherein:
A-Q is selected from the group consisting of C~ C~-- C~- C~ C~- C~-- C~- C~-- C
Me Et Me Et C~N- C~N C~MN- C~MN- ~N-H CC55\
Me ~Me g //~~ Me C~ a HZ N Me H2 ~N- ~ N C- C ~~N-C-NH ~ O S
Me Me Me Me Me Me M8 H
N-C N-Cz N-Cz N-C ~~N-CZ ~ ~ N-Cz O
Me ~ Me H HZ~ ~
~~N-CZ H~N- Me-~N- ~~N- HIy ,N- Me-~ -Me Me HzC- HOC- HzC- N O-H ~~ HyN MeZN Me3N Me3C Me3~ ~N N 'N N- N-Me Me 02NH2 SOZNHZ OZMe OzMe CONHZ CONHZ HZNHZ CHzNHZ
i i i i i i i i wNN- yN- yN- wNN- ANN- yN- wNN- ~NN-M IJ !J M M Me ~CH3 NY N- NY N- N~N- N/ ~ AJ'-- A-L- A
N
Me CONHZ CHZNHZ
wherein:
A is selected from the group consisting of:
Me M
I-l M~ Ef\ Me Et Et\ /~
N- N- N- /\N- \N- N- C N- ~ N- CN- C N-H ~ H M8 M~ Et ~/~
Me Me M N- N- N- N- N- ~N- M~N-M N- Q ,N- ~N- O~N- H( ~N- Me--NVN-N- N- OZ N- H ~N- Me~ ~N

R'a' and R'~ are independently selected from the group consisting of -H, -F, -C1 and -Br;
R'~2 and R'°3 are independently selected from the group consisting of -H, -F, -Cl, -Br, and -OCH3; and G is selected from the group consisting of Rlbt Rlb1 Rib2 Rtb7 I \N ~ ~NN ~ NN I ~ I \N
I I I N
I I
wherein:
R'b' is selected from the group consisting of-H, -CH3 and-CF3;
R'b2 is selected from the group consisting of-H, -CH3 and-CF3; and R'b3 is selected from the group consisting of -Cl, -NH2, -CH3 and -CF3.

Table 49 wherein:
A-Q is selected from the group consisting of C~- ~~ C~- C~ C~ C~ C
Me Et Me Et ~Me C Me tyle Me Me N- ~N- C~ ~N- C~N- N-O S H ~ S
Me Me ~~MNe ~~Me tla ~Me C~Ne Cz C~Me Hz N- - N- N- N- - N-C-N
Me Me H
\ N-C- N-C- \ N-C- N-C- N-C- N-C-C~Me Hz C Me Hz ~~ Hz ~NH Me Hz Hz ~ \~~ z O
Me ~~-Ne CZ H~N- Me-~N- H ~~N- H~ - Me-~ -S Me Me Me Hz ~ HzC- HOC- HZC- HN-- O-HZN MezN Me3N Me~C MesC ~N ~ ~N ~
Me Me OZNHz OzNHz OzMe OZMe ONHz ONHz CHzNHz CHZNHz i i i i i i i i 'N N- ' N- 'N tt- N- ' N- _ \N N- 'N N- _N tt-M M Me M
NYN- NYN- ~'/ ~ ~ H /CH3 O
Me CONHz ~2NH ~z wherein:
A is selected from the group consisting of:
Me M~ E' M~ E< Et\ /~
N- N- N- N- N- ~N- N- N- N- ' 'N-H H H MI M~ E vt Me Me M N- N- N- N- N- ~N-' M~N-M N- Q ,N- ~tt- Oz~N- H~N- Me- ~N-N- N- N O N- H CN- Me~~-R'a' and R'az are independently selected from the group consisting of -H, -F, -C1 and -Br;
R''z and R''3 are independently selected from the group consisting of-H, -F, -Cl, -Br, and -OCH3; and G is selected from the group consisting of:
R~ei R~c~ Riez R~ea N \N ~ ~~N ~N N ~ ~ \N
wherein:
R'b' is selected from the group consisting of -H, -CH3 and -CF3;
R'bz is selected from the group consisting of-H, -CH3 and-CF3; and R'b3 is selected from the group consisting of -Cl, -NHz, -CH3 and -CF3.

Rlb7 ~1b7 ttbt wherein:
R' is selected from the group consisting of -SOZNH2, -SOZCH3, ~N, -CONH2, -CONH(CH3), -CON(CH3)2, -CHZNHz, -CHZNH(CH3), -CHzN(CH3)2;
Rya is selected from the group consisting of -H, -F, -Cl and -Br;
R~b~ is selected from the group consisting of-H, -CH3 and-CF3; and R~~z and R''3 are independently selected from the group consisting of-H, -F, -Cl, -Br, and -OCH3.
Table SO

Table 51 ~tbt Ribt ttbl wherein:
R' is selected from the group consisting of -SOZNH2, -SOZCH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CHZNH2, -CHZNH(CH3), -CHZN(CH3)2;
Rya is selected from the group consisting of -H, -F, -Cl and -Br;
R~b~ is selected from the group consisting of-H, -CH3 and-CF3; and R~~2 and R'°3 are independently selected from the group consisting of-H, -F, -Cl, -Br, and -OCH3.

Table 52 z,b, wherein:
A-Q is selected from the group consisting of C~ C~-- C~- C~ C~- C~- C~-- C~- C
H \
Me Et Me Et Me Ma Me a C~~ ~r H \ S
Me //~~ Me //~~ ~A //-- /~ M8 H Me ~~MN- ~~N- ~~~e ~~Ne ~Ne C~N-Cz C~N-Cz NH ~ O S H t Me Me C~-~~2 C~-~~z ~r~~z ~~-~~Z ~~~Ne cZ ~~~NMa-c Me ~It Hz ~
~~~8 C? H~N- Me-~N- ~- Hty ,N- Me-N~N-S V M ~/e Me MB
Hz / ~ i i i HiC- HiC- H2C- CN- 3 /O- wN N- wN N- yN-HZN MezN Me3N Me3 Me tJC
Me M
SOZNHz OZNHz OZMe OZMe ONHz CONHz CHzNHz HZNHz i i i i i ~ i i N- ~N- ~N- N- N- ~N- N- N N-M M 'N N M N M
NYN- N/ 'N- NYN-\ \\
A A I A
Me CONHz CH2NHz wherein:
A is selected from the group consisting of Me M
M~ Ef\ M~ Et\ Et\ /~
HN- ~ N- N- N- /N- CN- ~N- CN- < 'N-H H M~ M~ E ~/t Me Me Me~N- CN- I .N- CN- CN- ~~ M
N- N- ~N- O~N- H~N- Me-N~N-~N- ~N- ~N- H ~N- Me~ ~N-R'a is selected from the group consisting of -H, -F, -Cl and -Br;
R~bl is selected from the group consisting of -H, -CH3 and -=-CF3; and Rl~z and Rl'3 are independently selected from the group consisting of -H, -F, -Cl, -Br and -OCH3.

Table 53 Rm wherein:
A-Q is selected from the group consisting of:

C'~- C~ C~-- C~ C~ C~ C ~~- C~- C
N NH
H
Me Et Me Et Me Me Me Me Me C~ C~ ~ j- C~~- C~-N- CAN- C
H
Me Me Me Me N Me C;~~ C;~N_ C~~ C
Me ~Me H2 Ile H N Me H2 N Me H2 ~ \ ~ H2 ~ N-C- ~ ~ N-C- ~N-C- ~N N-C- ~ ~~N-C- N-C
Me Me H z ~
~~N-C? H ~N- Me-~N- H ~~N- Hty N- Me ~1 ~ ~M
Me Me H2 ~ O- i i i z 2 2 HN- ~ _ HZ ~C MezN C Me3N C Me3Ll Me3 N N- ' /N_ Me IJM
SO2NH2 SO2NH2 SO2Me SO2Me CONHz CONH2 CH2NHz CH2NH2 N N-. ~N- ~N- N N- N N- ~N- ~N- ~N-M M M M
N/\ IJ- NY N- NY N- ~ ~ [[IJJIH i CH3 OII
A~ A~ A

wherein:
A is selected from the group consisting of Me M
M~ E' M~ Et Et~ /~
N- N- ~N- /N- /\N- /N- CN- ~N- CN- C .N-H H H M6 M8 E ~/t Me Me Me~N- CN- I .N- CN- CN- ~~ M
N- Q ,N- ~N- O~N- H ~ Me- ~N-N O N H~ Me~ ~N-R'a is selected from the group consisting of -H, -F, -Cl and -Br;
R'b' is selected from the group consisting of-H, -CH3 and ~F3; and R'~2 and R'°3 are independently selected from the group consisting of-H, -F, -Cl, -Br and -0CH3.
The following compounds are an embodiment of the present invention:
wherein:
R' is selected from the group consisting of -SOZNH2, -SOZMe, -CHZNHZ and -CH2NMe2;
R'a is selected from the group consisting of -H, -F, -C1 and -Br;
Rlb is selected from the group consisting of -CH3, -CF3, -CHZCH3, -SOzMe, -CONHZ and -NHSOzMe;
R''1 is selected from the group consisting of -H, -F, -Cl, -Br, -NHZ, -OH, -SOZMe, -SOZEt, -SOZNH2, -NO2, -CHZNH2, -CN, -CONHz, -CHZOH;
R'~z is selected from the group consisting of:
-H, -F, -Cl and -Br; and Rl°3 is selected from the group consisting of -H, -F, -Cl and -Br.
The following compounds are an embodiment of the present invention:
R,°, wherein Rl is selected from the group consisting of -SOZNH2, -SOZMe, -CHzNH2 and -CH2NMez;
Rya is selected from the group consisting of -H, -F, -Cl and -Br;

R~b is selected from the group consisting of:
-CH3, -CF3, -CHZCH3, -SOZMe, -CONHz and -NHSOZMe;
RI°' is selected from the group consisting of -H, -F, -Cl, -Br, -NHz, -OH, -SOZMe, -SOZEt, -SOZNHz, -NOz, -CHzNHz, -CN, -CONHz, -CHZOH;
R~~z is selected from the group consisting of -H, -F, -Cl, -Br and -OMe; and R1~3 is selected from the group consisting of -H, -F, -Cl, -Br, -OCH3, -NHz, -CHZNHz, -CONHz, -CONHMe, -CONMez.
The following compounds are an embodiment of the present invention:
wherein:
R' is selected from the group consisting o~
-SOZNHz, -SOZCH3, -CN, -CONHz, -CONH(CH3), -CON(CH3)z, -CH2NHz, -CHzNH(CH3), -CH2N(CH3)z;
R~ais selected from the group consisting of -H, -F, -C1 and -Br;
Rlb is selected from the group consisting of:
-CH3 and ~F3;
R'°1 is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHzNH2, -CHZOH, -CONHZ, -C(=NH)NH2, -COZH, -COZMe, -S02Me, -SOZNHz, -OH, -NH2, and -NOZ;
R~~2 is selected from the group consisting of -H, -F, -Cl, -Br, and -OCH3; and R'°3 is selected from the group consisting of -H, -F, -Cl, -Br, -OCH3, -NH2, -CH2NHz, -CONH2, -CONHMe, -CONMe2.
The following compounds are an embodiment of the present invention:
R'' wherein:
Rl is selected from the group consisting of -SOzNH2, -S02Me, -CHZNHZ and -CHZNMez;

Rya is selected from the group consisting of -H, -F, -Cl and -Br;
Rib is selected from the group consisting of -CH3, -CF3, -CH2CH3, -SOZMe, -CONHZ and -NHSOZMe; and Rl° is selected from the group consisting of -H, -F, -Cl, -Br, -NHZ, -OH, -SOZMe, -SOZEt, -SOZNH2, -NOZ, -CHZNH2, -CN, -CONH2, -CHZOH;

The following compounds are an embodiment of the present invention:
wherein:
Rlc1 R' is selected from the group consisting of:
-SOZNH2, -SOZMe, -CHzNH2 and -CHZNMez;
Rya is selected from the group consisting of -H, -F, -Cl and -Br;
Rib is selected from the group consisting of -CH3, -CF3, -CHZCH3, -SOZMe, -CONHz and -NHSOzMe;
R~'~ is selected from the group consisting of -H, -F, -Cl, -Br, -NH2, -OH, -SOZMe, -SOZEt, -SOZNHZ, -NO2, -CHZNH2, -CN, -CONH2, -CHzOH; and R1~2 and R1~3 are independently selected from the group consisting of:
-H, -F, -Cl and -Br.
The following compounds are an embodiment of the present invention:
wherein:
R"' A-Q is selected from the group consisting of:

C~ C~ C~- C~- C~ C~- C~- C~- C~--H
Me Et Me Et Me H1e Me Me Me C'~ C'~- ~-- CAN- C~-N- CAN- C~-~- C~-O S H \ O
Me Me Me a Me ~~ Me MB Hz Me H
~~nr- C~r~- ~~~- ~~.r~- ~r~- C~N-c- C~-~-c?
NH ~ O S H N
Me Me ~ Me H Me H Me H Me H Me H ~ Hz ~~N-C? ~~t~C? ~N-C? ~~~C? ~~N-Cz ~ \ N-C-O
Me H ~ /~1 ~~-N8 C? H~N- Me-fy ,N- ~~N- H~ Me-N
S ~/ M ~/ ~/e Me Me Hz~ H C- H C- H C- HN- O-HZN MezN Me~N Me3C Me3C ~N 'N ~ N
Me Me SOzNHz OZNHz 02Me O2Me CONHz CONHz HZNHz CHzNHz i i i i i ~ i i 'N N-- yN- yN- ' ~ ' ~ ~N- ' ~ ~N N-M M ~N N Me N M
\ \
NYN- NY N- NYN-N A A I A
Me CONHz CHzNHz wherein:
A is selected from the group consisting of:
Me M
I-l M~ E' M8 Et Et~ /~
N- N- N- \N- /\N- ~N- N- N- N- ' 'N-H H H M~ M8 E vt Me Me Me~N- CN- I -N- CN- CN- ( ,N- M N--N- Q ,N- ~N--- Oz~- H ~N- Me-N~N-N- N- O N- H'j N- M~'j .N

R'a is selected from the group consisting of -H, -F, -Cl and -Br;
R'b is selected from the group consisting of:
-Me,--CF3, -Et, -SOZMe, -CONHZ and -NHSOzMe;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -NHz, -OH, -SOZMe, -SOZEt, -SOZNHZ, -NOZ, -CHZNHz, -CN, -CONH2, -CHZOH;
R'~2 is selected from the group consisting of:
-H, -F, -Cl and -Br; and R'°3 is selected from the group consisting of -H, -F, -Cl and -Br.
The following compounds are an embodiment of the present invention:
wherein:
A-Q is selected from the group consisting of:

C~-- C~- C~-- C~-- C~ C~- C~ C~- C~-Me Et Me Et Me Me Me Me ~~ Me H ~~ jj / ~~//\
Me N'\ Me //~~N~'\ ~-N Me N~~e H Me Hz N- ~~N- ~~tJ \ j-N- CH N-C C~tI~J-C-S N N
Me Me ~ Me H Me H Me H Me H ~e Hz ~ Hz C ~?-N-CZ ~~t~C2 ~N-C? ~~--N-CZ ~~--N-C- ~ ~ N-C-O
Me ~ Hz ~
~~NQ CZ H~N- Me-~N- . ~~N- Hty tJ- Me-S~ M ~/e Me Me z z z N- O- _ H ~ H NBC Mez ~C Me NBC Me3~ Me3~ .
Me Me OZNHz OZNHz OZMe 02Me ONHz ONHz CHZNHz CHzNHz i i i i i i i i N- N N- N N- N- N-. N N- N N- N N-M M N N M M
NY N- NYN- N~N-N A A I A
Me CONHz CHZNHz wherein:
A is selected from the group consisting of Me I-l ~ E' M~ ~ E \ M
N- N- ~N- N- /N- N- CN- ~N- CN- N-H H H M~ M8 Et~
Me ~Me M~N- CN- I .N- CN- CN- ~N- M~N-N- N- ~N- O~N- H~N- Me- ~N-N- - ~N- O ~N- H ~N- Me' ~N-Rya is selected from the group consisting of -H, -F, -Cl and -Br;
Rib is selected from the group consisting o~
-CH3, -CF3, -CHZCH3, -SOzMe, -CONHZ and -NHSOZMe;
Rl'' is selected from the group consisting of -H, -F, -Cl, -Br, -NH2, -OH, -SOZMe, -SOZEt, -SOZNHZ, -NOZ, -CHZNH2, -CN, -CONHZ, -CHZOH;
Rl'2 is selected from the group consisting of -H, -F, -Cl, -Br and -OMe; and R''3 is selected from the group consisting of -H, -F, -Cl, -Br, -OH, -OCH3, NH2, -CONH2, -CH2NH2.

The following compounds are an embodiment of the present invention:
t to Rtn Rt Rte Rt Rtc I \N ~ ~ ~ / I \N ~ ~ ~ '~- I \N
N ~.j N ~ N
Rtct ~ / Rtct ~ / Rtct RtcJ / Rtc9 / Rtc9 /
Ricz Rtcz Rtc2 Rt Rta Rtn t Rtn t Rte I \N ~ ~ ~ / I \N ~ ~ ~ '~- I \N
N N N N W I
Rtct O / Rtct O / Rtct Rtc9 ~ / Rtn9 ~ / Rtc3 ~ /
Rtcz Rtc2 Rtc2 t Rta Rtb t Rte t Rtb I \N ~ ~ ~ / I \N / ~ ~ '~ I \N
N N N N N
Q / Rtct ~ / Rtct ~ / Rtct Rtc3 ~ / Rm7 / RtA ~ /
Rtcz Rtcz Rtcz t Rta / Rtb t / Rtn , t / Rtn I \ ~ ~ I \ ~ ~ ''~ /I \
~N ~ N ~N ~ N ~~N
Rtct O / Rmt ~IOI( /_ Rtct Rtc9 ~ / Rtc9 ~ / Rtc9 ~ /
Ruz Rtcz Rtcz Rt Rta / Rtc t Rte t Rtn ~ I \N ~ ~ ~ / ~ I \N ~ ~ ~ n/~- ~ I \N
\t~ N \N N \I~
Rtct O j Rlnt O / Rict Rtes ~ / Rtes ~ / Rtes ~ /
Rtcz Rtcz Rtcz Rtci Rmt wherein:
R' is selected from the group consisting of -SOzNH2, -SOZCH3, -CN, -CONHZ, -CONH(CH3), -CON(CH3)2, -CHZNHz, -CHZNH(CH3), -CHZN(CH3)z;
R'a is selected from the group consisting of -H, -F, -Cl and Br;
R'b is selected from the group consisting of -CH3 and -CF3;
R'~l is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONHz, -C(=NH)NH2, -COZH, -COZMe, -SOZMe, -SOZNHz, -OH, -NH2, and -N02;
R'~2 is selected from the group consisting of:
-H, -F, -Cl and -Br; and R'~3 is selected from the group consisting of:
-H, -F, -Cl and -Br.
The following compounds are an embodiment of the present invention:

_t _ta Rte Rt Rtn Rt Rta I \N ~ ~ ~ / I \N ~ ~ ~ ~ I \N
N N N ~N
Rtct ~ / Rtct IO / Rtct Rtca \ ~ Rtn3 \ ~ Rtca \
Rtc2 Rtcz Rtc2 Rt Rta Rtt t Rte t Rta I ~ \ ~ I \N I ~ \ ~ I \N ~ ~ ~ ~ I \N
N N N \~
Rtct ~ / Rtnt O / Rtct RtcJ \ ~ Rtc7 \ ~ Rtc9 Rtcz Rtcz Ric2 t Rta tb t Rta t Rtc I ~ ~ ~ I \N I ~ ~ / I \N ~ ~ ~ ~ I \N
N ~.j N N
Rtct ~ / Rtct O / Rtot \
Rtc3 \ Rtc3 \ Rtc3 Rtc2 Rtc2 ~ Rtcz Rt Rta / Rtn t / Rto t / Rtc I \N ~ ~ ~ ~ I \N ~ ~ \ ~ I \N
N N N \~
Rtct O / Rict O / Rtnt RtcJ \ Rtc9 \ Rtc7 \
Rtc2 Rtc2 . Rtc2 Rt Rta Rtc t R1b t 1b I ~N ~ ~ \ N ~ I N\N ~ ~ ~ ~ ~ I N\N.
\i Wi Rtnt O / Rtct O / Rtct Rtcs \ Rtes \ Rtc3 \
Rtcz Rtcz Rtnz Rt Rta H Rtb Rt H Rtb Rt H Rtc ~N \ N N ~ ~ ~ ~ I ~N
~N ~N
Rtct O / Rtct ~ / Rtnt Rtc3 \ ~ Rtca \ ~ Rtc3 Rtcz Ruz Rtcz wherein:
R' is selected from the group consisting of -CN, -CHZNHZ, -CONHZ, -C(=NH)NHZ" -SOzMe, -SOZNH2, and -NHZ;
R'a is selected from the group consisting of -H, -F, -Cl and -Br;
R'b is selected from the group consisting of:
-CH3, -CF3, -CHZCH3, -SOZMe, -CONHZ and -NHS02Me;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -NH2, -OH, -SOZMe, -SOZEt, -SOZNHZ, -NO2, -CHZNHZ, -CN, -l0 CONHZ, -CHZOH;
R'~Z is selected from the group consisting of -H, -F, -Cl, -Br and -0CH3;
Ru3 is selected from the group consisting of -H, -F, -Cl, -Br, -OCH3, -NHZ, -CHZNH2, -CONHZ, -CONHMe, -CONMe2.
The following compounds are an embodiment of the present invention:
R'°' wherein:
A-Q is selected from the group consisting of C~ C~- C~- C~-- C~- C~- C~ C~- C~-Me Et Me Et t~ Me t~ Me t~ Me Me Me C / N- CN N-, C / N- N- N-O S
Me ~~Ne ~~N- ~Ne C~N-C C~-~C2 N
Me Me a H ~~Me Hx _u Me H ~N~111e Hx ~ a Hx ~~~ Hx C- &&~ ~C- ~~N-C- ~ ~ N-C- ~ ~ C- ~ N-C-O
Me ~~-Ne Cz H~N- Me-~N- H ~- Hty ,N- Me-S M ~/e Me Me Hx ~ HOC- HOC- HiC- O- ~ _ i i HZN MexN Me3N Me3 ~pAe3~ wN N w ~ '~N-Me M
OZNHx SOxNHx OZMe OZMe CONHx CONHx CHZNHx HzNHx i i i i i ~ i i w ~ w ~ w/~ w%~ ~/~ ~ N w%~ w N N N N ~ N N
M M M M
~~----~~ ~--~ ,CH3 N'\ 'N- NY N- NYN- N~ ~ H N~~ OII
\N A~ A~ A
Me CONHx CHZNHx wherein:
A is selected from the group consisting of:

Me M
M E M E E
~N-- ~N- N- ~N- - N- N- N- N-H H Me Me Et a a M N- N- N- N- - N- Me~N-M N- N- ~N-- 02~N- H~N- Me-~N-_ _ O _ H ~~ MAN' \N-R~a~ is selected from the group consisting of -H, -F, -Cl and -Br;
Rib is selected from the group consisting of -CH3 and ~F3;
Rl°1 is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CH20H, -CONH2, -C(=NH)NH2, -COZH, -COZMe, -S02Me, -SOzNH2, -OH, -NH2, and -NOZ;
R~°Z is selected from the group consisting of -H, -F, -Cl, -Br, and -OCH3; and Ri°3 is selected from the group consisting of:
-H, -F, -Cl, -Br, -OCH3, -NH2, -CHZNHz, -CONH2, -CONHMe, -CONMe2.
The following compounds are an embodiment of the present invention:

wherein:
Rl is selected from the group consisting of Roc R"' -SOZNHz, -SOZCH3, -CN, -CONHz, -CONH(CH3), -CON(CH3)z, -CHzNHz, -CHzNH(CH3), -CHZN(CH3)z;
Rla is selected from the group consisting of -H, -F, -Cl and -Br;
R'b is selected from the group consisting of -H, -CH3 and -CF3;
R'°' is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONH2, -C(=NH)NHZ, -COZH, -COZMe, -SOZMe, -SOZNH2, -OH, -NH2, and -NOz;
R'°2 is selected from the group consisting of -H, -F, -Cl and -Br; and R'°3 is selected from the group consisting of:
-H, -F, -Cl and -Br.
The following compounds are an embodiment of the present invention:

wherein:
Rtn R' is selected from the group consisting of -SOzNHz, -SOZCH3, -CN, -CONHz, -CONH(CH3), -CON(CH3)z, -CHzNHz, CHzNH(CH3), -CHZN(CH3)z;
Rya is selected from the group consisting of -H, -F, -Cl and -Br;
R'b is selected from the group consisting of -H, -CH3 and -CF3;
Rl'1 is selected from the group consisting o~

-H, -F, -CN, -CHzNHz, -CONH2, -SOZMe, -SOZNHZ and -NO2;
R''2 is selected from the group consisting of:
-H, -F, -Cl, -Br and -0CH3; and R~°3 is selected from the group consisting of -H, -F, -Cl, -Br, -OCH3, -NH2, -CHZNH2, -CONHZ, -CONHMe, -CONMez.
The following compounds are an embodiment of the present invention:
Roc o1b wherein:
C~ C~- C~- C~- C~-- C~- C '~ C '~ C:
N O NH N N
H N \
Me Et Me Et Me Me Me a C ~-- C;~- ~- C~-N- Ct~N- C~~ C~-~- Cdr H \ O S
Me Me a Me 8 H Me C';~~ ~~ Cdr-~~ C~--~~_ N
Me Me ~~Me Hz ~ Me Hz ~II a H ~N~Me Hz ~~~e Hz ~ \~~ z H
N-c- N-c- \ N-c- ~ N-c- ~ N-c- N-C-Me Me Hz Hz~ ~
~~N-C- H~N- Me-~N- M~~N- Hty ,N- Me Me Me Hz ~ HzC- HOC- HzC- O- ~ N ' N- N-HZN MezN Me3N Me3 ~MQ3~ ~N ~N ~N
Me M
SOzNHz OZNHz OZMe 02Me ONHz ONHz CHZNHz CHZNHz i i i i i ~ i i N- N- /N- N- N- \ /N- ' N- ' N-~N ~N N ~N ~N 1J N N
M M M M
t'~ NH NII CH3 OI' NYC T N-Me ICONHz CHZNHz A-Q is selected from the group consisting of:
wherein:
A is selected from the group consisting of:

Me M
M E M E E
/ /N CN ~N N N-H H Me Me Et _8 Me M N- N- N- N- N- ( :N-- M~~.
M t~ N- N- oz$ .N- H~N- Me-~N-N_ O H M N-Rya is selected from the group consisting of -H, -F, -Cl and -Br;
Rlb is selected from the group consisting of -H, -CH3 and -CF3;
R''1 is selected from the group consisting of -H, -F, -Cl, -Br, -CN, -CHZNH2, -CHZOH, -CONHZ, -C(=NH)NH2, -C02H, -COZMe, -SOzMe, -SOZNHZ, -OH, -NHz, and -NO2;
R~'Z is selected from the group consisting of -H, -F, -Cl and -Br; and R'°3 is selected from the group consisting of -H, -F, -Cl and -Br.

The following compounds are an embodiment of the present invention:
~.m wherein:
A-Q is selected from the group consisting of C~-- C~- C~-- C~- C~-- C~- C~-- C~- C
Me Et Me Et Me Me Me Me Me C~-- C~-- ~ Ct~N_ C~-N_ C~--N_ C
H \ O
Me Me Me Me a ~~ Me a Me t~ ~~N- ~~-N- - ( 'rN- C~- -~ ~~t~'r-C2 NH ~ O S H
Me Me C~-n~r-cz C~r~r c? ~-N c? ~~-~c2 C~-n~Mte-c2 Me a H Hz ~
CZ Hr{ ,N- Me-~N- ~~N- H~ - Me-S ~/ M ~/e a a H2~ ~ H C- H C- H C- N- O- ~ _ i HZN MezN Me3N Me3C Me3~ ~N N ~N ~ ~N ~
Me Me OZNHz SOZNHz OZMe OZMe ONHz ONHz CHZNHz HTNHz i i i i i ~ i i wNN- wNN- wNN- w ~ ' ~ w N_ w ~ ' N-M M N N M N N M N
N- N N- NY N- ~ ~ ~JH /CH3 O'I
A~ A tJ~ A
Me CONHz CHZNHz wherein:
A is selected from the group consisting of M ~a Md E M E E /\
~N- \N- ~N- N- ~N- ~N- CN- ~N- CN- C .N-H H Me Me Et ~/~
a M N- N- N- N- N- N- Me~N-M N- N- ~N- O~N- H~N- Me-~N-N- O _ H N- N-Rla is selected from the group consisting of -H, -F, -Cl and -Br;
R'b is selected from the group consisting of -H, -CH3 and -CF3;
Rl~~ is selected from the group consisting of:
-H, -F, -CN, -CHZNH2, -CONH2, -SOZMe, -S02NHz and -NO2;
R~~2 is selected from the group consisting of -H, -F, -Cl, -Br and -0CH3; and l0 R'°3 is selected from the group consisting of -H, -F, -Cl, -Br, -OCH3, -NHZ, -CHzNH2, -CONH2, -CONHMe, -CONMe2.

The following compounds are an embodiment of the present invention:
wherein:
R' is selected from the group consisting of:
-SOZNH2, -SOZMe, -CHZNHZ and -CHZNMe2;
R'a is selected from the group consisting of -H, -F, -Cl and -Br;
R'b is selected from the group consisting of -CH3, -CF3, -CHZCH3, -SOZMe, -CONHZ and -NHSOZMe;
R'°2 and R'°3 are independently selected from the group consisting of:
l0 -H, -F, -Cl and -Br.

The following compounds are an embodiment of the present invention:
wherein:
R' is selected from the group consisting o~
-SOZNHz, -SOZMe, -CH2NHz and -CHZNMez;
Rla is selected from the group consisting of -H, -F, -Cl and -Br;
Rlb is selected from the group consisting of -CH3, -CF3, -CHZCH3, -SOzMe, -CONHz and -NHSOzMe;
R'°z and R'°3 are independently selected from the group consisting of:

-H, -F, -C1 and -Br.
This invention also encompasses all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives of the compounds of the formula (I). In addition, the compounds of formula (I) can exist in various isomeric and tautomeric forms, and all such forms are meant to be included in the invention, along with pharmaceutically acceptable salts, hydrates, solvates and prodrug derivatives of such isomers and tautomers.
The compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.
A number of methods are useful for the preparation of the salts described above and are known to those skilled in the art. For example, the free acid or free base form of a compound of one of the formulas above can be reacted with one or more molar equivalents of the desired acid or base in a solvent or. solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.
Preparation of Compounds The compounds of the present invention may be synthesized by standard organic chemical synthetic methods as described and referenced in standard textbooks.
These methods are well known in the art. See, e.g., March, "Advanced Organic Chemistry", John Wiley & Sons, New York" 1992; Joule, Mills and Smith, "Heterocyclic Chemistry", Chapman & Hall, London, 1995, et seq.
Starting materials used in any of these methods are commercially available from chemical vendors such as Aldrich, Fluka, Lancaster, TCI, Maybridge, Frontier, Fluorochem, Alfa Aesar, and the like, or may be readily synthesized by known procedures.
Reactions are carried out in standard laboratory glassware and reaction vessels under reaction conditions of standard temperature and pressure, except where otherwise indicated.
During the syntheses of these compounds, the functional groups of the substitutents are optionally protected by blocking groups to prevent cross reaction.
Examples of suitable protective groups and their use are described in Kocienski, "Protecting Groups", Thieme, Stuttgart, 1994; Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley & Sons, New York, 1999, and the disclosures of which are incorporated herein by reference.
Non-limiting exemplary synthesis schemes are outlined directly below, and specific steps are described in the Examples. The reaction products are isolated and purified by conventional methods, typically by solvent,extraction into a compatible solvent. The products may be further purified by any means known in the art such as, for example, flash column chromatography, reverse-phase preparative high performance liquid chromatography (HPLC) with high purity water and acetonitrile, or other appropriate methods.
General Synthesis General synthesis for compounds with a N-linked G ring is outlined in Scheme 1 below. In Scheme 1, A', Q', D', E', J' and X' are protected functional structures which can be converted to A, Q, D, E, J and X respectively by methods known in the art (e.g.
deprotection methods). For formation of the N-linked G ring, the appropriate aromatic amine precursor is treated under conditions described in Joule, Mills and Smith, "Heterocyclic Chemistry", Chapman & Hall, London, 1995, or the references cited therein, or as described later in the preparation section to give the G ring.

Scheme 1 For nitrogen-linked heterocycle G
A-Q-D
,-NHp heterOCyCle E A'-Q'-D A-Q-D-E N
formation / coupling / deprotection ~X ~ ~ ~X
A-Q ~ D~
x heterocycle A'-Q' ~ D~
formation A'-Q' ~ D~ ~ coupling A'-Q' D NHZ
J x, deprotection A q ~ D~ N
x Scheme 2 For pyrazole-linked compounds R,e A-O-D-H / ~ N
~X I
R,c R,b OMe Hz 1) N8NO2 NHNHZ ~ / ~N MeOH, THF, HOz / \N
HCI, 0°C R,e Co2Et E~z Water X I HOAc, THF' 2) SnCoz ~ X I X I
HCI, 0 C reflux R,c R,e coupling A'o'p'H / \N depro-tectio' A ~~H / \N
~I ~I
R,n i A- / D
NH
IX
Q NOMe 1 ) NaN02 ~ ,c HCI, O°C \ R'° CozEt ~ R
A'Q / D\ NHz ~ A'O / D \ NHNHZ HOA~ A O / p\ _ 2) -SnCo2 ~ reflux HCI, 0 C COZEt LiOH R,n R,n / \ deprotection aOH, THF, A'o / ~ ~ coupling A'Q D ' COZH
!H
R,p X.
i A- / D~
!H
X
Scheme 2 above shows the general synthesis of compounds with a N-linked pyrazole G ring. Appropriately protected aromatic amines are converted to aromatic hydrazines by reduction of their diazonium salts. The hydrazines are condensed with 1,3-diketones to yield the pyrazole structures.
Scheme 3 shows the general synthesis of compounds with a N-linked triazole G
ring. An appropriately protected aromatic amine is converted to aromatic azide from its diazonium salt. The azide is condensed with an alkyne to yield the triazole structure.

Scheme 3 For triazole-linked compounds A-Q-D-HN--~- ~~ N
N
N
NHz 1) NaNOy N3 ~~ LiOH ~N
TFA, 0°C - Co2Et E~z N~ MeOH, THF, Hp2 water 2) NaN3 X ~ toluene, hea ~ X
COUPIIng A,-O,_O, H. 1l // N deprOt~CtIOn A-~p H~ N
~H' A-O ~ D~ i~N
O
NH
I
X
1 ) NaNOz TFA, 0°C = COZEt ~t,~N
A.-Q. ~ p~ NHZ ~ p'-O~ ~ p~ N3 ~ A'-O.
2) NaN3 toluene, heat COZEt LiOH
MeOH, THF, A,-Q, ~ p~ ~~N coupling A'-q' ~ p~ ~~N deprotection water NH
I
x A-O ~ p~ i~N
O
NH
I
X

Scheme 4 For tetrazole-linked compounds N
A-Q-D-~~ N
N
NHZ ~ NH"COZEt E~2~~ MeOH, THF, HoZ~\N
G cozEt Ph3P, DEAD water Et3N ~ I X I X I
\ \
COUP A,-O,-D,-N-~-~NN depr0~ A-Q-p ~N-N
H' N' I
A-Q ~ D~ ~~ I
~N
O
NH
I
X
~ ~~ N
G' -G7 Et - ~ ~ Ph P, DEAD A~ O
A'-O'~NH2 ~ A' Q'~NH COzEt --~
Et3N ~ Et LiOH
watOeH' THF, A,-o. ~ D~ '~ ~ coupling A.-Q. ~ D~ ~~ ~ deprotection ~N ~ ~N
COZH O
NH
I
x A-o ~ D~ J'~ I
~N
O
NH
I
X

Scheme 4 shows the general synthesis of compounds with a N-linked tetrazole G
ring. An appropriately protected aromatic amine is acylated with ethyl chlorooxoacetate.
The resulting amide can be converted to the tetrazole by methods known in the art. See e.g. Journal of Organic Chemistry, ~, 2395 (1991); Synthesis, 767 (1993);
Journal of Organic Chemistry, ~, 32 (1993); Bioorganic & Medicinal Chemistry Letters, _6, ( 1996)).
General synthesis for compounds with a C-linked G ring is outlined in Scheme 5.
A', Q', D', E', J' and X' are protected functional structures which can be converted to A, Q, D, E, J and X respectively. For formation of the C-linked G ring, the appropriate aromatic aldehyde precursor is treated under conditions described in Joule, Mills and Smith, "Heterocyclic Chemistry", Chapman & Hall, London, 1995, or the references cited therein, or as described later in the preparation section to give the G ring.
The C-linked G
ring can also be connected to aromatic X or aromatic D using Suzuki cross-coupling method (Chemical Reviews, ~5, 2457 (1995)).

Scheme 5 For carbon-linked heterocycle G
G
A-O-D-E
~X I
CHO heterocycle / formation XI
G G G
E, A.-Q,_D.-E A-O-D-coupling deprotection --~ -w / B(OH)2 E'~ ~ ~ ~X I
yx I
Pd catalyst A- \ D/ G
x _ heterocycle formation A'-O' \ D/ CHO
A.-Q, p G coin A'-Q' \ D/ G
J, \ / , J
A'-Q' \ D/ B(OH)p -~ x' Pd catalyst deprotection A \ D/ G
x Scheme 6 shows the general synthesis of compounds with a C-linked isoxazole G
ring. A substituted aromatic aldehyde is reacted with hydroxylamine and then chlorinated to yield the hydroximinoyl choride (Journal of Organic Chemistry, 45, 3916 (1980)). It is treated with triethylamine to generate nitrite oxide in situ, which is reacted with methyl trans-3-mthoxyacrylate or methyl propiolate to give the isoxazole structure (Chemical Letters, -1, 85 (1987)).

Scheme 6 For isoxazole-linked hetereocycle compounds /g A-O-D-E
C ~COZMe /
Me02 / CHO ~ ) NHZOH / -~ Meo coupling ~x I 2) NCS ~x I Et A'-O'-D'-E / ~ deprotection A-~D-E /
I ~) q- ~p\ %~
NH
I
X
COZMe 1 ) NHyOH -OH Me ~ / \ /~
q,-O. ~ p\ CHO ~ A'-Q, ~ p\ /
2) NCS y Et3N
COzEt LiOH N q.-O, ~ p\ % ~ q-O
yMaOH. THF, q,-Q, / p\ / o coupling ~ deprotection -a --a o COzH i H NH
x x Scheme 7 shows the general synthesis of compounds with a C-linked thiozole G
ring. A substituted aromatic aldehyde is reacted with ethyl diazoacetate in presence of tin(II) chloride to afford the beta-ketoester. It is then converted to thiazole.

Scheme 7 For thiazole-linked hetereocycle compounds Rat \ N
A-Q-D-E
Rto S
'\N
O MeOz \
/ CHO NzCHzCO2Et / t) NBS _ cOUPllng \X~ -~_ x~ ~ /
SnCI , DCM ~ COZEt 2) R'°C(=S)NHZ
z Ran Rye A'-O'-D'-E ~ deprOteCtlOn A-~D-E
A / D\ ~~Rin O
NH
I
X
O Rm NZCHZCOZEt A~-O, ~ D~ 1) NB~ A-O
A,-Q, ~ D~ CHO ~ 2) R~tC~=S)NHZ
SnCl2, DCM EtOx COZEt Rie / ~ ~ Ric MeOH, THF, ~ ~ t~ Rib A~ Q~ D ~~ A D D
water A'-o' D ~ ~ coupling ~ deprotection s ~ o ---~ o COzH i H NH
x x Compositions and Formulations The compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.

A number of methods are useful for the preparation of the salts described above and are known to those skilled in the art. For example, reaction of the free acid or free base form of a compound of the structures recited above with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.
This invention also encompasses prodrug derivatives of the compounds contained herein. The term "prodrug" refers to a pharmacologically inactive derivative of a parent drug molecule that requires biotransformation, either spontaneous or enzymatic, within the organism to release the active drug. Prodrugs are variations or derivatives of the compounds of this invention which have groups cleavable under metabolic conditions.
Prodrugs become the compounds of the invention which are pharmaceutically active in vivo, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation. Prodrug compounds of this invention may be called single, double, triple etc., depending on the number of biotransformation steps required to release the active drug within the organism, and indicating the number'of functionalities present in a precursor-type form. Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA, 1992). Prodrugs commonly known in the art include acid derivatives well known to practitioners of the art, such as, for example, esters~prepared by reaction of the parent acids with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative.
Moreover, the prodrug derivatives of this invention may be combined with other features herein taught to enhance bioavailability.
Diagnostic applications of the compounds of this invention will typically utilize formulations such as solution or suspension. In the management of thrombotic disorders the compounds of this invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions or injectable administration, and the like, or incorporated into shaped articles.
Subjects in need of treatment (typically mammalian) using the compounds of this invention can be administered dosages that will provide optimal efficacy. The dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.
Formulations of the compounds of this invention are prepared for storage or administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations. Acceptable Garners or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., (A.R.
Gennaro edit. 1985). Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinalpyrrolidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.
Dosage formulations of the compounds of this invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods.
Formulations typically will be stored in lyophilized form or as an aqueous solution. The pH of the preparations of this invention typically will be between about 3 and about 11, more preferably from about S to about 9 and most preferably from about 7 to about 8. It will be understood that use of certain of the foregoing excipients, Garners, or stabilizers will result in the formation of cyclic polypeptide salts. While the preferred route of administration is by injection, other methods of administration are also anticipated such as intravenously (bolus and/or infusion), subcutaneously, intramuscularly, colonically, rectally, nasally or intraperitoneally, employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations and topical formulations such as ointments, drops and dermal patches. The compounds of this invention are desirably incorporated into shaped articles such as implants which may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers commercially available.
The compounds of this invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines. .~
The compounds of this invention may also be delivered by the use of antibodies, antibody fragments, growth factors, hormones, or other targeting moieties, to which the compound molecules are coupled. The compounds of this invention may also be coupled with suitable polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the factor Xa inhibitors of this invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stems, tubing, prostheses and the like.
Therapeutic compound liquid formulations generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by hypodermic injection needle.

Therapeutically effective dosages may be determined by either in vitro or in vivo methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required. The range of therapeutically effective dosages will naturally be influenced by the route of administration, the therapeutic objectives, and the condition of the patient.
For injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids.
For other routes of administration, the absorption efficiency must be individually determined for each inhibitor by methods well known in pharmacology.
Accordingly, it may be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. The determination of effective dosage levels, that is, the dosage levels necessary to achieve the desired result, will be within the ambit of one skilled in the art. Typically, applications of compound are commenced at lower dosage levels, with dosage levels being increased until the desired effect is achieved.
A typical dosage might range from about 0.001 mg/kg to about 1000 mg/kg, preferably from about 0.01 mg/kg to about 100 mg/kg, and more preferably from about 0.10 mg/kg to about 20 mg/kg. Advantageously, the compounds of this invention may be administered several times daily, and other dosage regimens may also be useful.
Typically, about 0.5 to about 500 mg of a compound or mixture of compounds of this invention, as the free acid or base form or as a pharmaceutically acceptable salt, is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor etc., as called for by accepted pharmaceutical practice.
The amount of active ingredient in these compositions, is such that a suitable dosage in the range indicated is obtained.
Typical adjuvants which may be incorporated into tablets, capsules and the like are a binder such as acacia, corn starch or gelatin, and excipient such as microcrystalline cellulose, a disintegrating agent like corn starch or alginic acid, a lubricant such as magnesium stearate, a sweetening agent such as sucrose or lactose, or a flavoring agent.
When a dosage form is a capsule, in addition to the above materials it may also contain a liquid carrier such as water, saline, a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit.
Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.
In practicing the methods of this invention, the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this inventions may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice, such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or warfarin. The compounds of this invention can be utilized in vivo, ordinarily in mammals such as primates, such as humans, sheep, horses, cattle; pigs, dogs, cats, rats and mice, or in vitro.
The preferred compounds of the present invention are characterized by their ability to inhibit thrombus formation with acceptable effects on classical measures of coagulation parameters, platelets and platelet function, and acceptable levels of bleeding complications associated with their use. Conditions characterized by undesired thrombosis would include those involving the arterial and venous vasculature.
With respect to the coronary arterial vasculature, abnormal thrombus formation characterizes the rupture of an established atherosclerotic plaque which is the major cause of acute myocardial infarction and unstable angina,. as well as also characterizing the occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA).
With respect to the venous vasculature,,abnormal thrombus formation characterizes the condition observed in patients undergoing major surgery in the lower extremities or the abdominal area who often suffer from thrombus formation in the venous vasculature resulting in reduced blood flow to the affected extremity and a predisposition to pulmonary embolism. Abnormal thrombus, formation further characterizes disseminated intravascular coagulopathy commonly occurs within both vascular systems during septic shock, certain viral infections and cancer, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure.
The compounds of this present invention, selected and used as disclosed herein, are believed to be useful for preventing or treating a condition characterized by undesired thrombosis, such as (a) the treatment or prevention of any thrombotically mediated acute coronary syndrome including myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, (b) the treatment or prevention of any thrombotically mediated cerebrovascular syndrome including embolic stroke, thrombotic stroke or transient ischemic attacks, (c) the treatment or prevention of any thrombotic syndrome occurring in the venous system including deep venous thrombosis or pulmonary embolus occurring either spontaneously or in the setting of malignancy, surgery~or trauma, (d) the treatment or prevention of any coagulopathy including disseminated intravascular coagulation (including the setting of septic shock or other infection, surgery, pregnancy, trauma or malignancy and whether associated with multi-organ failure or not), thrombotic thrombocytopenic purpura, thromboangiitis obliterans, or thrombotic disease associated with heparin induced thrombocytopenia, (e) the treatment or prevention of thrombotic complications associated with extracorporeal circulation (e.g. renal dialysis, cardiopulmonary bypass or other oxygenation procedure, plasmapheresis), (f) the treatment or prevention of thrombotic complications associated with instrumentation (e.g.
cardiac or other intravascular catheterization, infra-aortic balloon pump, coronary stmt or cardiac valve), and (g) those involved with the fitting of prosthetic devices.
Anticoagulant therapy is also useful to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage.
Thus the compounds of this invention can be added to or contacted with any medium containing or suspected to contain factor Xa and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material such as vascular grafts, stents, orthopedic prostheses, cardiac stems, valves and prostheses, extra corporeal circulation systems and the like.
Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.
Examples Exam 1.
Step 1. To the solution of 2-naphthylboronic acid (5.00 g, 29.1 mmol) and ethyl 3-methylpyrazole-S-carboxylate (4.48 g, 29.1 mmol) in 100 mL dry dichloromethane (DCM) were added pyridine (4.7 mL, 58.2 mmol) and anhydrous powder of copper(II) acetate (7.94 g, 43.7 mmol). Some activated molecular sieve powder was added afterwards. The resulting slurry was stirred for 2 days under argon. The mixture was diluted with DCM. It was filtered through a celite bed. The blue filtrate was washed with water (X2), dried over MgS04, concentrated, purified by silica column to yield ethyl 3-methyl-1-(2-naphthyl)-1H-pyrazole-5-carboxylate arid its regioisomer in a 1:1 ratio in 70% yield. Rf 0.59 (1:2 EtOAc: hexane), M+H 281; regioisomer, ethyl 5-methyl-1-(2-naphthyl)-1H-pyrazole-3-carboxylate, Rf 0.44 (1:2 EtOAc: hexane). ES-MS:
(M+H)+
281.
Step 2. To a solution of2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (50 mg, 0.16 mmol) in 1 mL DCM was added trimethylaluminum (2.0M in hexane, 0.41 mL, 0.82 mmol) under argon at room temperature. After being stirred for 30 minutes, to the mixture was added the above-prepared ester (46 mg, 0.16 mmol) in 1 mL DCM. The resulting mixture was stirred overnight. The reaction was quenched using 5 mL
saturated Rochelle salt aq solution. The mixture was extracted-using DCM (X3). The organic phases were combined, dried, rotovaped and subjected on flash column to give the coupled product in 52% yield (46 mg). Rf 0.46 ( 1:1. EtOAc: hexane). ES-MS:
(M+H)+
539.
Step 3. The above-prepared compound (42 mg, 0.078 mmol) was placed in 3 mL
trifluoroacetic acid (TFA). The solution was stirred in 60°C bath for 30 minutes. TFA was removed on rotovap. The residue was dissolved in methanol and purified by preparative HPLC to afford the title compound in 95% yield. ES-MS: (M+H)+ 483.
to am 1e 2.
Step 1. A mixture of tin(II) chloride (2.08 g, 10.96 mmol) and ethyl diazoacetate (2.76 mL, 26.28 mmol) in 50 mL DCM was stirred for 2 hours. Naphthalene-2-carbaldehyde was added. After stirred at room temperature for 18 hours, the mixture was concentrated, dissolved in EtOAc, washed with water (X3), dried and evaporated. The crude material was purified to give product ethyl 3-(2-naphthyl)-3-oxoprppionate. Rf 0.61 (1:1 EtOAc:
hexane). ES-MS: (M+H)+ 243.
Step 2. To a solution of the above-prepared ester (240 mg, 1 mmol) in 15 mL
MeCN at 65°C was added hydroxy(tosyloxy)iodobenzene (430 mg, 1.1 mmol). After stirred for 1 hour, to the mixture was added thiourea (83 mg, 1.1 mmol). The resulting mixture was stirred overnight at 65°C. The solution was cooled and concentrated.
The residue was dissolved in EtOAc, washed with brine, dried over MgS04, and evaporated to give crude 2-methyl-4-(2-naphthyl)-S-(carboethoxy)thiazole. Rf 0.64 (1:3 EtOAc: hexane).
ES-MS:
(M+H)+ 298.

Step 3. To a solution of the above-prepared product (148 mg, 0.50 mmol) and 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (152 mg, 0.50 mmol) in 3 mL DCM
was added trimethylaluminum (2.0M in hexane, 0.75 mL, 1.5 mmol), and the mixture was stirred at room temperature for 20 hours. The reaction was neutralized with 4 mL 1N
HCl and extracted with EtOAc. The organic layer was washed with brine, dried over MgS04, and concentrated to give the coupling product (170 mg, 61%). Rf 0.25 (1:3 EtOAc: hexane). ES-MS: (M+H)+ 556.
Step 4. The above-prepared product (100 mg) was placed in 3 mL TFA. The solution was stirred in 80°C bath for 60 minutes. TFA was removed on rotovap. The residue was dissolved in methanol and purified by preparative HPLC to afford the title compound in over 90% yield. ES-MS: (M+H)+ 500.
Example 3.
Step 1. 3-Amino-2-naphthoic acid (40.4 g, 216 mmol) was placed in 200 mL
concentrated HCI. At 0°C, the slurry was stirred vigorously using a mechanical stirring blade. To it was added a cold solution of sodium nitrite (29.8 g, 432 mmol) in 70 mL water.
After completion, the cold slurry was stirred for 30 minutes at 0°C. To it was added cold tetrafluoroboric acid (48 wt. % in water, 56 mL; 432 mmol). After stirred at 0°C for 30 minutes, the solid was filtered using a Buchner funnel. The soild cake was carefully rinsed with cold water (10 mL X2), cold tetrafluoroboric acid (10 mL X2) and cold ethanol (5 mL X2). The solid was dried in vacuuo. It was then placed in 300 mL
xylene and refluxed overnight. Xylene was removed on rotovap. The residue was acidified to pH 1 with aq HCl and taken into EtOAc. It was washed with brine (X2), dried, evaporated to give 3-fluoro-2-naphthoic acid (32.6 g, 78%). ES-MS: (M+H)+ 191.
Step 2. The above-prepared acid (14.7 g, 77 mmol) was dissolved in 200 mL
CHC13. To it was added 0.5 mL dry DMF. Then at room temperature, oxalyl chloride (20 mL, mmol) was added dropwise. The reaction solution was stirred for overnight. All solvent was removed in vacuuo. The residue was pumped till dryness. It was dissolved in 150 mL
dry dioxane, chilled to 0°C and vigorously stirred. To it, at the cold tempareture, was added the cold solution of sodium azide (10 g, 155 mmol, in 30 mL water and 15 mL
dioxane) in small portions. The reaction was allowed for 2 hours at 0°C. The solvent was removed in vacuuo. The residue was taken into EtOAc and washed with brine (X3). The organic phase was dried and evaporated to dryness in vacuuo to give 3-fluoro-2-naphthoyl azide. Rf 0.83 (1:1 EtOAc: hexane). It was dissolved in 80 mL DMF.
To it was added 40 mL water. The milky mixture was refluxed overnight. The solvent was removed in vacuuo. The residue was taken into EtOAc, and washed with brine (X2). The organic phase was dried, concentrated and purified with flash silica column to yield 3-fluoro-2 naphthylamine (8.1 g, 65%). Rf 0.40 (1:3 EtOAc: hexane). ES-MS: (M+H)+ 162.
Step 3. The above-prepared compound (7.5 g, 46 mmol) was placed in 50 mL
concentrate HCI. The mixture was vigorously stirred in ice bath. To it was dropwise added cold sodium nitrite ( 3.8 g, 55 mmol) solution in 10 mL water. After completion, the mixture was stirred at 0°C for half an hour. At 0°C, to it was dropwise added cold SnClz.2H20 (26.3 g, 116 mmol) solution in 20 mL concentrate HCI. The slurry was stirred for half an hour at 0°C, chilled, and filtered through a Buchner funnel to isolate the solid hydrazine.
It was dried in vacuuo. The solid hydrazine was dissolved~in 100 mL glacial acetic acid.
To it were added ethyl 2-N-(methoxy)imino-4-oxopentanoate (10.4 g, 56 mmol, prepared from ethyl 2,4-dioxovalerate and methoxylamine hydrogen chloride in ethanol) and 50 mL THF. The mixture was refluxed for 2 hours. The solvent was removed in vacuuo. The residue was taken into EtOAc, washed with brine and water. The organic phase was dried, concentrated and purified with flash column to yield ethyl 3-methyl-1-(3-fluoro-2-naphthyl)-1H-pyrazole-5-carboxylate (9.0 g, 65%). Rf 0.52 (1:2 EtOAc: hexane).
ES-MS:
(M+H)+ 299.

Step 4. To a solution of2'-N-tent-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (77mg, 0.25 mmol) in 1 mL dry DCM was added trimethylaluminum (2.0M in hexane, 0.51 mL, 1.0 mmol). The mixture was stirred for 20 minutes. The above-prepared ester (50 mg, 0.17 mmol) was dissolved in 3 mL dry DCM and added into the aluminum mixture.
The reaction was stirred at room temperature for overnight and quenched using saturated Rochelle's salt aq solution. It was extracted with CHC13 (X3). The organic phases were combined, dried, concentrated and purified with flash column to yield the coupling product (85 mg, 90%). Rf 0.45 (1:1 EtOAc: hexane). ES-MS: (M+H)+ 557.
Step 5. The above-prepared product was placed into 3 mL TFA. The mixture was stirred overnight at room temperature. It was evaporated, dissolved in methanol, purified with prep HPLC to afford the title compound in over 90% yield. ). ES-MS: (M+H)+
501.
Example 4.
Step 1. The preparation of ethyl 3-methyl-1-(3-fluoro-2-naphthyl)-1H-pyrazole-carboxylate was the same as that in Step 3 for Example 3. This ester ( 13.2 g, 44 mmol) was dissolved in 80 mL methanol. To it were added LiOH.H20 (3.7 g, 49 mmol) and 40 mL water. The mixture was stirred for overnight at room temperature. It was evaporated in vacuuo to remove methanol. The residue was acidified with 1N HCl till pH 1.
The mixture was extracted with EtOAc (X4). The organic extracts were combined, dried, evaporated and pumped to dryness to afford 3-methyl-1-(3-fluoro-2-naphthyl)-1H-pyrazolecarboxylic acid in over 90% yield. ES-MS: (M+H)+ 271.
Step 2. The above-prepared acid (33 mg, 0.12 mmol), 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine (77 mg, 0.24 mmol) and catalytic amount of DMAP (S
mg) were dissolved in 2 mL pyridine. The solution was stirred at 0°C.
To it was added POC13 (45 pL, 0.48 mmol). The mixture was stirred for 1 hour and quenched with ice chips. To it was added EtOAc. It was washed with brine (X2), dried, and concentrated. To the residue was added 3 mL TFA. The mixture was stirred at 60°C for 1 hour, concentrated, dissolved in methanol and subjected on prep HPLC to afford the title compound in 50% yield (31 mg). ES-MS: (M+H)+ 519.
Exam 1p a 5.
This compound was prepared by the same methodology described for Example 4 with 2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 535.
Example 6.
This compound was prepared by the same methodology described for Example 4 with 2'-N-tert-butylaminosulfonyl-3-bromo-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 579, 581 (Br pattern).

Example 7.
This compound was prepared by the same methodology described for Example 4 with 2-amino-5-(2-(N-tert-butylaminosulfonyl)phenyl)pyridine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 502.
Example 8.
This compound was prepared by the same methodology described for Example 4 with 2-amino-5-(2-(N-tert-butylaminosulfonyl)phenyl)pyrimidine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 503.

E a This compound was prepared by the same methodology described for Example 4 with 2'-cyano-[1,1']-biphenyl-4-ylamine substituted 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine, without the TFA treatment. ES-MS: (M+H)+ 447.
Example 10.
The title compound (40 mg, 0.09 mmol) of Example 9 was dissolved in 2 mL dry DMF.
At 0°C, to it were added sodium borohydride (27 mg, 0.72 mmol) and anhydrous Co(II) chloride (23 mg, 0.18 mmol). The mixture was stirred for 2 hours and quenched with 1 mL acetic acid. The mixture was evaporated, dissolved in methanol, filtered, loaded on prep HPLC to afford the title compound in 60% yield. ES-MS: (M+H)+ 451.

Example 11.
N
~N
N~
/
F
The title compound (40 mg, 0.09 mmol) of Example 9 was dissolved in 2 mL dry DMF.
At 0°C, to it were added sodium borohydride (27 mg, 0.72 mmol) and anhydrous Co(II) chloride (23 mg, 0.18 mmol). The mixture was stirred for 2 hours. To it was added 10 mL
acetone. The mixture was stirred for 1 hour at room temperature. The reaction was quenched with 1 mL acetic acid. The mixture was evaporated, dissolved in methanol, filtered, loaded on prep HPLC to afford the title compound in 50% yield. ES-MS:
(M+H)+ 493.
Example 12.
F
This compound was prepared by the same methodology described for Example 4 with 2'-(N-dimethylamino)methyl-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine, without the TFA
treatment. ES-MS: (M+H)+ 479.

Example 13.
Step 1. The preparation of 3-methyl-1-(3-fluoro-2-naphthyl)-1H-pyrazolecarboxylic acid was the same as that in Step 1 of Example 4.
Step2. This acid (65 mg, 0.24 mmol), 4-aminobenzonitrile (57 mg, 0.48 mmol) and DMAP (5 mg) were dissolved in 3 mL pyridine. The solution was stirred at 0°C. To it was added POCl3 (90 ~,L, 0.96 mmol). The mixture was stirred for 1 hour. The reaction was then quenched with ice chips. It was diluted with EtOAc. The organic phase was washed with brine (X2). It was dried, concentrated and purified with flash column to afford the coupling product (60 mg, 68%). Rf 0.40 (1:1 EtOAc: hexane). ES-MS:
(M+H)+
371.
Step 3. The above-prepared nitrite was dissolved in 10 mL dry methanol. It was chilled and stirred in an ice bath. To this solution was bubbled dry HCl gas via a long needle till saturation reached (indicated by a blown-up balloon attached on the top of the reaction flask). The resulting solution was stirred overnight. ES-MS: (M+H)+ 403. The solvent was removed in vacuuo. The residue was pumped to dryness. The solid was dissolved in 5 mL dry methanol. To it was added anhydrous N-methylethylenediamine (0.5 mL).
The mixture was refluxed for 1 hour, concentrated and loaded on prep HPLC to afford the title compound in 80% yield. ES-MS: (M+H)+ 428.

Exam In a 14.
This compound was prepared by the same methodology described for Example 13 with pyrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 442.
Example 15.
This compound was prepared by the same methodology described for Example 13 with piperidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 456.
Example 16.
This compound was prepared by the same methodology described for Example 13 with dimethylamine (commercial 2M solution in THF) substituted for N-methylethylenediamine. ES-MS: (M+H)+ 416.

Exam 1p a 17.
This compound was prepared by the same methodology described for Example 13 with thiomorpholine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 474.
Exam 1 This compound was prepared by the same methodology described for Example 13 with morpholine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 458.
Example 19.
This compound was prepared by the same methodology described for Example 13 with piperazine substituted for N-methylethylenediamine.'ES-MS: (M+H)+ 457.

Example 20.
This compound was prepared by the same methodology described for Example 13 with N-methylpiperazine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 471.
Exam 1p a 21.
This compound was prepared by the same methodology described for Example 13 with ammonium acetate substituted for N-methylethylenediamine. ES-MS: (M+H)+ 388.
Exam 1p a 22.
Step 1. 2-Fluoro-4-iodoaniline (5.0 g, 21 mmol) was dissolved in 20 mL dry DMF. To it were added CuCN (3.8 g, 42 mmol) and catalytic amount of CuI (200 mg). The slurry was refluxed for 1 hour. Diluted with EtOAc. Filtered.through celite.
Concentrated in vacuuo to yield solid 4-amino-3-fluorobenzonitrile (2.9 g, 100%). ES-MS:
(M+H)+ 137.

Step 2. The preparation of 3-methyl-1-(3-fluoro-2-naphthyl)-1H-pyrazolecarboxylic acid was the same as that in Step 1 of Example 4. This acid (270 mg, 1.0 mmol), 4-amino-3-fluorobenzonitrile (272 mg, 2.0 mmol) and DMAP (10 mg) were dissolved in 15 mL
pyridine. The solution was stirred at 0°C. To it was added POC13 (380 ~L, 4.0 mmol).
The mixture was stirred for 1 hour. The reaction was then quenched with ice chips. It was diluted with EtOAc. The organic phase was washed with brine (X2). It was dried, concentrated and purified with flash column to afford the coupling product (350 mg, 97%). Rf 0.77 (7:3 EtOAc: hexane). ES-MS: (M+H)+ 389. .
Step 3. The above-prepared nitrile (30 mg, 0.077 mmol) was dissolved in 10 mL
dry methanol. It was chilled and stirred in an ice bath. To this solution was bubbled dry HCI
gas via a long needle till saturation reached (indicated by a blown-up balloon attached on the top of the reaction flask). The resulting solution was stirred overnight.
ES-MS:
(M+H)+ 421. The solvent was removed in vacuuo. The residue was pumped to dryness.
The solid was dissolved in 5 mL dry methanol. To it was added anhydrous N-methylethylenediamine (0.5 mL). The mixture was refluxed for 1 hour, concentrated and loaded on prep HPLC to afford the title compound in 80% yield. ES-MS: (M+H)+
446.
Example 23 This compound was prepared by the same methodology described for Example 22 with pyrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 460.
Exam In a 24.

This compound was prepared by the same methodology described for Example 22 with piperidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 474.
Example 25.
This compound was prepared by the same methodology described for Example 22 with hexamethyleneimine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 488.
Example 26.
This compound was prepared by the same methodology described for Example 22 with morpholine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 476.
Example 27.

This compound was prepared by the same methodology described for Example 22 with ammonium acetate substituted for N-methylethylenediamine. ES-MS: (M+H)+ 406.
Example 28.
Step 1. The preparation of 3-methyl-1-(3-fluoro-2-naphthyl)-1H-pyrazolecarboxylic acid was the same as that in Step 1 of Example 4. This acid (50 mg, 0.18 mmol), 4-amino-2,5-difluorobenzonitrile (57 mg, 0.36 mmol) and DMAP (5 mg) were dissolved in 8 mL
pyridine. The solution was stirred at 0°C. To it was added POCl3 (70 pL, 0.74 mmol).
The mixture was stirred for 1 hour. The reaction was then quenched with ice chips. It was diluted with EtOAc. The organic phase was washed with brine (X2). It was dried, concentrated and purified with flash column to afford the coupling product (70 mg, 93%).
Rf 0.69 (7:3 EtOAc: hexane). ES-MS: (M+H)+ 407.
Step 2. The above-prepared nitrile (30 mg, 0.074 mmol) was dissolved in 10 mL
dry methanol. It was chilled and stirred in an ice bath. To this solution was bubbled dry HCl gas via a long needle till saturation reached (indicated by a blown-up balloon attached on the top of the reaction flask). The resulting solution was stirred overnight.
ES-MS:
(M+H)+ 439. The solvent was removed in vacuuo. The residue was pumped to dryness.
The solid was dissolved in S mL dry methanol. To it was added anhydrous N-methylethylenediamine (0.5 mL). The mixture was refluxed for 1 hour, concentrated and loaded on prep HPLC to afford the title compound in 80%' yield. ES-MS: (M+H)+
464.

Example 29 F
This compound was prepared by the same methodology described for Example 28 with pyrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 478.
Example 30.
This compound was prepared by the same methodology described for Example 28 with ammonium acetate substituted for N-methylethylenediamine. ES-MS: (M+H)+ 424.
Exam 1p a 31.
This compound was prepared by the same methodology from Step 3 to Step 5 described for Example 3 with 3-chloro-2-naphthylamine substituted for 3-fluoro-2-naphthylamine.
ES-MS: (M+H)+ 517.

Example 32.
This compound was prepared by the same methodology from Step 3 to Step 5 described for Example 3 with 3-bromo-2-naphthylamine substituted for 3-fluoro-2-naphthylamine.
ES-MS: (M+H)+ 561, 563 (Br pattern).
Example 33.
This compound was prepared by the same methodology from Step 3 to Step 5 described for Example 3 with 3-hydroxy-2-naphthylamine substituted for 3-fluoro-2-naphthylamine. ES-MS: (M+H)+ 499.
Exam lnn a 34.

Step 1. The synthesis of ethyl 3-methyl-1-(3-bromo-2-naphthyl)-1H-pyrazole-carboxylate followed the same methodology described for Step 3 of Example 3 with commercial with 3-bromo-2-naphthylamine substituted for 3-fluoro-2-naphthylamine. Yield 60%.
Rf 0.42 (1:3 EtOAc: hexane). ES-MS: (M+H)+ 359, 361 (Br pattern).
Step 2. The above-prepared bromide (370 mg, 1.0 mmol) was dissolved in 3 mL
dry DMF. To it were added CuCN (180 mg, 2.0 mmol) and CuI (20 mg). The slurry mixture was refluxed for 2 hours. It was diluted with EtOAc. Filtered through celite.
Concentrated and purified by flash column to yield of ethyl 3-methyl-1-(3-cyano-2-naphthyl)-pyrazole-carboxylate (220 mg, 70%). Rf 0.48 (1:2 EtOAc: hexane). ). ES-MS:
(M+H)+
l0 306.
Step 3. To a solution of2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (164 mg, 0.54 mmol) in 2 mL dry DCM was added trimethylaluminum (2.0M in hexane, 1.1 mL, 2.2 mmol). The mixture was stirred for 20 minutes.. The above-prepared ester (137 mg, 0.45 mmol) was dissolved in 6 mL dry DCM and added into the aluminum mixture.
The reaction was stirred at room temperature for overnight and quenched using saturated Rochelle's salt aq solution. It was extracted with CHC13 (X3). The organic phases were combined, dried, concentrated and purified with flash column to yield 3-methyl-1-(3-cyano-2-naphthyl)-1 H-pyrazole-5-(N-(2'-N-tent-butylaminosulfonyl-[ 1,1' ]-biphen-4-yl))carboxyamide (170 mg, 67%). Rf 0.40 (1:1 EtOAc: hexane). ES-MS: (M+H)+
564.
Step 4. The above-prepared compound (30 mg, 0.05 mmol) was dissolved in 5 mL
dry DCM. At 0°C, to it was added BF3.OEt2 (62 p,L, 0.5 mmol) dropwise. The mixture was stirred overnight. Extra 1.0 mmol BF3.OEt2 was added in small portions at room temperature the next day. After another overnight, deprotection was about 70%
complete.
The mixture was loaded on a short flash column for separation. The title product was purified using prep HPLC (55% yield). ES-MS: (M+H)+ 508.

Example 35.
Step 1. The synthesis of 3-methyl-1-(3-cyano-2-naphthyl)-1H-pyrazole-5-(N-(2'-N-tert-butylaminosulfonyl-[1,1']-biphen-4-yl))carboxyamide followed the same procedure of Step 3 for Example 34.
Step 2. The above-prepared compound (30 mg, 0.05 mmol) was placed in 3 mL TFA
and refluxed for 1 hour. After concentration, it was purified with prep HPLC to yield the title compound (85%). ES-MS: (M+H)+ 526.
Example 36 SOiNHz F
H O ~ \N
CN
l0 This compound was prepared by the same methodology described for Example 34 with 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 526.

This compound was prepared by the same methodology described for Example 35 with 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tent-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 544.
Example 38 Step 1. The synthesis of ethyl 3-methyl-1-(3-cyano-2-naphthyl)-1H-pyrazole-carboxylate followed the same procedure of Step 2 for Example 34.
Step 2. The above-prepared ester (930 mg, 3.0 mmol) was dissolved in 20 mL
methanol.
To it were added LiOH.H20 (256 mg, 6.0 mmol) and 10 mL water. The mixture was stirred for 3 hours at room temperature. Methanol was removed in vacuuo. The residue was carefully acidified with 1N HCl till pH 1. It was extracted with EtOAc (X4). The organic phases were combined, dried and evaporated~in vacuuo till dryness to give 3-methyl-1-(3-cyano-2-naphthyl)-1H-pyrazole-5-carboxylic acid (720 mg, 85%). ES-MS:
(M+H)+ 278.

Step 3. The mixture of the above-prepared acid (110 mg, 0.40 mmol), 2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphenyl-4-ylamine (0.21 g, 0.60 mmol), DMAP (S
mg) were dissolved in 5 mL pyridine and stirred at 0°C. To it was added POC13 (120 pL, 1.2 mmol). The mixture was stirred for 2.5 hours and quenched with ice chips.
It was diluted with EtOAc, washed with brine (X2), dried, concentrated and purified with flash column to give 3-methyl-1-(3-cyano-2-naphthyl)-1H-pyrazole-5-(N-(2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphen-4-yl))carboxyamide (240 mg, 95%). Rf 0.65 (1:1 EtOAc: hexane). ES-MS: (M+H)+ 598.
Step 4. The above-prepared compound (30 mg, 0.05 mmol) was dissolved in 5 mL
dry DCM. At 0°C, to it was added BF3.OEtz (62 ~.L, 0.5 mmol) dropwise. The mixture was stirred overnight. Extra 1.0 mmol BF3.OEt2 was added in small portions at room temperature the next day. After another overnight, deprotection was about 70%
complete.
The mixture was loaded on a short flash column for separation. The title product was purified using prep HPLC (52% yield). ES-MS: (M+H)+ 542.
Example 39.
Step 1. The synthesis of 3-methyl-1-(3-cyano-2-naphthyl)-1H-pyrazole-5-(N-(2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphen-4-yl))carboxyamide followed the same procedure of Step 3 for Example 38.
Step 2. The above-prepared compound (30 mg, 0.05 mmol) was placed in 3 mL TFA
and refluxed for 1 hour. After concentration, it was purified with prep HPLC to yield the title compound (85%). ES-MS: (M+H)+ 560.

Example 40 This compound was prepared by the same methodology described for Example 38 with 2'-N-tert-butylaminosulfonyl-3-bromo-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 586, (Br pattern).
Example 41.
This compound was prepared by the same methodology described for Example 39 with 2'-N-tert-butylaminosulfonyl-3-bromo-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 604, (Br pattern).

Example 42 This compound was prepared by the same methodology described for Example 38 with 2-amino-5-(2-(N-tert-butylaminosulfonyl)phenyl)pyridine substituted for 2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 509.
Example 43.
This compound was prepared by the same methodology described for Example 39 with 2-amino-5-(2-(N-tert-butylaminosulfonyl)phenyl)pyridine substituted for 2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 527.

Example 44 This compound was prepared by the same methodology described for Example 38 with 2-amino-5-(2-(N-tert-butylaminosulfonyl)phenyl)pyrimidine substituted for 2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 510.
Example 45.
This compound was prepared by the same methodology described for Example 39 with 2-amino-5-(2-(N-tent-butylaminosulfonyl)phenyl)pyrimidine substituted for 2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 528.
Example 46.

Step 1. To a solution of 4-nitroaniline (1.0 g, 6.7 mmol) in 50 mL anhydrous ethanol at 0°C was bubbled dry HCl gas via a long needle till saturation reached.
The resulting solution was stirred overnight. The solvent was removed in vacuuo. The residue was pumped to dryness. It was dissolved in 50 mL anhydrous ethanol. To it was added 2 mL
N-methylethylenediamine. The mixture was refluxed for 1 hour and evaporated in vacuuo to give the 1-methyl-2-(4-nitrophenyl)-2-imidazoline HCl salt in 90% yield. ES-MS:
(M+H)+ 206.
Step 2. To a solution of the above-prepared nitro compound (500 mg, 2.4 mmol) in 4 mL
4N HCl and 50 mL methanol was added 10% Pd/C (50 mg). The mixture was stirred for 2 hours under a hydrogen balloon. It was filtered through celite and concentrated in vacuuo to give the 4-(1-methyl-2-imidazolin-2-yl)aniline HCl salt in 90% yield. ES-MS: (M+H)+
176.
Step 3. To a solution of the above-prepared amine (40 mg, 0.22 mmol), 3-methyl-1-(3-cyano-2-naphthyl)-1H-pyrazole-5-carboxylic acid (15 mg, 0.054 mmol, see Step 2, Example 38), DMAP (2 mg) in 2 mL pyridine at 0°.C was added POC13 (20 ~,L, 0.22 mmol). The mixture was stirred for 2 hours. It was concentrated in vacuuo and loaded on prep HPLC to afford the title compound in 60% yield. ES-MS: (M+H)+ 435.
Example 47.
C
The title compound in Example 46 ( 10 mg) was placed in TFA. It was refluxed for 1 hour and subjected on prep HPLC purification to afford the title compound in 85%
yield..ES-MS: (M+H)+ 453.

Example 48.
Step 1. To a solution of 2-fluoro-4-nitroaniline (300 mg, 2.2 mmol) in 20 mL
anhydrous methanol at 0°C was bubbled dry HCl gas via a long needle till saturation reached. The resulting solution was stirred overnight. The solvent was removed in vacuuo.
The residue was pumped to dryness. It was dissolved in 10 mL anhydrous methanol. To it was added 1 mL N-methylethylenediamine. The mixture was refluxed for 1 hour and evaporated in vacuuo to give the 1-methyl-2-(2-fluoro-4-nitrophenyl)-2-imidazoline HCl salt in 90%
yield. ES-MS: (M+H)+ 224.
Step 2. To a solution of the above-prepared nitro compound in 2 mL 4N HCl and 25 mL
methanol was added 10% PdIC (20 mg). The mixture was stirred for 2 hours under a hydrogen balloon. It was filtered through celite and concentrated in vacuuo to give the 2-fluoro-4-(1-methyl-2-imidazolin-2-yl)aniline HCl salt in 90% yield. ES-MS:
(M+H)+ 194.
Step 3. To a solution of the above-prepared amine (100 mg, 0.51 mmol) in 2 mL
DCM
was added trimethylaluminum (2.0M in hexane, 2 mL, 4.0 mmol). The mixture was stirred for 20 minutes. Ethyl 3-methyl-1-(3-cyano-2-naphthyl)-1H-pyrazole-carboxylate (76 mg, 0.25 mmol, see Step 2 of Example 34) was dissolved in 2 mL DCM and added into the reaction flask. The mixture was stirred for 2 days at room temperature. It was quenched with saturated Rochelle's salt aq solution and extracted with CHC13 (X4). The organic phases were combined, dried, concentrated and purifed with prep HPLC
to yield the title compound (55%). ES-MS: (M+H)+ 453.

Example 49.
The title compound in Example 48 (10 mg) was placed in TFA. It was refluxed for 1 hour and subjected on prep HPLC purification to afford the title compound in 85%
yield. ES-MS: (M+H)+ 471.
Example 50.
Step 1. Compound 3-methyl-1-(3-cyano-2-naphthyl)-1H-pyrazole-5-(N-(2'-N-tert-butylaminosulfonyl-[1,1']-biphen-4-yl))carboxyamide was prepared by the same procedure shown in Step 3 of Example 34.
Step 2. The above-prepared compound (70 mg, 0.12 mmol) was dissolved in 2 mL
dry DMF. At 0°C, to it were added sodium borohydride (36 mg, 0.96 mmol) and CoCl2 (32 mg, 0.24 mmol). It was stirred for 2 days. Diluted with EtOAc and stirred for 1 hour. The mixture was filtered through celite. The filtrate was evaporated to give crude 3-methyl-1-(3-aminomethyl-2-naphthyl)-1H-pyrazole-5-(N-(2'-N-tert-butylaminosulfonyl-[1,1']-biphen-4-yl))carboxyamide. ES-MS: (M+H)+ 568.

Step 3. The above-prepared crude compound was taken into 3 mL TFA. The mixture was stirred for 1 hour at 60°C. The mixture was evaporated and subjected on prep HPLC to isolate the title compound (35% yield). ES-MS: (M+H)+ 512.
Exam 1p a 51.
Step 1. Compound 3-methyl-1-(3-cyano-2-naphthyl)-1H-pyrazole-5-(N-(2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphen-4-yl))carboxyamide was prepared by the same methodology shown in Step 3 of Example 34, with 2.'-N-tert-butylaminosulfonyl-fluoro-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 582.
Step 2. To a solution of the above-prepared compound (77 mg, 0.13 mmol) in 3 mL
anhydrous methanol and 3 mL anhydrous EtOAc at -20°C was bubbled dry HCl gas via a long needle till saturation reached. The mixture was stirred for overnight.
The solvent was removed in vacuuo. The dry residue was dissolved in 5 mL anhydrous methanol.
To it was added 50 mg ammonium acetate. The mixture was refluxed for 2.5 hours. It was subjected on prep HPLC to isolate the title compound (5S% yield). ES-MS:
(M+H)+ 543.

Example 52.
Step 1. 3-Amino-2-naphthoic acid (5.8 g, 31 mmol) was placed in 50 mL
concentrate HCI. The slurry was vigorously stirred at 0°C. To it was added dropwise a cold solution of sodium nitrite (2.35 g, 34 mmol, in 14 mL water): After completion, the mixture was stirred for 40 minutes at 0°C. Under vigorously stirring, a cold solution of SnC12.2H20 (21 g, 93 mmol, in 30 mL concentrate HCl) was added dropwise. The mixture was stirred for 30 minutes and chilled in ice bath. The crude 3-carboxyl-2-naphthylhydrazine was collected with a Buchner funnel and pumped to dryness in vacuuo.
Step 2. The crude hydrazine prepared above was taken into 60 mL glacial acetic acid and 30 mL THF. To it was added ethyl 2-N-(methoxy)imino-4-oxopentanoate (2.6 g, 14 mmol). The mixture was refluxed for overnight. The solvent was removed in vacuuo. The residue was dissolved in EtOAc and washed with brine (X2). The organic phase was dried, concentrated and purified with flash column to yield ethyl 3-methyl-1-(3-carboxyl-2-naphthyl)-1H-pyrazole-5-carboxylate (4.1 g, 90%). Rf0.15 (1:1 EtOAc:
hexane). ES-MS: (M+H)+ 325.
Step 3. To a solution of 2'-N-tent-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (36 mg, 0.12 mmol) in 1 mL dry DCM was added trimethylaluminum (2.0M in hexane, 0.5 mL, 1.0 mmol). The mixture was stirred for 20 minutes. The above-prepared ester (38 mg, 0.12 mmol) was dissolved in 3 mL dry DCM and added into the aluminum mixture.
The reaction was stirred at room temperature for overnight and quenched using saturated Rochelle's salt aq solution. It was extracted with CHCl3 (X3). The organic phases were combined, dried, concentrated and purified with flash column to yield the coupling product (60%). ES-MS: (M+H)+ 583.

Step 4. The above-prepared compound (15 mg) was placed in 3 mL TFA and stirred overnight. It was concentrated and purified with prep HPLC to afford the title compound in 90% yield. ES-MS: (M+H)+ 527.
Example 53.
This compound was prepared by the same methodology described for Example 52 with 2'-N-tent-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 545.
Step 1. The above-prepared crude acid was dissolved in 150 mL anhydrous ethanol. To it was added pTSA (3.3 g). The mixture was refluxed for 4 days till the esterification was over 95% complete. The solvent was removed in vacuuo. The residue was dissolved in EtOAc, washed with brine (X3), dried and purified by a short silica column to afford ethyl 3-methyl-1-(3-methylthio-2-naphthyl)-1H-pyrazole-5-carboxylate in over 80%
yield. ES-MS: (M+H)+ 327.
Step 2. The above-prepared ester (4.95 g, 1 S mmol) was dissolved in 150 mL
DCM. At 0°C, to the vigorously stirred solution was added MCPBA (11 g, 38 mmol) in small portions over 20 minutes. The reaction was allowed for 1 hour and diluted with CHC13. It was washed with NaHC03 saturated aq solution (X3), dried, concentrated and purified with flash column to give ethyl 3-methyl-1-(3-methylsulfonyl-2-naphthyl)-1H-pyrazole-5-carboxylate (3.49 g, 65%). Rf 0.52 (1:1 EtOAc: hexane). ES-MS: (M+H)+ 359.
Step 3. To a solution of 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (21 mg, 0.068 mmol) in 1 mL dry DCM was added trimethylaluminum (2.0M in hexane, 0.14 mL, 0.28 mmol). The mixture was stirred for 20 minutes: The above-prepared ester (16 mg, 0.045 mmol) in Step 4 was dissolved in 4 mL dry DCM and added into the aluminum mixture. The reaction was stirred at room temperature for overnight and quenched using saturated Rochelle's salt aq solution. It was extracted with CHC13 (X3). The organic phases were combined, dried, concentrated and purified with flash column to yield the coupling product (52%). Rf 0.17 (1:1 EtOAc: Hexane). ES-MS: (M+H)+ 617.
Step 4. The above-prepared compound was dissolved in 2 mL acetonitrile and 2 mL TFA.
The mixture was stirred for 1 hour at 70°C. The mixture was evaporated and purified with prep HPLC to afford the title compound in 90% yield. ES-MS: (M+H)+ 561.
Exam 1p a 54.
Step 1. The synthesis of ethyl 3-methyl-1-(3-methylsulfonyl-2-naphthyl)-1H-pyrazole-5-carboxylate was the same as that described in Step 4 of Example 53.
Step 2. The above-prepared ester (3.4 g, 9.7 mmol) was dissolved in 20 mL
methanol. To it were added LiOH.H20 (0.82 g, 19.5 mmol) and 10 mL water. The mixture was stirred at room temperature for overnight. The solvent was evaporated. The residue was acidified with 1N HCl till pH 1. The mixture was extracted with EtOAc (X4). The organic phases were combined, dried, evaporated to dryness to afford 3-methyl-1-(3-methylsulfonyl-2-naphthyl)-1H-pyrazole-5-carboxylic acid (3.24 g, 99%). ES-MS: (M+H)+ 331.
Step 3. The above-prepared acid (102 mg, 0.31 mmol), 2'-N-tent-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine (150 mg, 0.46 mmol), DMAP (10 mg) were dissolved in 3 mL pyridine. To this stirred solution at 0°C was added POC13 (87 pL, 0.93 mmol). The mixture was stirred for 2 hours and quenched with ice chips. It was diluted with EtOAc, washed with brine (X2), dried, concentrated and purified with flash column to give the coupling product (130 mg, 66%). Rf 0.29 (1:1 EtOAc: hexane). MS: (M+H)+ 635.
Step 4. The above-prepared compound ( 100 mg) was taken into 5 mL TFA and stirred at room temperature for overnight. After evaporation, the mixture was subjected on prep HPLC to isolate the title compound (90%). MS: (M+H)+ 579.
Exam In a 55.
This compound was prepared by the same methodology described for Example 54 with 2'-N-tent-butylaminosulfonyl-3-chloro-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tent-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 595.
Exam 1p a 56.
This compound was prepared by the same methodology described for Example 54 with IS 2'-N-tert-butylaminosulfonyl-3-bromo-[l,l']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 639, (Br pattern).
Exa 1p a 57.
This compound was prepared by the same methodology described for Example 54 with 2-amino-5-(2-(N-tert-butylaminosulfonyl)phenyl)pyridine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 562.
Example 58.
This compound was prepared by the same methodology described for Example 54 with 2-amino-S-(2-(N-tent-butylaminosulfonyl)phenyl)pyrimidine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 563.

Example 59.
This compound was prepared by the same methodology described for Example 54 with for 2'-methylsulfonyl-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine, without the final TFA
treatment.
ES-MS: (M+H)+ 560.
Example 60.
This compound was prepared by the same methodology described for Example 54 with for 2'-cyano-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-3-l0 fluoro-[1,1']-biphenyl-4-ylamine, without the final TFA treatment. ES-MS:
(M+H)+ 507.

Example 61.
The title compound of Example 60 (55 mg, 0.11 mmol) was dissolved in 2 mL
anhydrous DMF. To this stirred solution at 0°C were added sodium borohydride (33 mg, 0.88 mmol) and CoCl2 (30 mg, 0.22 mmol). The reaction was allowed for 2 hours and quenched with acetic acid. The mixture was evaporated, diluted with EtOAc, and washed with NaHC03 aq solution. The organic phase was dried, evaporated and purified with prep HPLC to afford the title compound in 55% yield. ES-MS: (M+H)+ S 11.
Example 62.
This compound was prepared by the same methodology described for Example 54 with for 2'-(N-dimethylaminomethyl)-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine, without the final TFA
treatment.
ES-MS: (M+H)+ 539.

Example 63.
This compound was prepared by the same methodology described for Example 54 with for 3'-(N-tent-Boc-aminomethyl)-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 511.
Exam 1p a 64.
SOzMe This compound was prepared by the same methodology described for Example 54 with for 1-(4-Aminophenyl)-4-methylpiperazine hydrochloride substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine, without the final TFA
treatment.
ES-MS: (M+H)+ 504.

Example 65.
This compound was prepared by the same methodology described for Example 54 with for 1-(N-methylpiperidin-4-yl)-piperazine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine, without the final TFA treatment. ES-MS:
(M+H)+ 496.
Exam 1p a 66.
This compound was prepared by the same methodology described for Example 54 with for 1-(4-pyridyl)-piperazine substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine, without the final TFA treatment. ES-MS: (M+H)+ 476.
Example 67.

This compound was prepared by the same methodology described for Example 54 with for 4-(N-pyrrolidinylcarbonyl)-aniline substituted for 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine, without the final TFA treatment. ES-MS:
(M+H)+ 503.
Example 68.
Step 1. The synthesis of 3-methyl-1-(3-methylsulfonyl-2-naphthyl)-1H-pyrazole-S-carboxylic acid was the same as that described in Step 2 of Example 54.
l0 Step 2. The above-prepared acid (200 mg, 0.61 mmol), 4-aminobenzonitrile (108 mg, 0.91 mmol) and DMAP (10 mg) were dissolved in 6 mL pyridine. The solution was stirred at 0°C. To it was added POC13 (170 p,L, 1.8 mmol). The mixture was stirred for 1 hour. The reaction was then quenched with ice chips. It was diluted with EtOAc. The organic phase was washed with brine (X2). It was dried, concentrated and purified with flash column to afford the coupling product (250 mg, 95%). Rf 0.20 (1:1 EtOAc:
hexane).
ES-MS: (M+H)+ 431.
Step 3. The above-prepared nitrite (70 mg, 0.16 mmol) was dissolved in 6 mL
dry methanol. It was chilled and stirred in an ice bath. To this solution was bubbled dry HCl gas via a long needle till saturation reached (indicated by a blown-up balloon attached on the top of the reaction flask). The resulting solution was stirred overnight.
ES-MS:
(M+H)+ 463. The solvent was removed in vacuuo. The residue was pumped to dryness.
The solid was dissolved in 6 mL dry methanol. To it was added anhydrous N-methylethylenediamine (0.5 mL). The mixture was refluxed for 1 hour, concentrated and loaded on prep HPLC to afford the title compound in 80% yield. ES-MS: (M+H)+
488.

Example 69.
This compound was prepared by the same methodology described for Example 68 with pyrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 502.
Example 70.
This compound was prepared by the same methodology described for Example 68 with morpholine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 518.
Example 71.
This compound was prepared by the same methodology described for Example 68 with N-methylpiperazine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 531.

Example 72.
This compound was prepared by the same methodology described for Example 68 with 4-amino-3-fluorobenzonitrile (preparation described in Step 1 of Example 22) substituted for 4-aminobenzonitrile. ES-MS: (M+H)+ 506.
Example 73.
This compound was prepared by the same methodology described for Example 68 with 4-amino-3-fluorobenzonitrile substituted for 4-aminobenzonitrile, and with N-methyl-1,3-propanediamine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 520.

Exam 1p a 74.
This compound was prepared by the same methodology described for Example 68 with 4-amino-3-fluorobenzonitrile substituted for 4-aminobenzonitrile, and with pyrrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 520.
Exam 1p a 75.
This compound was prepared by the same methodology described for Example 68 with 4-amino-3-fluorobenzonitrile substituted for 4-aminobenzonitrile, and with piperidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 534.

Example 76.
This compound was prepared by the same methodology described for Example 68 with 4-amino-3-fluorobenzonitrile substituted for 4-aminobenzonitrile, and with dimethylamine (2M solution in THF) substituted for N-methylethylenediamine. ES-MS: (M+H)+
494.
Exam 1p a 77.
This compound was prepared by the same methodology described for Example 68 with 4-amino-3-fluorobenzonitrile substituted for 4-aminobenzonitrile, and with ammonium acetate substituted for N-methylethylenediamine. ES-MS: (M+H)+ 466.
Example 78.

Step 1. To a solution of 2-bromo-6-methoxynaphthalene (2.0 g, 8.4 mmol) in 20 mL
anhydrous THF at -78°C was added BuLi (1.6M, 7.9 mL, 12.6 mmol) dropwise with a syringe. The mixture was stirred for 30 minutes, then to it was added triisopropyl borane (2.34 mL, 10.1 mmol) dropwise. The dry ice bath was removed. The reaction mixture was allowed to warm up to room temperature. After 15 hours, THF was mostly removed in vacuuo. To the residue was added 40 mL 3M HCI. The mixture was stirred at room temperature for 8 hours. Ether was used to extract the product (X3). The organic phases were combined, dried, concentrated in vacuuo and pumped to dryness to afford 6-methoxy-2-naphthylboronic acid (75% yield) as a white solid. Rf 0.34 (1:1 EtOAc:
hexane).
Step 2. To a solution of the above-prepared boronic acid (0.84 g, 3.2 mmol) and ethyl 3-methylpyrazole-5-carboxylate (0.49 g, 3.2 mmol) in 20 mL dry DCM were added pyridine (0.77 mL, 9.5 mmol) and anhydrous powder of copper(II) acetate (1.15 g, 6.3 mmol). Some activated molecular sieve powder was added afterwards. The resulting slurry was stirred for 4 days under argon. The mixture was diluted with DCM.
It was filtered through celite. The blue filtrate was washed with water (X2), dried, concentrated and purified by flash column to separately afford ethyl 3-methyl-1-(6-methoxy-naphthyl)-1H-pyrazole-5-carboxylate [37% yield. Rf 0.80 (1:1 EtOAc: hexane).
ES-MS:
(M+H)+ 311] and ethyl 5-methyl-1-(6-methoxy-2-naphthyl)-1H-pyrazole-3-carboxylate [25% yield. Rf 0.69 (1:1 EtOAc: hexane). ES-MS: (M+H)+ 311] in a 1.5:1 ratio.
Step 3. To a solution of 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (44 mg, 0.14 mmol) in 1 mL DCM was added trimethylaluminum (2.0M in hexane, 0.35 mL, 0.70 mmol) at room temperature. The mixture was stirred for 30 minutes, and to it was added the above-prepared ethyl 3-methyl-1-(6-methoxy-2-naphthyl)-1H-pyrazole-5-carboxylate (44 mg, 0.14 mmol) in 2 mL DCM. The resulting mixture was stirred overnight.
The reaction was quenched using S mL saturated Rochelle salt aq solution. The mixture was extracted using DCM (X3). The organic phases were combined, dried, concentrated and subjected on flash column to afford the coupling product in 84% yield (67 mg).
Rf 0.41 (1:1 EtOAc: hexane). ES-MS: (M+H)+ 569.

Step 4. The above-prepared compound was placed in 3 mL TFA and stirred at 65°C for 30 minutes. After evaporation, the residue was dissolved in methanol and purified with prep HPLC to afford the title compound in 95% yield. ES-MS: (M+H)+ 513.
Exam 1p a 79.
Step 1. The preparation of ethyl 3-methyl-1-(6-methoxy-2-naphthyl)-1H-pyrazole-carboxylate was the same as described in Step 2 of Example 83.
Step 2. The above-prepared compound (150 mg, 0.48 mmol) was dissolved in 2 mL
DCM. At 0°C, to the stirred solution was added boron tribromide ( 1.0M
in DCM, 0.72 mL, 0.72 mmol). The mixture was stirred overnight at room temperature. It was directly subjected to flash column to afford ethyl 3-methyl-1-(6-hydroxy-2-naphthyl)-1H-pyrazole-5-carboxylate (78 mg, 55%). Rf 0.73 (2:1 EtOAc: hexane). ES-MS:
(M+H)+
297.
Step 3. To a stirred solution of 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (80 mg, 0.26 mmol) in 1 mL DCM was added trimethylaluminum (2.0M in hexane, 0.65 mL, 1.3 mmol) at room temperature. After 30 minutes, to the mixture was added ethyl 3-methyl-1-(6-hydroxy-2-naphthyl)-1H-pyrazole-5-carboxylate (78 mg, 0.26 mmol) in 3 mL DCM. The resulting mixture was stirred 4 hours. The reaction was quenched using 5 mL saturated Rochelle salt aq solution. The mixture was extracted using DCM
(X3). The organic phases were combined, dried, concentrated and purified with flash column to afford the coupling product in 65% yield. Rf 0.32 (1:1 EtOAc: hexane). ES-MS:
(M+H)+
555.

Step 4. The above-prepared compound was placed in 3 mL TFA and stirred at 70°C for 30 minutes. After evaporation, the residue was dissolved in methanol and purified with prep HPLC to afford the title compound in 95% yield. ES-MS: (M+H)+ 499.
Exam 1p a 80.
Step 1. A mixture of 6-bromo-2-naphthoic acid (1.1 l g, 4.4 mmol) and 2 mL
thionyl chloride was refluxed for overnight. Thionyl chloride was removed in vacuuo.
The dry acid chloride was dissolved in 5 mL dioxane. At 0°C to it was added a solution of sodium azide (0.52 g, 8.0 mmol) in 2.5 mL water and 2.5 mL dioxane dropwise. The mixture was stirred for 2 hours. After evaporation in vacuuo to remove the solvent, the residue was dissolved in EtOAc, washed with brine, dried, concentrated in vacuuo to give the azidoketone (1.22 g, 99%). Rf 0.88 (1:1 EtOAc: hexane).
Step 2. The above-prepared compound was dissolved in 20 mL DMF. To it was added 10 mL water. The mixture was refluxed overnight. It was diluted with S00 mL
EtOAc, washed with brine (X2), dried, concentrated in vacuuo to afford 6-bromo-2-naphthylamine (1.2 g, 99%). Rf 0.73 (1:1 EtOAc: hexane), ES-MS: (M+H)+ 222, 224 (Br pattern).
Step 3. The above-prepared compound (1.2 g, 5.4 mmol) was placed in 6 mL
concentrate HCI. At 0°C to it was added a solution of sodium nitrite (0.37 g, 5.4 mmol) in 2 mL water dropwise. The mixture was stirred for 30 minutes. At 0°C to the mixture was added a solution of SnC12.2Hz0 (3.66 g, 16.2 mmol) in 6 mL concentrate HCl dropwise.
After stirring for 10 minutes, the mixture was placed in a freezer for overnight.
The solid was collected on a cold Buchner funnel. It was washed by ice-cold brine (7 mL) and ice-cold hexane (7 mL). The solid cake was transferred into a flask and pumped to dryness. To it were added 30 mL acetic acid, 15 mL THF, and ethyl 2-N-(methoxy)imino-4-oxopentanoate (1.3 g, 7.0 mmol). The resulting mixture was refluxed for overnight. The solvent was removed in vacuuo. The residue was dissolved in EtOAc, washed with brine (X2), dried, concentrated and purified by flash column to yield ethyl 3-methyl-1-(6-bromo-2-naphthyl)-1H-pyrazole-5-carboxylate (0.64 g, 33%). Rf 0.71 (1:2 EtOAc:
hexane). ES-MS: (M+H)+ 359, 361 (Br pattern).
Step 4. To a stirred solution of 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (93 mg, 0.31 mmol) in 1 mL DCM was added trimethylaluminum (2.0M in hexane, 0.70 mL, 1.4 mmol) at room temperature. After 30 minutes, to the mixture was added the above-prepared ethyl ester (100 mg, 0.28 mmol) in 3 mL DCM. The resulting mixture was stirred overnight. The reaction was quenched using 5 mL saturated Rochelle's salt aq solution. The mixture was extracted using DCM (X3). The organic phases were combined, dried, evaporated and purified with flash column to yield the coupling product (146 mg, 85%). Rf 0.44 (1:1 EtOAc: hexane). ES-MS: (M+H)+ 617, 619 (Br pattern).
Step 5. 'The above-prepared compound was placed in 3 mL TFA and stirred at 65°C for 40 minutes. After evaporation, the residue was dissolved in methanol and purified with prep HPLC to afford the title compound in 95% yield. ES-MS: (M+H)+ 561, 563 (Br pattern).

Example 81.
This compound was prepared by the same methodology described for Example 80 with 2'-N-tert-butylaminosulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 579, 581 (Br pattern).
Exam 1p a 82.
This compound was prepared by the same methodology described for Example 80 with 2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 595, 597 (BrCI
pattern).

Example 83.
This compound was prepared by the same methodology described for Example 80 with 2'-N-tert-butylaminosulfonyl-3-bromo-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 640, 642, 644 (Br2 pattern).
Example 84.
This compound was prepared by the same methodology described for Example 80 with 2'-N-tent-butylaminosulfonyl-5'-chloro-[1,1']-biphenyl-4-ylamine substituted for 2'-N-to tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 595, 597 (BrCI
pattern).

Example 85.
This compound was prepared by the same methodology described for Example 80 with 5-(2-N-tert-butylaminosulfonyl-1-phenyl)-2,3-dihydroindole substituted for 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 587, 589 (Br pattern).
Example 86.
Step 1. The synthesis of ethyl 3-methyl-1-(6-bromo-2-naphthyl)-1H-pyrazole-S-carboxylate was the same as Step 3 of Example 80.
Step 2. The above-prepared ethyl ester (1.0 g, 2.8 mmol) was dissolved in 20 mL
methanol. To the solution were added LiOH.H20 (350 mg, 8.3 mmol) and 10 mL
water.
The mixture was stirred for overnight and evaporated in vacuuo. The residue was acidified with 1N HCI. It was extracted with EtOAc (X4). The organic phases were combined, dried and concentrated in vacuuo to give 3-methyl-1-(6-bromo-2-naphthyl)-1H-pyrazole-5-carboxylic acid (0.97 g, 100%). ES-MS: (M+H)+ 331, 333 (Br pattern).
Step 3. A mixture of the above-prepared acid (33 mg, 0.10 mmol), 2-amino-5-(2-(N-tert-butylaminosulfonyl)phenyl)pyridine (61 mg, 0.20 mmol), DMAP (5 mg) were dissolved in 3 mL pyridine and stirred at 0°C. To it was added POC13 ~(55 pL, 0.6 mmol). The mixture was stirred for 2 hours and quenched with ice chips. It was diluted with EtOAc, washed with brine (X2), dried, concentrated and purified with flash column to give the coupling product (34 mg, 55%). Rf 0.35 (1: l EtOAc: hexane). ES-MS: (M+H)+
618, 620 (Br pattern).
Step 4. . The above-prepared compound was placed in 3 mL TFA and stirred at 65°C for 40 minutes. After evaporation, the residue was dissolved in methanol and purified with prep HPLC to afford the title compound in 95% yield. ES-MS: (M+H)+ 562, 564 (Br pattern).
Example 87.
This compound was prepared by the same methodology described for Example 86 with 2-amino-5-(2-(N-tert-butylaminosulfonyl)phenyl)pyrimidine substituted for 2-amino-5-(2-(N-tert-butylaminosulfonyl)phenyl)pyridine. ES-MS: (M+H)+ 563, 565 (Br pattern).

Example 88.
Step 1. The synthesis of 3-methyl-1-(6-bromo-2-naphthyl)-1H-pyrazole-5-carboxylic acid was the same as Step 2 of Example 86.
Step 2. A mixture of the above-prepared acid (970 mg, 2.9 mmol), 4-aminobenzonitrile (700 mg, 5.8 mmol), DMAP (40 mg) were dissolved in 15 mL pyridine and stirred at 0°C.
To it was added POC13 (1.1 mL, 12 mmol). The mixture was stirred for 1 hour and quenched with ice chips. It was diluted with EtOAc, washed with brine (X2), dried, concentrated and purified with flash column to give the coupling product (720 mg, 58%).
Rf 0.30 (1:1 EtOAc: hexane). ES-MS: (M+H)+ 431, 433 (Br pattern).
Step 3. The above-prepared nitrile (40 mg, 0.09 mmol) was dissolved in 6 mL
dry methanol. It was chilled and stirred in an ice bath. To this solution was bubbled dry HCl gas via a long needle till saturation reached. The resulting solution was stirred overnight.
ES-MS: (M+H)+ 463, 465 (Br pattern). The solvent was removed in vacuuo. The residue was pumped to dryness. The solid was dissolved in 6 mL dry methanol. To it was added anhydrous N-methylethylenediamine (0.5 mL). The mixture was refluxed for 1 hour, concentrated and loaded on prep HPLC to afford the title compound in 85%
yield. ES-MS: (M+H)+ 488, 490 (Br pattern).

Example 89.
This compound was prepared by the same methodology described for Example 88 with pyrrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 502, 504 (Br pattern).
Example 90.
This compound was prepared by the same methodology described for Example 88 with piperidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ S 16, 518 (Br pattern).
Example 91.

This compound was prepared by the same methodology described for Example 88 with morpholine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 518, 520 (Br pattern).
Example 92.
This compound was prepared by the same methodology described for Example 88 with N-methylpiperazine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 531, (Br pattern).
Example 93.
This compound was prepared by the same methodology described for Example 88 with 4-amino-3-fluorobenzonitrile substituted for 4-aminobenzonitrile. ES-MS: (M+H)+
506, 508 (Br pattern).

Example 94.
This compound was prepared by the same methodology described for Example 88 with 4-amino-2,5-difluorobenzonitrile substituted for 4-aminobenzonitrile. ES-MS:
(M+H)+ 524, 526 (Br pattern).
Example 95.
C
This compound was prepared by the same methodology described for Example 88 with 4-amino-3-chlorobenzonitrile substituted for 4-aminobenzonitrile. ES-MS: (M+H)+
522, 524 (BrCI pattern).

Example 96.
This compound was prepared by the same methodology described for Example 88 with 4-amino-2-chlorobenzonitrile substituted for 4-aminobenzonitrile. ES-MS: (M+H)+
522, 524 (BrCI pattern).
Example 97.
This compound was prepared by the same methodology described for Example 88 with 4-amino-2-chlorobenzonitrile substituted for 4-aminobenzonitrile, and with N-ethyl ethylenediamine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 536, (BrCI pattern).

Example 98.
This compound was prepared by the same methodology described for Example 88 with 4-amino-3-chlorobenzonitrile substituted for 4-aminobenzonitrile, and with ethylenediamine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 508, (BrCI pattern).
Example 99.
This compound was prepared by the same methodology described for Example 88 with 4-amino-3-chlorobenzonitrile substituted for 4-aminobenzonitrile, and with N-methyl-1,3-propanediamine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 536, 538 (BrCI pattern).

Example 100.
This compound was prepared by the same methodology described for Example 88 with 4-amino-3-chlorobenzonitrile substituted for 4-aminobenzonitrile, and with 1,3-propanediamine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 522, 524 (BrCI pattern).
Example 101.
This compound was prepared by the same methodology described for Example 88 with 4-amino-3-fluorobenzonitrile substituted for 4-aminobenzonitrile, and with pyrrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 520, 522 (Br pattern).

Example 102.
This compound was prepared by the same methodology described for Example 88 with 4-amino-3-fluorobenzonitrile substituted for 4-aminobenzonitrile, and with 2-methylpyrrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 534, (Br pattern).
Example 103.
This compound was prepared by the same methodology described for Example 88 with 4-amino-2,5-difluorobenzonitrile substituted for 4-aminobenzonitrile, and with pyrrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 538, 540 (Br pattern).

Exam 1p a 104.
This compound was prepared by the same methodology described for Example 88 with 4-amino-3-chlorobenzonitrile substituted for 4-aminobenzonitrile, and with pyrrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 536, 538 (BrCI
pattern).
Exam In a 105.
This compound was prepared by the same methodology described for Example 88 with 4-amino-2-chlorobenzonitrile substituted for 4-aminobenzonitrile, and with pyrrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 536, 538 (BrCI
pattern).

Example 106.
This compound was prepared by the same methodology described for Example 88 with 4-amino-3-fluorobenzonitrile substituted for 4-aminobenzonitrile, and with thiomorpholine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 552, 554 (Br pattern).
Example 107.
This compound was prepared by the same methodology described for Example 88 with 4-amino-3-fluorobenzonitrile substituted for 4-aminobenzonitrile, and with ammonium acetate substituted for N-methylethylenediamine. ES-MS: (M+H)+ 466, 468 (Br pattern).

Exam In a 108.
This compound was prepared by the same methodology described for Example 88 with 4-amino-2,5-difluorobenzonitrile substituted for 4-aminobenzonitrile, and with methylamine (2M in methanol) substituted for N-methylethylenediamine. ES-MS:
(M+H)+ 498, 500 (Br pattern).
Example 109.
This compound was prepared by the same methodology described for Example 88 with 4-amino-3-chlorobenzonitrile substituted for 4-aminobenzonitrile, and with dimethylamine (2M in THF) substituted for N-methylethylenediamine. ES-MS: (M+H)+ 510, 512 (BrCI
pattern).

Example 110.
Step 1. To a solution of 6-bromo-2-naphthoic acid (4.4 g, 17.5 mmol) in 50 mL
anhydrous DMF were added CuCI (8.7 g, 87.5 mmol) and CuI (0.2 g). The slurry was refluxed for 1 hour. At room temperature it was diluted with 300 mL EtOAc and stirred for 2 hours. It was filtered through celite. The filtrate was evaporated in vacuuo to afford 6-chloro-2-naphthoic acid (2.7 g, 75%). ES-MS: (M+H)+ 207.
Step 2. The title compound was prepared using the same methodology shown for Example 80, with 6-chloro-2-naphthoic acid substituted for 6-bromo-2-naphthoic acid.
ES-MS: (M+H)+ 517.
Example 111.
The title compound was prepared using the same methodology shown for Example 110, with 2'-N-tert-butylaminosulfonyl-3-fluoro-[l,l']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl- [1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 535.

Example 112.
T'he title compound was prepared using the same methodology shown for Example 110, with 2'-methylsulfonyl-3-fluoro-[1,1']-biphenyl-4-ylamine substituted for 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine. ES-MS: (M+H)+ 534.
Example 113.
The title compound was prepared using the same methodology shown for Example 93, with 6-chloro-2-naphthoic acid substituted for 6-bromo-2-naphthoic acid. ES-MS:
(M+H)+ 462.
l0 Example 114.

The title compound was prepared using the same methodology shown for Example 101, with 6-chloro-2-naphthoic acid substituted for 6-bromo-2-naphthoic acid. ES-MS:
(M+H)+ 476.
Example 11 S.
The title compound was prepared using the same methodology shown for Example 114, with piperidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 490.
Example 116.
The title compound was prepared using the same methodology shown for Example 114, with dimethylamine (2M in THF) substituted for N-methylethylenediamine. ES-MS:
(M+H)+ 450.

Example 117.
Step 1. The synthesis of 3-methyl-1-(3-cyano-2-naphthyl)-1H-pyrazole-S-(N-(2'-N-tert-butylaminosulfonyl-[1,1']-biphen-4-yl))carboxyamide followed the same procedure shown in Step 3 of Example 34.
Step 2. To a solution of the above-prepared compound (30 mg) in 10 mL
anhydrous ethanol at 0°C was bubbled dry HCl gas via a long needle till saturation reached. The mixture was stirred for overnight. The solvent was removed in vacuuo. The dry residue was dissolved in 5 mL anhydrous methanol. To it was added 0.5 mL N-methylethylenediamine. The mixture was refluxed for 2 hours. ES-MS: (M+H)+
621. It was concentrated in vacuuo. To the residue was added 3 mL TFA and the mixture was stirred at 70°C for 1 hour. After evaporation, the reaction mixture was subjected on prep HPLC to isolate the title compound (20% yield). ES-MS: (M+H)+ 565.
Example 118.
The title compound was prepared using the same methodology shown for Example 117, with dimethylamine (2M in THF) substituted for N-methylethylenediamine. ES-MS:
(M+H)+ 553.

Example 119.
The title compound was prepared using the same methodology shown for Example 117, with pyrrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 579.
Example 120.
SOZNHZ
/ H O I ~N
N
/ SOzNHz The title compound was prepared using the same methodology shown for Example 1, with 2-N-tert-butylaminosulfonylphenylboronic acid substituted for 2-naphthylboronic acid. ES-MS: (M+H)+ S 12.
Exam~e 121.
SOZNHZ
H O I ~N
/ SOZMe The title compound was prepared using the same methodology shown for Example 1, with 2-methylsulfonylphenylboronic acid substituted for 2-naphthylboronic acid. ES-MS:
(M+H)+ 511.
Example 122.
SOzNHZ
H ~ ~N
~J LJ N
/ NOZ
\
The title compound was prepared using the same methodology shown for Example 52, with commercial 2-nitrophenylhydrazine substituted for 3-carboxyl-2-naphthylhydrazine.
ES-MS: (M+H)+ 478.
Example 123.
SOZNHZ
H ~ \N
/ S02Me HyNO \ I
Step 1. 4-methylsulfonyl-3-nitrobenzoic acid (0.90 g, 3.7 mmol) was dissolved in 10 mL
ethanol. To it were added hydrazine monohydrate (0.46 mL, 15 mmol) and catalytic amount of 10% Pd/C. The mixture was refluxed for 1.5 hour, diluted with methanol, filtered through celite and concentrated in vacuuo to afford 3-amino-4-methylsulfonylbenzoic acid (>70%). ES-MS: (M+H)+ 216.
Step 2. The above-prepared aniline (2.2 g, 10 mmol) was stirred in 16 mL
concentrate HCl in ice bath. To it was dropwise added a cold solution of sodium nitrite (1.1 g, 15 mmol, in 7 mL, water). After completion, the mixture was stirred for 30 minutes at 0°C.
To it was added dropwise a cold solution of SnC12.2H20 (9.2 g, 40 mmol, in 14 mL

concentrate HC1). The mixture was stirred for 30 minutes and filtered through a Buchner funnel. The solid crude hydrazine was collected and dried.
Step 3. The crude hydrazine was dissolved in 40 mL acetic acid. To it were added 20 mL
THF and ethyl 2-N-(methoxy)imino-4-oxopentanoate (2.8 g, 15 mmol). The mixture was refluxed for overnight. After removal of the solvent in vacuuo, the reaction mixture residue was dissolved in 800 mL ether. The organic solution was washed with brine (X2), dried, concentrated and purified with flash column to afford ethyl 3-methyl-1-(5-carboxyl-2-methylsulfonylphenyl)-1H-pyrazole-5-carboxylate (2.1 g, 60%). Rf 0.17 (pure EtOAc). ES-MS: (M+H)+ 353.
Step 4. The above-prepared acid (2.1 g, 6.5 mmol) was dissolved in 50 mL dry DMF. To it were added tert-butylamine (1.4 mL, 13 mmol), DIEA (9.2 mL, 52 mmol) and PyBOP
( 13 g, 26 mmol) in order. The resulting mixture was stirred for overnight at room temperature. DMF was removed in vacuuo. The residue was taken into EtOAc and washed with brine (X2). The organic phase was dried, concentrated and subjected on flash column to isolate ethyl 3-methyl-1-(5-N-tert-butylaminocarbonyl-2-methylsulfonylphenyl)-1H-pyrazole-5-carboxylate (0.74 g, 30%). Rf 0.70 (pure EtOAc).
ES-MS: (M+H)+ 408.
Step 5. To a solution of 2'-N-tent-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (100 mg, 0.33 mmol) in 2 mL DCM was added trimethylaluminum (2.0M in hexane, 0.66 mL, 1.3 mmol) under argon at room temperature. After being stirred for 30 minutes, to the mixture was added the above-prepared ester (90 mg, 0.22 mmol) in 10 mL DCM.
The resulting mixture was stirred overnight. The reaction was quenched using 10 mL
saturated Rochelle's salt aq solution. The mixture was extracted using DCM
(X3). The organic phases were combined, dried, rotovaped and subjected on flash chromatography column to give the coupled product in 62% yield (90 mg). Rf 0.10 (1:1 EtOAc:
hexane).
ES-MS: (M+H)+ 666.
Step 6. The above-prepared compound (20 mg) was placed in 5 mL TFA. It was stirred at 70°C for 1 hour and subjected on prep HPLC to isolate the title compound (90%) after evaporation. ES-MS: (M+H)+ 554.

Example 124.
Step 1. To a solution of 4-biphenylboronic acid ( 1.0 g, 5.1 mmol) and ethyl 3-methylpyrazole-5-carboxylate (0.78 g, 5.1 mmol) in 25 mL dry DCM were added pyridine (1.2 mL, 15 mmol) and anhydrous powder of copper(II) acetate (1.84 g, mmol). Some activated molecular sieve powder was added afterwards. The resulting slurry was refluxed for 2 days under argon. The mixture was diluted with DCM, filtered through celite. The blue filtrate was washed with water (X2), dried, concentrated, purified with flush column to yield ethyl 3-methyl-1-(4-phenylphenyl)-1H-pyrazole-5-carboxylate (26%), Rf 0.67 (1:2 EtOAc: hexane), ES-MS: (M+H)+ 307; and its regioisomer, ethyl 5-methyl-1-(4-phenylphenyl)-1H-pyrazole-3-carboxylate (31%), Rf 0.50 (1:2 EtOAc:
hexane), ES-MS: (M+H)+ 307.
Step 2. To a stirred solution of 4-chloroaniline (24 mg, 0.18 mmol) in 1 mL
DCM was added trimethylaluminum (2.0M, 0.43 mL, 0.86 mmol) at room temperature. After minutes, to the mixture was added ethyl 3-methyl-1-(4-phenylphenyl)-1H-pyrazole-5-carboxylate (52 mg, 0.17 mmol) in 3 mL DCM. The resulting mixture was stirred for overnight. It was quenched using 5 mL saturated Rochelle's salt aq solution.
The mixture was extracted using DCM (X3). The organic phases were combined, dried, concentrated and subjected on flash column to afford the title compound (46 mg, 70%). Rf 0.46 (1:1 EtOAc: hexane). ES-MS: (M+H)+ 388.

Example 125.
The title compound was prepared using the same methodology shown for Example 124, with 4-methoxyaniline substituted for 4-chloroaniline. ES-MS: (M+H)+ 384.
Exam 1p a 126.
Step 1. 2'-N-tert-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (1.9 g, 6.2 mmol) was placed in 8 mL concentrate HCI. At 0°C to this stirred mixture was added a cold solution of sodium nitrite (0.43 g, 6.2 mmol in 2 mL water) dropwise. After 30 minutes, to it was added a cold solution of SnC12.2H20 (4.2 g, 18.4 mmol in 8 mL concentrate HCl). The mixture was stirred at 0°C for 1 hour and the solid was collected with a Buchner funnel.
The crude solid hydrazine was dried.
Step 2. The above-prepared crude hydrazine was dissolved in 20 mL acetic acid.
To it was added 10 mL THF and ethyl 2-N-(methoxy)imino-4-oxopentanoate (0.93 g, 5.0 mmol). The mixture was refluxed for 3 hours. The solvent was removed in vacuuo. The residue was taken into EtOAc, washed with brine, dried, concentrated and purified with flash column to yield ethyl 3-methyl-1-(4-(2-aminosulfonylphenyl)-phenyl)-1H-pyrazole-5-carboxylate (0.95 g, 40%). Rf 0.51 (1:1 EtOAc: hexane). ES-MS: (M+H)+ 386.
Step 3. The above-prepared ethyl ester was dissolved in 20 mL methanol. To it were added LiOH.H20 (0.31 g, 7.4 mol) and 10 mL water. The mixture was stirred for 3 hours, acidifed till pH 5 with acetic acid, and evaporated in vacuuo. The residue was soaked with acetonitrile and decanted for several times to extract out the organic product. The acetonitrile solutions were combined and evaporated in vacuuo to give yield 3-methyl-1-(4-(2-aminosulfonylphenyl)-phenyl)-1H-pyrazole-5-carboxylic acid (0.81 g, 92%). ES-MS: (M+H)+ 358. It was further purified using prep HPLC.
l0 Step 4. The above-prepared acid (20 mg, 0.056 mmol) was dissolved in 1 mL
dry DMF.
To it were added 4-bromoaniline (10 mg, 0.056 mmol), DIEA (30 pL, 0.17 mmol) and PyBOP (58 mg, 0.12 mmol) in order. The reaction mixture was directly loaded on prep HPLC to yield the title compound in 45% yield. ES-MS: (M+H)+ 511, 513 (Br pattern).
Example 127.
The title compound was prepared using the same methodology shown for Example 126, with 4-methoxyaniline substituted for 4-bromoariiline. ES-MS: (M+H)+ 463.

Example 128.
The title compound was prepared using the same methodology shown for Example 126, with 4-methoxy-2-nitroaniline substituted for 4-bromoaniline. ES-MS: (M+H)+
508.
Example 129.
The title compound was prepared using the same methodology shown for Example 126, with 6-bromo-2-naphthylamine substituted for 4-bromoaniline. ES-MS: (M+H)+
562, 564 (Br pattern).

Example 130.
The title compound was prepared using the same methodology shown for Example 126, with 2-naphthylamine substituted for 4-bromoaniline. ES-MS: (M+H)+ 483.
Example 131.
The title compound was prepared using the same methodology shown for Example 126, with 7-aminoisoquinoline substituted for 4-bromoaniline. ES-MS: (M+H)+ 484.

Example 132.
The title compound was prepared using the same methodology shown for Example 126, with 2-amino-5-chloropyridine substituted for 4-bromoaniline. ES-MS: (M+H)+
468.
Example 133.
The title compound was prepared using the same methodology shown for Example 126, with 2-amino-5-bromopyridine substituted for 4-bromoaniline. ES-MS: (M+H)+
512, 154 (Br pattern).

Example 134.
Step 1. A mixture of 4-cyanophenylhydrazine hydrochloride (5.7 g, 33 mmol), ethyl 2-N-(methoxy)imino-4-oxopentanoate (7.5 g, 40 mmol), 100 mL acetic acid and SO mL
THF
was refluxed for 2 hours. The solvent was removed in vacuuo. The residue was taken into 500 mL EtOAc, which was washed with brine, dried and evaporated in vacuuo to afford ethyl 3-methyl-1-(4-cyanophenyl)-1H-pyrazole-5-carboxylate (10 g, 99%). ES-MS:
(M+H)+ 256.
Step 2. The above-prepared ester (10 g) was dissolved in 100 mL THF. To it were added LiOH.H20 (4.2 g, 100 mmol), 100 mL methanol and 50 mL water. The mixture was stirred for 1 hour. It was acidified to pH 1 with 1N HCI. It was evaporated to remove organic solvent. The residue was extracted with EtOAc (X4). The organic phases were combined, dried and evaporated to dryness to afford 3-methyl-1-(4-cyanophenyl)-pyrazole-5-carboxylatic acid (95%). ES-MS: (M+H)+ 228.
Step 3. The above-prepared acid (1.4 g, 6.2 mmol) was dissolved in 20 mL
pyridine. To it were added 2-amino-5-bromopyridine (2.2 g, l3 mmol) and DMAP (100 mg). At 0°C to this mixture was added POC13 (2.3 mL, 25 mmol). The reaction was allowed for 1.5 hour and quenched with ice chips. After evaporation in vacuuo, the residue was taken into 300 mL EtOAc, which was washed with brine, dried, evaporated and purified with flash column to yield the coupling product (45%). Rf 0.52 (1:1 EtOAc: hexane). ES-MS:
(M+H)+ 382, 384 (Br pattern).
Step 4. To a solution of the above-prepared nitrile (30 mg) in 10 mL anhydrous methanol at 0°C was bubbled dry HCl gas via a long needle till saturation reached. The mixture was stirred for overnight. The solvent was removed in vacuuo. The dry residue was dissolved in 5 mL anhydrous methanol. To it was added 0.5 mL N-methylethylenediamine.
The mixture was refluxed for 1 hour. After evaporation, the reaction mixture was subjected on prep HPLC to isolate the title compound (80% yield). ES-MS: (M+H)+ 439, 441 (Br pattern).
Example 135.
The title compound was prepared using the same methodology shown for Example 134, with ethylenediamine substituted for N-methylethylenediamine. ES-MS: (M+H)+
425, 427 (Br pattern).
l0 Example 136.
The title compound was prepared using the same methodology shown for Example 134, with pyrrolidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 453, 455 (Br pattern).

Exam 1p a 137.
The title compound was prepared using the same methodology shown for Example 134, with 2-methylpyrrolidine substituted for N-methylethylenediamine. ES-MS:
(M+H)+ 467, 469 (Br pattern).
Example 138.
The title compound was prepared using the same. methodology shown for Example 134, with piperidine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 467, 469 (Br pattern).
l0 Example 139.
The title compound was prepared using the same methodology shown for Example 134, with morpholine substituted for N-methylethylenediamine. ES-MS: (M+H)+ 469, 471 (Br pattern).
Example 140.
The title compound was prepared using the same methodology shown for Example 134, with thiomorpholine substituted for N-methylethylenediamine. ES-MS: (M+H)+
485, 487 (Br pattern).

Exam In a 141.
The title compound was prepared using the same methodology shown for Example 134, with N-methylpiperazine substituted for N-methylethylenediamine. ES-MS: (M+H)+
482, 484 (Br pattern).
Example 142.
The title compound was prepared using the same methodology shown for Example 134, with hexamethyleneimine substituted for N-methylethylenediamine. ES-MS: (M+H)+
481, 483 (Br pattern).

Example 143.
The title compound was prepared using the same methodology shown for Example 134, with 1-methylhomopiperazine substituted for N-methylethylenediamine. ES-MS:
(M+H)+
496, 498 (Br pattern).
Example 144.
The title compound was prepared using the same methodology shown for Example 134, with dimethylamine (2M in THF) substituted for N-methylethylenediamine. ES-MS:
(M+H)+ 427, 429 (Br pattern).

Example 145.
The title compound was prepared using the same methodology shown for Example 134, with ammonium acetate substituted for N-methylethylenediamine. ES-MS: (M+H)+
399, 401 (Br pattern).
Examyple 146.
2'-N-tent-butylaminosulfonyl-[1,1']-biphenyl-4-ylamine (50 mg, 0.16 mmol) was dissolved in 1 mL dry DCM. To this stirred solution was added Me3A1 (2.0M, 0.4 mL, 0.8 mmol). The mixture was stirred for 30 minutes. To it was added a solution of commercial ethyl 1-(6-chloro-1,3-benzothiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (50 mg, 0.16 mmol) in 2 mL DCM. The resulting mixture was stirred for 4 hours. After quenched with saturated Rochelle's salt aq solution, this reaction was diluted with DCM. The mixture was washed with brine (X2), dried, evaporated in vacuuo and exposed to 3 mL
TFA. After stirnng overnight, the reaction mixture was evaporated and purified with reverse-phase prep HPLC to afford the title compound in 55% yield. ES-MS:
(M+H)+ 524 (C1 pattern).

BIOLOGICAL ACTIVITY EXAMPLES
Evaluation of the compounds of this invention is guided by in vitro protease activity assays (see below) and in vivo studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters.
The compounds of the present invention are dissolved in buffer to give solutions containing concentrations such that assay concentrations range from 0 to 100 ~M. In the assays for thrombin, prothrombinase and factor Xa, a synthetic chromogenic substrate is added to a solution containing test compound and the enzyme of interest and the residual catalytic activity of that enzyme is determined spectrophotometrically. The ICSp of a compound is determined from the substrate turnover. The IC50 is the concentration of test compound giving 50% inhibition of the substrate turnover. The compounds of the present invention desirably have an IC50 of less than 500 nM in the factor Xa assay, preferably less than 200 nM, and more preferred compounds have an IC50 of about 100 nM or less in the factor Xa assay. The compounds of the present invention desirably have an ICSp of less than 4.0 pM in the prothrombinase assay, preferably less than 200 nM, and more preferred compounds have an IC50 of about 10 nM or less in the prothrombinase assay. The compounds of the present invention desirably have an of greater than 1.0 p.M in the thrombin assay, preferably greater than 10.0 pM, and more preferred compounds have an IC50 of greater than 100.0 ~M in the thrombin assay.
Amido_lytic Assays for determining_protease inhibition activity The factor Xa and thrombin assays are performed at room temperature, in 0.02 M
Tris~HCl buffer, pH 7.5, containing 0.15 M NaCI. The rates of hydrolysis of the para-nitroanilide substrate S-2765 (Chromogenix) for factor Xa, and the substrate Chromozym TH (Boehringer Mannheim) for thrombin following preincubation of the enzyme with inhibitor for 5 minutes at room temperature, and were determined using the Softmax 96-well plate reader (Molecular Devices), monitored at 405 nm to measure the time dependent appearance of p-nitroaniline.

The prothrombinase inhibition assay is performed in a plasma free system with modifications to the method described by Sinha, U. et al., Thromb. Res., Z, (1994). Specifically, the activity of the prothrombinase complex is determined by measuring the time course of thrombin generation using the p-nitroanilide substrate Chromozym TH. The assay consists of preincubation (5 minutes) of selected compounds to be tested as inhibitors with the complex formed from factor Xa (0.5 nM), factor Va (2 nM), phosphatidyl serine:phosphatidyl choline (25:75, 20 pM) in 20 mM Tris~HCl buffer, pH 7.5, containing 0.15 M NaCI, 5 mM CaCl2 and 0.1% bovine serum albumin.
Aliquots from the complex-inhibitor mixture are added to prothrombin (1 nM) and Chromozym TH (0.1 mM). The rate of substrate cleavage is monitored at 405 nm for two minutes.
Eight different concentrations of inhibitor are assayed in duplicate. A
standard curve of thrombin generation by an equivalent amount of untreated complex are used for determination of percent inhibition.
Antithrombotic Efficacy in a Rabbit Model of Venous Thrombosis A rabbit deep vein thrombosis model as described by Hollenbach, S. et al., Thromb.
Haemost. 71, 357-362 (1994), is used to determine the in-vivo antithrombotic activity of the test compounds. Rabbits are anesthetized with LM. injections of Ketamine, Xylazine, and Acepromazine cocktail. A standardized protocol consists of insertion of a thrombogenic cotton thread and copper wire apparatus into the abdominal vena cava of the anesthetized rabbit. A
non-occlusive thrombus is allowed to develop in the central venous circulation and inhibition of thrombus growth is used as a measure of the antithrombotic activity of the studied compounds.
Test agents or control saline are administered through a marginal ear vein catheter. A femoral vein catheter is used for blood sampling prior to and during steady state infusion of test compound. Initiation of thrombus formation begins immediately after advancement of the cotton thread apparatus into the central venous circulation. Test compounds are administered from time = 30 min to time = 150 min at which the experiment is terminated.
The rabbits are euthanized and the thrombus excised by surgical dissection and characterized by weight and histology. Blood samples are analyzed for changes in hematological and coagulation parameters.

Effects of Compounds in Rabbit Venous Thrombosis model Administration of compounds in the rabbit venous thrombosis model demonstrates antithrombotic efficacy at the higher doses evaluated. There are no significant effects of the compound on the aPTT and PT prolongation with the highest dose ( 100 ~g/kg +
2.57 pg/kg/min). Compounds have no significant effects on hematological parameters as compared to saline controls. All measurements are an average of all samples after steady state administration of vehicle or (D)-Arg-Gly-Arg-thiazole. Values are expressed as mean ~ SD.
Without further description, it is Believed that one of ordinary skill in the art can, using the preceding description and the illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. It should be understood that the foregoing discussion and examples merely present a detailed description of certain preferred embodiments. It will be apparent to those of ordinary skill in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention. All the patents, journal articles and other documents discussed or cited above are herein incorporated by reference.

Claims (36)

WHAT IS CLAIMED IS:
1. A compound of the formula (I):
A-Q-D-E-G-J-X
Wherein:
A is selected from:
(a) C1-C6-alkyl;
(b) C3-C8-cycloalkyl;
(c) -N(R2,R3), -C(=NR2)-R3, -C(=NR2)N(R2,R3), -N(R3)-C(=NR2)N(R2, R3)-, and N(R2)C(=NR3)-R2 (d) phenyl, which is independently substituted with 0-2 R1 substituents;
(e) naphthyl, which is independently substituted with 0-2 R1 substituents; and (f) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O
and S, and wherein the ring system may be substituted with 0-2 R1 substituents;
R1 is selected from:
Halo, -CN, -C(=O)-N(R2, R3), -NO2, -SO2N(R2, R3), -SO2R2, -(CH2)mNR2R3, -(CH2)m-C(=NR3)-R2, -(CH2)m-C(=NR2)-N(R2,R3), -(CH2)m-N(R2)-C(=NR2)-N(R2,R3), -(CH2)mNR2-C3-6heterocyclics, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, 8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CF3, -OR2, and a 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl-CN, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl and -NO2;

R2 and R3 are independently selected from the group consisting of:
-H, -OR2, -N(-Ra, -Rb), -C1-4alkyl, -C2-6alkenyl; -C2-6alkynyl, -C3-8cycloalkyl, -C0-4alky1C3-8cycloalkyl, -C0-4alkylphenyl and -C0-4alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl-CN, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-4alkylC3-8cycloalkyl, -CN, and -NO2;
or R2 and R3 taken together can form a 3-8 membered cycloalkyl or a heterocyclic ring system, wherein the heterocyclic ring system may have from 3 to 10 ring atoms, with 1 to 2 rings being in the ring system and contain from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic ring system may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl-CN, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-4alkylC3-8cycloalkyl and -NO2;
R a and R b are independently selected from the group consisting of -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-4alkylC3-8cycloalkyl, or R a and R b can be taken together with a nitrogen atom to which they are attached to form a 3-8 heterocyclic ring sytem containing 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic ring system may be independently replaced with a member selected from the group consisting of halo, -CN, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-4alky1C3-8cycloalkyl and -NO2;
m is an integer of 0-2;
Q is selected from the group consisting of a direct link, divalent -C1-4alkyl, divalent -C2-4alkenyl, divalent -C2-4alkynyl, -C(=O)-, -C(=NH)-, -C(=NMe)-, -N(-R4)-, -N(-R4)-CH2-, -C(=O)-N(-R4)-, -N(-R4)-C(=O)-, -S(=O)2-, -O-, -S(=O)2-N(-R4)- and N(-R4)-S(=O)2-, wherein one or more hydrogens on each of the divalent C1-4alkyl, divalent C2-4alkenyl and divalent C2-4alkynyl moieties can be replaced with a -R4 group;

R4 is selected from the group consisting of:
-H, -CF3, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-4alkylC3-8cycloalkyl, -C0-4alkylphenyl and -C0-4alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-4alkylC3-8cycloalkyl, -CN, -CF3, and -NO2;
D is selected from the group consisting of:
(a) a direct link;
(b) phenyl, which is independently substituted with 0-2 R1a substituents;
(c) naphthyl, which is independently substituted with 0-2 R1a substituents;
and (d) monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be subsituted from 0-2 R1a substituents;
R1a is selected from the group consisting of:
halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CN, -NO2, (CH2)nNR2aR3a, SO2NR2aR3a, SO2R2a, CF3, OR2a, and a 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from N, O
and S, wherein from 1-4 hydrogen atoms on the aromatic heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CN and -NO2;
R2a and R3a are independently selected from the group consisting of:

-H, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, C0-4alkylphenyl and C0-4alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CN and -NO2;
n is an integer of 0-2;
E is selected from the group consisting of a direct link, -(CH2)q-C(=O)-, -(CH2)q-N(-R5)-C(=O)-(CH2)x-, -(CH2)q-C(=O)-N(-R5)-(CH2)x-, -(CH2)q-N(-R5)-(CH2)x-, , -(CH2)q-N(R5)CO-NR6(CH2)x and -SO2-;
q and x are independently an integer of 0-2;
R5 and R6 are independently selected from the group consisting of:
H, -C1-6alkyl, -C1-6alkyloxy, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-6alkylC3-8cycloalkyl, -C1-4alkyl-C(=O)-OH, -C0-6alkyl-(carbocyclic aryl), -C0-4alkyl-(monocyclic heteroaryl) and -C1-4alkyl-C(=O)-O-C1-4alkyl, wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety and the monocyclic heteroaryl moieties may be independently replaced with a member selected from the group consisting of halo, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-4alkylC3-8cycloalkyl, -S(=O)2-OH, -CN, -CF3 and -NO2;
G is selected from the group consisting of:
phenyl, which is substituted with 0-2 R1b groups; and a 5-6 membered aromatic and non-aromatic heterocyclic ring containing 1-4 hetero atoms selected from N, O and S wherein the heterocyclic ring is substituted with 0-2 R1b groups;
R1b is independently selected from the group consisting of:

halo, -C1-6alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-6alkylC3-8cycloalkyl, -C1-4alkyl-C(=O)-OH, -CN, -COOR2b, -CONR2bR3b, -NO2, -S(=O)2-OH, -N(-R2b, -R3b), -C(=O)-N(-R2b,-R3b), -S(=O)2-N(-R2b, -R3b),-S(=O)2-R2b, -CF3, -O-R2b, -O-CH2-CH2-O-R2b, -O-CH2-C(=O)-O-R2b, -N(-R2b)-CH2-CH2-O-R2b, -N(-CH2-CH2-O-R2b)2, -N(-R2b)-C(=O)-R3b, -N(-R2b)-S(=O)2-R3b, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S substituted with 0-4 R1b' groups;
alternatively, when two R1b may be present on adjacent ring atoms of G and combine to form a benzene ring substituted with 0-4 R1b' groups or a 5-6 membered aromatic or non-aromatic heterocyclic ring having 1-3 heteroatoms selected from N, O and S substituted with 0-4 R1b' groups;
in a second alternative, one of the R1b groups of G can cylize with the -N-R5 group of E to form a 5-7 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, which is subtituted with 0-4 R1b' groups, wherein two of the R1b' groups attached to the same ring carbon may form a (=O) group;
R2b and R3b are independently selected from the group consisting of -H, -C1-6alkyl, -C1-6alkyloxy, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-6alkylC3-8cycloalkyl and -C0-6alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-4alkylC3-8cycloalkyl, -S(=O)2-OH, -CN, -CF3 and -NO2;
R1b' is independently selected from the group consisting of:
halo, -C1-6alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-6alkylC3-8cycloalkyl, -C1-4alkyl-C(=O)-OH, -CN, -NO2, -S(=O)2-OH, -N(-R2b' -R3b') -C(=O)-N(-R2b', -R3b',), -S(=O)2-N(-R2b', -R3b'), -S(=O)2-R2b', -CF3, -O-R2b', -O-CH2-CH2-O-R2b', -O-CH2-C(=O)-O-R2b', -N(-R2b')-CH2-CH2-O-R2b', -N(-CH2-CH2-O-R2b')2, -N(-R2b')-C(=O)-R3b' and -N(-R2b')-S(=O)2-R3b';

R2b' and R3b' are independently selected from the group consisting of:
-H, -C1-6alkyl, -C1-6alkoxy, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-6alkylC3-8cycloalkyl and -C0-6alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloakyl, -C0-4alkylC3-8cycloalkyl, -S(=O)2-OH, -CN, -CF3 and -NO2;
J is selected from the group consisting of:
a direct link, -S(=O)2-, -C(=O)-, -N(-R7)-S(=O)2-, -C(=O)-N(-R7)-S(=O)2-, -C(=O)-N(-R7)-(CHz)y , -S(=O)2-N(-R7) -(CH2)y-, and -N(-R7)-C(=O)-(CH2)y-;
y is an integer of 0-2;
R7 is selected from the group consisting of:
-H, -C2-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-6alkylC3-8cycloalkyl, -C1-6alkyl-C(=O)-OH, -C1-6alkyl-OH, -C1-6alkyl-O-C1-4alkyl, -C0-4alkyl-(carbocyclic aryl), -C0-4alkyl-(monocyclic or bicyclic heterocyclic ring system having from 0-4 heteroatoms selected from the group consisting of N, O
and S), -CH2-C(=O)-O-C1-4alkyl and -CH2-C(=O)-O-C1-4alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety or the heterocyclic ring system may be independently replaced with a member selected from the group consisting of halo, -C1-4alkyl, -C2-6alkenyl, -6alkynyl, -C3-8cycloalkyl, -C0-4alkylC3-8cycloalkyl, -S(=O)2-OH, -CN, -CF3 and -NO2;
X is selected from the group consisting of:
phenyl, which is substituted with 0-3 R1c groups;
naphthyl, which is substituted with 0-3 R1c groups;

a 6-membered heteroaromatic ring containing from 1-2 nitrogen atoms, wherein the ring is substituted with 0-3 R1c groups; and a fused heterobicyclic ring system, wherein the ring system contains 1-3 heteroatoms selected from N, O and S and is substituted with 0-3 R1c groups;

R1c is independently selected from the group consisting of:

halo, -CF3, -C1-6alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-6alkylC3-8cycloalkyl, -C1-4alkyl-C(=O)-OH, -CF3, -CN, -NO2, -(CH2)z-N(-R2c, -R3c), -C(=O)-N(-R2c,-R3c), -C(=NH)-N(-R2c, -R3c), -C(=NMe)-N(-R2c, -R3c) -S(=O)2-N(-R2c, -R3c), -S(-O)2-R2c, -S(=O)2-OH, -CF3, -O-R2c, -O(-CH2)z-O-R2c, -O(-CH2)z-C(=O)-O-R2c, -N(-R2c), -O(-CH2)z-O-R2c, -N[(-CH2)z-O-R2c]2, -(CH2)z-N(-R2c)-C(=O)-R3c, -(CH2)z-N(-R2c)-S(=O)2-R3c, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

z is an integer of 0-4;

R2c and R3c are independently selected from the group consisting of:

-H, -C1-6alkyl, -C1-6alkyloxy, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-6alkylC3-8cycloalkyl and -C0-6alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-4alkylC3-8cycloalkyl, -S(=O)2-OH, -CN, -CF3 and -NO2;

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
2. A compound of claim 1, wherein:
A is selected from the group consisting of:
-C1-6alkyl and -C3-8cycloalkyl;

phenyl, which is substituted with 0-2 R1 groups;
naphthyl, which is substituted with 0-2 R1 groups; and a 5-10 membered aromatic or non-aromatic heterocyclic ring system which may be a monocyclic ring system or a fused bicyclic ring system, wherein the heterocyclic ring system contains 1-4 heteroatoms selected from N, O and S and is substituted with 0-2 R1 groups;

R1 is independently selected from the group consisting of:

halo, -C1-4alkyl, -CN, -NO2, -(CH2)m-N(-R2,-R3), -C(=O)-N(-R2,-R3), -S(=O)2-N(-R2,-R3), -S(=O)2-R2, -(CH2)m-C(=NR3)-R2, -(CH2)m,-C(=NR2)-N(R2,R3), -(CH2)m-N(R2)-C(=NR2)-N(R2,R3), -CF3, -(CH2)m-O-R2 and a 5-6 membered aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

R2 and R3 are independently selected from the group consisting of:

-H, -C1-4alkyl, or R2 and R3 taken together can form a 3-8 membered cycloalkyl or a heterocyclic ring system, wherein the heterocyclic ring system may have from 3 to 10 ring atoms, with 1 to 2 rings being in the ring system and contain from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic ring system may be independently replaced with a member selected from the group consisting of halo, C1-C4-alkyl-CN, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, -C0-4alkylC3-8cycloalkyl and -NO2;

m is an integer of 0-2;

Q is selected from the group consisting of:

a direct link, -C1-4alkyl, -C2-4alkenyl, -C2-4alkynyl, -C(=O)-, -C(=NH)-, -C(=NMe)-, -N(-R4)-, -N(-R4)-CH2-, -C(=O)-N(-R4)-, -N(-R4)-C(=O)-, -S(=O)2-, -O-, -S(=O)2-N(-R4)- and N(-R4)-S(=O)2-;

R4 is selected from the group consisting of:

-H, -CF3, -C1-4alkyl, D is selected from the group consisting of:

a direct link;

phenyl, which is substituted with 0-2 1a groups; and a 5-10 membered aromatic or non-aromatic heterocyclic ring system which may be a monocyclic ring system or a fused bicyclic ring system, wherein the heterocyclic ring system contains 1-4 heteroatoms selected from N, O and S and the ring system is substituted with 0-2 R1a groups;

R1a is independently selected from the group consisting of:

halo, -C1-4alkyl, -CN, -NO2, -(CH2)n-N(-R2a, -R3a), -S(=O)2-N(-R2a, -R3a), -S(=O)2-R2a, -CF3, -(CH2)n-OR2a, -C(=O)-O-R2a, -C(=O)-N(-R2a, -R3a) and a 5-6 membered aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

n is an integer of 0-2;

R2a and R3a are independently selected from the group consisting of:

-H, -CF3 and -C1-4alkyl, E is selected from the group consisting of:

a direct link, -(CH2)q-C(=O)-, -(CH2)q-N(-R5)-C(=O)-(CH2)x-, -(CH2)q-C(=O)-N(-R5)-(CH2)x-, -(CH2)q-N(-R5)-(CH2)x-, -(CH2)q-N(R5)CO-NR6(CH2)x-and -SO2-;

R5 and R6 are each H, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C3-8cycloalkyl, or -C0-4alkylC3-8cycloalkyl;

q and x are independently an integer of 0-2;

G is selected from the group consisting of:

phenyl, which is substituted with 0-2 R1b groups; and a 5-6 membered aromatic and non-aromatic heterocyclic ring containing 1-4 hetero atoms selected from O, S and N, wherein the heterocyclic ring is substituted with 0-2 R1b groups;

R1b is independently selected from the group consisting of:

halo, -C1-4alkyl, -CN, -NO2, -N(-R2b,-R3b), -C(=O)-N(-R2b, -R3b), -S(=O)2-N(-R2b -R3b), -S(=O)2-R2b, CF3, -O-R2b, -O-CH2-CH2-O-R2b, -O-CH2-C(=O)-O-R2b -N(-R2b)-CH2-CH2-O-R2b, -N(-CH2-CH2-O-R2b)2, -N(-R2b)-C(=O)-R3b -N(-R2b)-S(=O)2-R3b and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

alternatively, when two R1b may be present on adjacent ring atoms of G and combine to form a benzene ring substituted with 0-4 R1b' groups or a 5-6 membered aromatic or non-aromatic heterocyclic ring having 1-3 heteroatoms selected from N, O and S substituted with 0-4 R1b' groups;

in a second alternative, one of the R1b groups of G can cylize with the -N-R5 group of E to form a 5-7 membered saturated, unsaturated or partially unsaturated heterocyclic ring containing 1-4 heteroatoms selected from N, O and S, which is substituted with 0-4 R1b' groups, wherein two of the R1b' groups attached to the same ring carbon may form a (=O) group;

R2b and R3b are independently selected from the group consisting of:

-H, -CF3, -C1-4alkyl and -C1-4alkyl-(carbocyclic aryl);

R1b' is independently selected from the group consisting of:

halo, -C1-4alkyl, -CN, -NO2, -N(-R2b',-R3b'), -C(=O)-N(-R2b',-R3b'), -S(=O)2-N(-R2b',-R3b'), -S(=O)2-R2b', -CF3, -O-R2b', -O-CH2-CH2-O-R2b', -O-CH2-C(=O)-O-R2b', -N(-R2b')-CH2-CH2-O-R2b', -N(-CH2-CH2-O-R2b')2, -N(-R2b')-C(=O)-R3b', -N(-R2b')-S(=O)2-R3b';

R2b' and R3b' are independently selected from the group consisting of:

-H, -C1-4alkyl and -C1-4alkyl-(carbocyclic aryl);

J is selected from the group consisting of:

a direct link, -S(=O)2-, -C(=O)-, -N(-R7)-S(=O)2-, -C(=O)-N(-R7)-S(=O)2-, -C(=O)-N(-R7)-(CH2)y, -S(=O)2-N(-R7)-, -(CH2)y and -N(-R7)-C(=O)-(CH2)y-;

y is an integer of 0-2;

R7 is selected from the group consisting of:

-H, -C1-4alkyl, -C2-6alkenyl, -C2-6alkynyl, -C0-4alkyl-(carbocyclic aryl), -C0-4alkyl-(heterocyclic ring system), -CH2-C(=O)-O-C1-4alkyl and -CH2-C(=O)-O-C1-4alkyl-(carbocyclic aryl);

X is selected from the group consisting of:

phenyl, which is substituted with 0-3 R1c groups;

naphthyl, which is substituted with 0-3 R1c groups;

a 6-membered heteroaromatic ring containing from 1-2 nitrogen atoms, wherein the ring is substituted with 0-3 R1c groups; and a fused heterobicyclic ring system, wherein the ring system contains 1-3 heteroatoms selected from N, O and S and is substituted with 0-3 R1c groups;

R1c is independently selected from the group consisting of:

halo, -C1-4alkyl, -CN, -NO2, -(CH2)z-N(-R2c, -R3c), -C(=O)-N(-R2c, -R3c), -C(=NH)-N(-R2c,-R3c), -C(=NMe)-N(-R2c,-R3c), -S(=O)2-N(-R2c,-R3c), -S(=O)2-R2c, -S(=O)2-O -, -CF3, -O-R2c, -O-CH2-CH2-O-R2c, -O-CH2-C(=O)-O-R2c, -N(-R2c)-CH2-CH2-O-R2c, -N(-CH2-CH2-O-R2c)2, -(CH2)z-N(-R2c)-C(=O)-R3c, -(CH2)z-N(-R2c)-S(=O)2-R3c, and a 5-6 membered heterocyclic ring containing 1-heteroatoms selected from N, O and S;

z is an integer of 0-2;

R2c and R3c are independently selected from the group consisting of:

-H, -C1-4alkyl and -C1-4alkyl-(carbocyclic aryl);

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
3. A compound of claim 1, wherein:
A is selected from the group consisting of:

Q is selected from the group consisting of:

a direct link, -C(=NH), -C(=NMe)-, -C(=O)-, -CH2-, -NH-, -N(-CH3)-, -O-, -NH-CH2-, -CH2-NH-, -N(-CH3)-CH2-, and -CH2-N(-CH3)-;

D is selected from the group consisting of:

E is selected from the group consisting of:

a direct link, -NH-C(=O)-, -N(-CH3)-C(=O)-, -N(-CH2CO2H)-C(=O)-, -C(=O)-NH-, -C(=O)-N(-CH3)-, -NH-CH2- and -CH2-NH-;

G is a member selected from the group consisting of:

R1b is independently selected from the group consisting of:

-H, -Me, -CF3, -F, -Cl, -Br, -SO2Me, -CN, -CONH2, -CONMe2, -NH2, -NO2, -NHCOMe, -NHSO2Me, -CH2NH2 and -CO2H;

J is selected from the group consisting of:

a direct link, -NH-, -O-, -S(=O)2-, -S(=O)2-NH, -NH-S(=O)2-, -C(=O)-, -NH-C(=O)- and -C(=O)-NH-;

X is selected from the group consisting of:

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
4. A compound of claim 1, wherein:
A is selected from the group consisting of:

phenyl, which is substituted with 0-2 R1 groups;
naphthyl, which is substituted with 1 R1 group; and a 5-7 membered aromatic or non-aromatic monocyclic heterocyclic ring, wherein the heterocyclic ring contains 1-2 heteroatoms selected from N, O and S and is substituted with 0-1 R1 groups;

R1 is selected from the group consisting of:

-S(=O)2-N(-R2, -R3), -S(=O)2-R2, -CH2N(-R2, -R3), -CN and halo.

R2 and R3 are independently selected from the group consisting of -H and -C1-4alkyl;

Q is selected from the group consisting of:

a direct link, -C(=NH), -C(=NMe)-, -C(=O)-, -CH2-, -NH-, and -N(-CH3)-;
D is selected from the group consisting of:
a direct link;
phenyl, which is substituted with 0-2 R 1a groups; and a 5-6 membered aromatic heterocyclic ring, wherein the heterocyclic ring contains 1-2 heteroatoms selected from N and S and is substituted with 0-1 R
1a groups;

R 1a is selected from the group consisting of:
-H and halo;
E is selected from the group consisting of:
a direct link, -NH-C(=O)- and -C(=O)-NH-;
G is selected from the group consisting of:
Pyrazole, pyrazoline, triazole and tertrazole, which are substituted with 0-2 R 1b groups; and a 5-membered aromatic heterocyclic ring, wherein the heterocyclic ring contains 2 heteroatoms selected from N, O and S and is substituted with 0-1 R 1b groups and;
R 1b is selected from the group consisting of:
-Me, -Et, -CF3, -C(=O)-NH2, -NH2, -NH-C(=O)-Me, -NH-S(=O)2-Me, -SMe, -S(=O)2-Me and halo;

alternatively, when two R 1b groups may be present on adjacent ring atoms of G
and combine to form a benzene ring;

in a second alternative, one of the R 1b groups of G can cyclize with the NH
group of E to form a 5-6 membered non-aromatic heterocyclic ring containing 1-2 nitrogen atoms and which is substituted with 0-2 C=O groups;
J is selected from the group consisting of:

a direct link, -NH-C(=O)- and -C(=O)-NH-;
X is selected from the group consisting of phenyl, which is substituted with 1-3 R 1c groups;
naphthyl, which is substituted with 0-3 R 1c groups;
pyridinyl, which is substituted with 1-3 R 1c groups; and a 9-10 membered fused bicyclic aromatic ring, wherein the aromatic ring contains 0-2 heteroatoms selected from N and O and is substituted with 0-3 R 1c groups;
R 1c is independently selected from the group consisting of:
-H, halo, -Me, -CF3, -OH, -OMe, -NH2, -CN, -NO2, -CH2-R 2c, -C(=O)-N(-R 2c, -R 3c), -s(=O)2-R 2c, -S(=O)2-N(-R 2c, -R 3c), -S(=O)2-OH, -C(=NH)-N(-R 2c, -R
3c), 2-imidazolin-2-yl and 1-methyl-2-imidazolin-2-yl;

R 2c and R 3c are independently selected from the group consisting of:
-H, -OH, -NH2 and -C1-4alkyl;

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
5. A compound of claim 1 selected from the group consisting of:

wherein:

R1 is selected from the group consisting of:

-SO2NH2, -SO2Me, -CH2NH2 and -CH2NMe2;
R 1a is selected from the group consisting of -H, -F, -Cl and -Br;
R 1b is selected from the group consisting of -CH3, -CF3, -CH2CH3, -SO2Me, -CONH2 and -NHSO2Me;
R 1c1 is selected from the group consisting of:

-H, -F, -Cl, -Br, -NH2, -OH, -SO2Me, -SO2Et, -SO2NH2, -NO2, -CH2NH2, -CN, -CONH2, -CH2OH;

R 1c2 is selected from the group consisting of:

-H, -F, -Cl and -Br; and R 1c3 is selected from the group consisting of:
-H, -F, -Cl and -Br and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
6. A compound of claim 1 selected from the group consisting of:

wherein:
R1 is selected from the group consisting of:

-SO2NH2, -SO2Me, -CH2NH2 and -CH2NMe2;

R 1a is selected from the group consisting of:

-H, -F, -Cl and -Br;
R 1b is selected from the group consisting of:

-CH3, -CF3, -CH2CH3, -SO2Me, -CONH2 and -NHSO2Me;
R 1c1 is selected from the group consisting of:

-H, -F, -Cl, -Br, -NH2, -OH, -SO2Me, -SO2Et, -SO2NH2, -NO2, -CH2NH2, -CN, -CONH2, -CH2OH;

R 1c2 is selected from the group consisting of:

-H, -F, -Cl, -Br and -OMe; and R 1c3 is selected from the group consisting of:

-H, -F, -Cl, -Br, -OCH3, -NH2, -CH2NH2, -CONH2, -CONHMe, -CONMe2 and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
7. A compound of claim 1 selected from the group consisting of:

wherein:
R1 is selected from the group consisting of:
-SO2NH2, -SO2CH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CH2NH2, -CH2NH(CH3), -CH2N(CH3)2;
R1a is selected from the group consisting of:
-H, -F, -Cl and -Br;
R1b is selected from the group consisting of:
-CH3 and -CF3;
R1c1 is selected from the group consisting of:
-H, -F, -Cl, -Br, -CN, -CH2NH2, -CH2OH, -CONH2, -C(=NH)NH2, -CO2H, -CO2Me, -SO2Me, -SO2NH2, -OH, -NH2, and -NO2;
R1c2 is selected from the group consisting of:
-H, -F, -Cl, -Br, and -OCH3; and R1c3 is selected from the group consisting of:

-H, -F, -Cl, -Br, -OCH3, -NH2, -CH2NH2, -CONH2, -CONHMe, -CONMe2 and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
8. A compound of claim 1 selected from the group consisting of:

wherein:
R1 is selected from the group consisting of:
-SO2NH2, -SO2Me, -CH2NH2 and -CH2NMe2;
R1a is selected from the group consisting of:
-H, -F, -Cl and -Br;
R1b is selected from the group consisting of:
-CH3, -CF3, -CH2CH3, -SO2Me, -CONH2 and -NHSO2Me; and R1c is selected from the group consisting of:

-H, -F, -C1, -Br, -NH2, -OH, -SO2Me, -SO2Et, -SO2NH2, -NO2, -CH2NH2, -CN, -CONH2, -CH2OH
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
9. A compound of claim 1 selected from the group consisting of:

wherein:

R1 is selected from the group consisting of:
-SO2NH2, -SO2Me, -CH2NH2 and -CH2NMe2;
R1a is selected from the group consisting of:
-H, -F, -Cl and -Br;
R1b is selected from the group consisting of:
-CH3, -CF3, -CH2CH3, -SO2Me, -CONH2 and -NHSO2Me;
R1c1 is selected from the group consisting of:
-H, -F, -Cl, -Br, -NH2, -OH, -SO2Me, -SO2Et, -SO2NH2, -NO2, -CH2NH2, -CN, -CONH2, -CH2OH; and R1c2 and R1c3 are independently selected from the group consisting of:
-H, -F, -Cl and -Br, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
10. A compound of claim 1 selected from the group consisting of:

wherein:

A-Q is selected from the group consisting of:

wherein:
A is selected from the group consisting of:

R1a is selected from the group consisting of -H, -F, -Cl and -Br;
R1b is selected from the group consisting of:
-Me, -CF3, -Et, -SO2Me, -CONH2 and -NHSO2Me;
R1c1 is selected from the group consisting of:
-H, -F, -Cl, -Br, -NH2, -OH, -SO2Me, -SO2Et, -SO2NH2, -NO2, -CH2NH2, -CN, -CONH2, -CH2OH;
R1c2 is selected from the group consisting of:
-H, -F, -Cl and -Br; and R1c3 is selected from the group consisting of:
-H, -F, -Cl and -Br and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
11. A compound of claim 1 selected from the group consisting of:

wherein:
A-Q is selected from the group consisting of:

wherein:
A is selected from the group consisting of:

R1a is selected from the group consisting of:
-H, -F, -Cl and -Br;
R1b is selected from the group consisting of:
-CH3, -CF3, -CH2CH3, -SO2Me, -CONH2 and -NHSO2Me;
R1c1 is selected from the group consisting of:
-H, -F, -Cl, -Br, -NH2, -OH, -SO2Me, -SO2Et, -SO2NH2, -NO2, -CH2NH2, -CN, -CONH2, -CH2OH;
R1c2 is selected from the group consisting of:
-H, -F, -Cl, -Br and -OMe; and R1c3 is selected from the group consisting of:
-H, -F, -Cl, -Br, -OH, -OCH3, NH2, -CONH2, -CH2NH2, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
12. A compound of claim 1 selected from the group consisting of:

wherein:
R1 is selected from the group consisting of:

-SO2NH2, -SO2CH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CH2NH2, -CH2NH(CH3), -CH2N(CH3)2;

R1a is selected from the group consisting of:

-H, -F, -Cl and Br;

R1b is selected from the group consisting of:

-CH3 and -CF3;

R1c1 is selected from the group consisting of:

-H, -F, -Cl, -Br, -CN, -CH2NH2, -CH2OH, -CONH2, -C(=NH)NH2, -CO2H, -CO2Me, -SO2Me, -SO2NH2, -OH, -NH2, and -NO2;

R1c2 is selected from the group consisting of:

-H, -F, -Cl and -Br; and R1c3 is selected from the group consisting of:

-H, -F, -Cl and -Br, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
13. A compound of claim 1 selected from the group consisting of:

wherein:

R1 is selected from the group consisting of:
-SO2NH2, -SO2CH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CH2NH2, -CH2NH(CH3), -CH2N(CH3)2;

R1a is selected from the group consisting of:

-H, -F, -Cl and -Br;

R1b is selected from the group consisting of:

-CH3, -CF3, -CH2CH3, -SO2Me, -CONH2 and -NHSO2Me;

R1c1 is selected from the group consisting of:

-H, -F, -Cl, -Br, -NH2, -OH, -SO2Me, -SO2Et, -SO2NH2, -NO2, -CH2NH2, -CN, -CONH2, -CH2OH;

R1c2 is selected from the group consisting of:

-H, -F, -Cl, -Br and -OCH3; and R1c3 is selected from the group consisting of:

-H, -F, -Cl, -Br, -OCH3, -NH2, -CH2NH2, -CONH2, -CONHMe, -CONMe2, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
14. A compound of claim 1 selected from the group consisting of:

wherein:

A-Q is selected from the group consisting of:

wherein:

A is selected from the group consisting of:

R1a1 is selected from the group consisting of:

-H, -F, -Cl and -Br;

R1b is selected from the group consisting of:

-CH3 and -CF3;

R1c1 is selected from the group consisting of:

-H, -F, -Cl, -Br, -CN, -CH2NH2, -CH2OH, -CONH2, -C(=NH)NH2, -CO2H, -CO2Me, -SO2Me, -SO2NH2, -OH, -NH2, and -NO2;

R1c2 is selected from the group consisting of:

-H, -F, -Cl, -Br, and -OCH3; and R1c3 is selected from the group consisting of:

-H, -F, -Cl, -Br, -OCH3, -NH2, -CH2NH2, -CONH2, -CONHMe, -CONMe2, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
15. A compound of claim 1 selected from the group consisting of:

wherein:

R1 is selected from the group consisting of:

-SO2NH2, -SO2CH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CH2NH2, -CH2NH(CH3), -CH2N(CH3)2;

R1a is selected from the group consisting of:

-H, -F, -Cl and -Br;

R1b is selected from the group consisting of:

-H, -CH3 and -CF3;

R1c1 is selected from the group consisting of:

-H, -F, -Cl, -Br, -CN, -CH2NH2, -CH2OH, -CONH2, -C(=NH)NH2, -CO2H, -CO2Me, -SO2Me, -SO2NH2, -OH, -NH2, and -NO2;

R1c2 is selected from the group consisting of:

-H, -F, -Cl and -Br; and R1c3 is selected from the group consisting of:

-H, -F, -Cl and -Br and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
16. A compound of claim 1 selected from the group consisting of:

wherein:

R1 is selected from the group consisting of:

-SO2NH2, -SO2CH3, -CN, -CONH2, -CONH(CH3), -CON(CH3)2, -CH2NH2, -CH2NH(CH3), -CH2N(CH3)2;

R1a is selected from the group consisting of:

-H, -F, -Cl and -Br;

R1b is selected from the group consisting of:

-H, -CH3 and -CF3;

R1c1 is selected from the group consisting of:

-H, -F, -CN, -CH2NH2,-CONH2, -SO2Me,-SO2NH2 and -NO2;

R1c2 is selected from the group consisting of:

-H,-F,-C1,-Br and -OCH3; and R1c3 is selected from the group consisting of -H,-F,-C1,-Br,-OCH3,-NH2,-CH2NH2,-CONH2,-CONHM e,-CONM e2 and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
17. A compound of claim 1 selected from the group consisting of:

wherein:

A-Q is selected from the group consisting of:

wherein:

A is selected from the group consisting of:

R1a is selected from the group consisting of:

-H,-F,-C1 and -Br;

R1b is selected from the group consisting of:

-H, -CH3 and -CF3;

R1c is selected from the group consisting of:

-H,-F,-C1,-Br,-CN,-CH2NH2,-CH2OH,-CONH2,-C(=NH)NH2,-CO2H,-CO2Me,-SO2Me,-SO2NH2,-OH,-NH2,and-NO2;

R1c2 is selected from the group consisting of:

-H,-F,-C1 and -Br; and R1c3 is selected from the group consisting of:

-H,-F,-C1 and -Br, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
18. A compound of claim 1 selected from the group consisting of:

wherein:

A-Q is selected from the group consisting of:

wherein:

A is selected from the group consisting of:

R1a is selected from the group consisting of:

-H,-F,-C1 and -Br;

R1b is selected from the group consisting of:

-H,-CH3 and -CF3;

R1c2 is selected from the group consisting of:

-H,-F,-CN,-CH2NH2,-CONH2,-SO2Me,-SO2NH2 and -NO2;

R1c2 is selected from the group consisting of:

-H,-F,-C1,-Br and -OCH3; and R1c3 is selected from the group consisting of:

-H,-F,-C1,-Br,-OCH3,-NH2,-CH2NH2,-CONH2,-CONHMe,-CONMe2, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
19. A compound of claim 1 selected from the group consisting of wherein:

R1 is selected from the group consisting of:

-SO2NH2,-SO2Me,-CH2NH2 and -CH2NMe2;

R1a is selected from the group consisting of:

-H,-F,-C1 and -Br;

R1b is selected from the group consisting of:

-CH3,-CF3,-CH2CH3,-SO2Me,-CONH2 and -NHSO2Me; and R1c2 and R1c3 are independently selected from the group consisting of -H,-F,-C1 and -Br, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
20. A compound of claim 1 selected from the group consisting of:

wherein:

R1 is selected from the group consisting of:

-SO2NH2,-SO2Me,-CH2NH2 and -CH2NMe2;

R1a is selected from the group consisting of:

-H,-F,-C1 and -Br;

R1b is selected from the group consisting of:

-CH3,-CF3,-CH2CH3,-SO2Me,-CONH2 and -NHSO2Me; and R1c2 and R1c3 are independently selected from the group consisting of:

-H,-F,-C1 and -Br, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, thereof.
21. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 1.
22. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.
23. The method of claim 22, wherein the condition is selected from the group consisting of:

acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation, and thrombotic complications associated with the fitting of prosthetic devices.
24. A method for inhibiting the coagulation of biological samples, comprising the step of administering a compound of claim 1.
25. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 2.
26. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound of claim 2.
27. The method of claim 26, wherein the condition is selected from the group consisting of:
acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation, and thrombotic complications associated with the fitting of prosthetic devices.
28. A method for inhibiting the coagulation of biological samples, comprising the step of administering a compound of claim 2.
29. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 3.
30. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound of claim 3.
31. The method of claim 30, wherein the condition is selected from the group consisting of:

acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation, and thrombotic complications associated with the fitting of prosthetic devices.
32. A method for inhibiting the coagulation of biological samples, comprising the step of administering a compound of claim 3.
33. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 4.
34. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound of claim 4.
35. The method of claim 34, wherein the condition is selected from the group consisting of:
acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation, and thrombotic complications associated with the fitting of prosthetic devices.
36. A method for inhibiting the coagulation of biological samples, comprising the step of administering a compound of claim 4.
CA002385589A 1999-09-17 2000-09-15 Inhibitors of factor xa Abandoned CA2385589A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15433299P 1999-09-17 1999-09-17
US60/154,332 1999-09-17
PCT/US2000/025195 WO2001019798A2 (en) 1999-09-17 2000-09-15 INHIBITORS OF FACTOR Xa

Publications (1)

Publication Number Publication Date
CA2385589A1 true CA2385589A1 (en) 2001-03-22

Family

ID=22550934

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002385589A Abandoned CA2385589A1 (en) 1999-09-17 2000-09-15 Inhibitors of factor xa

Country Status (16)

Country Link
EP (1) EP1216231A2 (en)
JP (1) JP2003509412A (en)
CN (1) CN1390206A (en)
AU (1) AU781880B2 (en)
BR (1) BR0014078A (en)
CA (1) CA2385589A1 (en)
CZ (1) CZ2002959A3 (en)
HU (1) HUP0203954A2 (en)
IL (1) IL148698A0 (en)
MX (1) MX228790B (en)
NO (1) NO20021230L (en)
NZ (1) NZ517828A (en)
RU (1) RU2002110295A (en)
TR (1) TR200201413T2 (en)
WO (1) WO2001019798A2 (en)
ZA (4) ZA200202116B (en)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2349330C (en) 1998-12-23 2009-09-29 Dupont Pharmaceuticals Company Nitrogen containing heterobicycles as factor xa inhibitors
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2002010154A2 (en) 2000-07-27 2002-02-07 Eli Lilly And Company Substituted heterocyclic amides
HUP0400558A3 (en) 2000-11-22 2010-03-29 Astellas Pharma Inc Substituted benzene derivatives or salts thereof and pharmaceutical compositions containing them
US7163938B2 (en) 2000-11-28 2007-01-16 Eli Lilly And Company Substituted carboxamides
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
CA2444571A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1, 4, 5, 6-tetrahydropyrazolo-¬3, 4-c|-pyridin-7-ones as factor xa inhi bitors
CA2441772A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-¬3,4-c|-pyridin-7-ones as factor xa inhibitors
CA2447488A1 (en) 2001-05-22 2002-11-28 Irina Jacobson Bicyclic inhibitors of factor xa
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
GEP20074098B (en) 2001-09-21 2007-05-10 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
WO2003050088A1 (en) 2001-12-07 2003-06-19 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
WO2003099276A1 (en) 2002-05-10 2003-12-04 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
MXPA04011465A (en) 2002-05-24 2005-02-14 Millennium Pharm Inc Ccr9 inhibitors and methods of use thereof.
BR0312294A (en) * 2002-06-29 2005-04-12 Zentaris Gmbh Arylcarbonyl piperazines and hteroarylcarbonylpiperazines and their use to treat benign and malignant diseases
EP1537112B1 (en) 2002-08-06 2006-04-19 Astrazeneca AB Condensed pyridines and pyrimidines with tie2 (tek) activity
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
KR100874292B1 (en) 2002-11-18 2008-12-18 케모센트릭스 Aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
EP1433788A1 (en) * 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor Xa inhibitors
ATE444292T1 (en) * 2002-12-23 2009-10-15 Sanofi Aventis Deutschland PYRAZOLE DERIVATIVES AS FACTOR XA INHIBITORS
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
EP1479678A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor xa inhibitors
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
WO2004069824A1 (en) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
CA2525325A1 (en) * 2003-05-01 2004-11-18 Abbott Laboratories Pyrazole-amides and sulfonamides as sodium channel modulators
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
AU2004261459B2 (en) 2003-07-22 2008-06-26 Astex Therapeutics Limited 3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
SE0302573D0 (en) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0415179A (en) 2003-10-07 2006-11-28 Renovis Inc amide derivatives such as ion channel ligands and pharmaceutical compositions and methods of employing them
AU2004303602C1 (en) 2003-12-23 2009-05-28 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
EP1735284A1 (en) 2004-03-18 2006-12-27 Pfizer Limited N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008506702A (en) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Method for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
CN101213194A (en) 2004-08-03 2008-07-02 惠氏公司 Indazoles useful in treating cardiovascular diseases
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP4958785B2 (en) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
KR101269869B1 (en) 2004-09-24 2013-06-07 네오메드 인스티튜트 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
WO2006070195A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
CA2593550A1 (en) 2005-01-07 2006-08-10 Synta Pharmaceutical Corp. Compounds for inflammation and immune-related uses
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
US20090036435A1 (en) 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
EP1845974A1 (en) 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
DE602006009231D1 (en) 2005-03-10 2009-10-29 Pfizer SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXYACETAMIDE COMPOUNDS
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2006136821A1 (en) 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
US8541461B2 (en) 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
GB0521244D0 (en) 2005-10-19 2005-11-30 Astrazeneca Ab Benzamide compounds
JP5474354B2 (en) 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド Pharmaceutical compounds
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
EP3231442B1 (en) 2006-06-23 2019-12-25 ADC Therapeutics SA Polynucleotides and polypeptide sequences involved in cancer
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008127682A2 (en) * 2007-04-13 2008-10-23 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
CN102448951B (en) 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 Therapeutic compositions and related methods of use
MX2011013016A (en) 2009-06-05 2012-04-20 Link Medicine Corp Aminopyrrolidinone derivatives and uses thereof.
BRPI1011587B1 (en) 2009-06-29 2020-03-24 Agios Pharmaceuticals, Inc. QUINOLIN SULPHONAMIDE COMPOUNDS WITH PMK2 MODULATING ACTIVITY AND USE OF THE SAME
ES2594402T3 (en) 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Methods and compositions for disorders related to cell proliferation
CN106866667B (en) 2009-11-05 2019-11-15 圣母大学 Imidazo [1,2-a] pyridine compounds and their and its synthesis and application method
AU2011238616B2 (en) 2010-03-30 2016-08-04 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
CN101870636B (en) * 2010-04-01 2013-01-23 大唐(杭州)医药化工有限公司 Preparation method of 2-bromo-6-fluoronaphthalene
JP5837091B2 (en) 2010-12-17 2015-12-24 アジオス ファーマシューティカルズ， インコーポレイテッド Novel N- (4- (azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as modulators of pyruvate kinase M2 (PKM2)
WO2012088314A1 (en) 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (en) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 Therapeutic compounds and compositions
DK2691421T3 (en) 2011-03-31 2017-02-20 Alethia Biotherapeutics Inc ANTIBODIES AGAINST NON-REFERENCE ANTIGEN 1 AND ANTIGIN BINDING FRAGMENTS
CN103608016A (en) 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 Pyruvate kinase activators for use in therapy
SMT201800354T1 (en) 2011-05-03 2018-09-13 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
CN102827170A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Active treatment compositions and use method thereof
US20170174753A1 (en) 2012-01-09 2017-06-22 Alethia Biotherapeutics Inc. Method for treating breast cancer
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CN103483242A (en) * 2012-06-15 2014-01-01 上海朴颐化学科技有限公司 Preparation methods of 4-(2'-pyridyl)benzyl hydrazine and its intermediate
CA2885259A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
US9951025B2 (en) 2013-03-15 2018-04-24 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
PT2968297T (en) 2013-03-15 2019-01-10 Verseon Corp Multisubstituted aromatic compounds as serine protease inhibitors
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3019480B1 (en) 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
DK3054936T5 (en) 2013-10-10 2024-03-18 Eastern Virginia Medical School 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS
UA121211C2 (en) 2014-03-14 2020-04-27 Аджіос Фармасьютикалз, Інк. PHARMACEUTICAL COMPOSITION CONTAINING SOLID DISPERSION AND METHOD OF TREATMENT OF ACUTE MYELOGENIC / MYELOID LEUKEMIA (GML)
CN106458918B (en) * 2014-06-11 2019-07-09 拜耳作物科学股份公司 The method of bis- (halogenated alkyl) pyrazoles of 3,5- is prepared via the acylation of ketimide
CN104016944B (en) * 2014-06-16 2016-05-18 山东大学 N-(2-(amine methyl) phenyl) thiazole-4-carboxamide derivative and preparation method thereof and application
CN106687445A (en) 2014-09-17 2017-05-17 维颂公司 Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
SG11201706411YA (en) 2015-02-27 2017-09-28 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
JP7320339B2 (en) 2015-06-11 2023-08-03 アジオス ファーマシューティカルズ， インコーポレイテッド Methods of using pyruvate kinase activators
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
JP7055378B2 (en) 2015-09-17 2022-04-18 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック Benzylamine-containing heterocyclic compounds and compositions useful against mycobacterial infections
JP7033061B2 (en) 2015-10-15 2022-03-09 アジオス ファーマシューティカルズ， インコーポレイテッド Combination therapy to treat malignant tumors
CA3002067C (en) 2015-10-15 2023-11-28 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
WO2019071073A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
SI3752501T1 (en) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP7242702B2 (en) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド PD-1/PD-L1 inhibitor
KR102596598B1 (en) 2018-04-26 2023-11-03 화이자 인코포레이티드 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin-dependent kinase inhibitors
CA3098628A1 (en) 2018-05-17 2019-11-21 Forma Therapeutics, Inc. Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
SI3820572T1 (en) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SMT202300164T1 (en) 2018-10-05 2023-07-20 Forma Therapeutics Inc Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SI3986890T1 (en) 2019-06-18 2024-03-29 Ctxt Pty Ltd Benzisoxazole sulfonamide derivatives
SMT202400488T1 (en) 2019-12-06 2025-01-14 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
UY39800A (en) 2021-06-04 2023-01-31 Vertex Pharma N–(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS SODIUM CHANNEL MODULATORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6645998A (en) * 1996-12-23 1998-07-17 Du Pont Pharmaceuticals Company Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
AU730224B2 (en) * 1996-12-23 2001-03-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
WO1998057934A1 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS

Also Published As

Publication number Publication date
NO20021230L (en) 2002-05-21
NZ517828A (en) 2003-10-31
AU781880B2 (en) 2005-06-16
IL148698A0 (en) 2002-09-12
NO20021230D0 (en) 2002-03-12
AU7486600A (en) 2001-04-17
EP1216231A2 (en) 2002-06-26
MXPA02002762A (en) 2003-10-14
CN1390206A (en) 2003-01-08
ZA200202116B (en) 2004-02-10
WO2001019798A2 (en) 2001-03-22
JP2003509412A (en) 2003-03-11
TR200201413T2 (en) 2003-02-21
BR0014078A (en) 2002-12-31
MX228790B (en) 2005-06-30
HUP0203954A2 (en) 2003-03-28
WO2001019798A3 (en) 2001-10-25
ZA200202117B (en) 2004-02-25
ZA200306488B (en) 2004-04-28
RU2002110295A (en) 2003-12-10
ZA200306490B (en) 2004-05-26
CZ2002959A3 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
CA2385589A1 (en) Inhibitors of factor xa
US6632815B2 (en) Inhibitors of factor Xa
CA2385592C (en) Benzamides and related inhibitors of factor xa
CA2401778C (en) Benzamides and related inhibitors of factor xa
US6720317B1 (en) Inhibitors of factor Xa
US6844367B1 (en) Benzamides and related inhibitors of factor Xa
CA2374650A1 (en) Inhibitors of factor xa
WO2001012600A1 (en) INHIBITORS OF FACTOR Xa
CA2374641A1 (en) Inhibitors of factor xa
CA2361428A1 (en) Inhibitors of factor xa
CA2374820A1 (en) Inhibitors of factor xa
US20030069250A1 (en) Benzamide inhibitors of factor Xa
CA2371904A1 (en) Inhibitors of factor xa
WO2002079145A1 (en) BENZAMIDE INHIBITORS OF FACTOR Xa
CA2392576A1 (en) .beta.-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa
WO2002026718A2 (en) Bicyclic pyrimidin-4-one based inhibitors of factor xa
US20040077690A1 (en) Quaternary amidino based inhibitors of factor xa
CA2422873A1 (en) Piperazin-2-one amides as inhibitors of factor xa

Legal Events

Date Code Title Description
FZDE Discontinued